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ABSTRACT
The clinico-pathogical characteristics, diagnostic protocois and management of events 
which cause graft or systemic complications following liver transplantation are 
inadequately defined. In this thesis, the principal categories of such post-transplant 
compiications were determined from a systematic examination of 127 consecutive 
faiied liver transplants and classified. Several clinical and experimental protocols for 
assessment and management of the defined major clinico-pathological categories were 
then examined.
Primary graft dysfunction, secondary to impaired donor organ viability, was an 
important but not easily predictable determinant of early post-transplant outcome. 
Measurement of liver cell enzyme activities in the preservation solution, washed-out 
at the end of graft storage, was found to be valuable in prediction of early graft 
function. Recipients with the highest AST enzyme activity in this fluid experienced the 
most impaired biochemical graft dysfunction. More significantly, rejection frequency 
was higher and one month graft survival lower in this group compared to patients with 
low levels. Markers of liver endothelial cell (CK-BB, PNP} damage did not correlate 
with early graft viability.
Vascular complications were also a common cause of severe graft dysfunction and 
failure. The value of hepatic angiography in defining the extent and pattern of arterial 
lesions and their significance in graft survival was examined. Intrahepatic attenuation 
of the arterial tree in early graft dysfunction was associated with an unfavourable 
outcome. Similarly, during chronic rejection the presence of arteriopathy, even if 
absent on histological assessment, was accompanied by a poor prognosis. Angiography 
was also found to be more sensitive than doppler ultrasonography in assessing hepatic 
arterial thrombosis or stenosis and is recommended as the preferred investigation.
Vascular compromise and systemic haemodynamic derangements are present in 
primary graft dysfunction. N-acetylcysteine was shown to improve systemic oxygen 
delivery, consumption and ICG extraction in post-transplant patients. These properties 
should be clinically useful in critical illnesses {especilly following transplantation) 
where the systemic and hepatic-splanchnic circulation is compromised.
af ! |I
Allograft rejection was found to be the single largest pathological process leading to 
transplant failure. Characterisation of clinical risk factors for rejection may provide 
insight into underlying mechanisms and development of therapeutic strategies, in renal 
transplantation the ethnic origin of graft recipients is recognised as an important 
determinant of graft survival. In this investigation, non-caucasoid liver recipients 
were found to have inferior patient and graft survival figures as compared to caucasoids 
with different frequencies of chronic allograft rejection contributing to the differences.
Patients from ethnic minorities transplanted from a predominantly Caucasian donor 
population should be considered at higher risk of rejection.
Immune monitoring may allow prediction of a rejection episode and the response to 
treatment. Stable end-products of the L-arginine:nitric oxide biosynthetic pathway 
were found to be increased during acute allograft rejection. Levels correlated with i;
histological severity and declined following supplemental corticosteroids. Correlations 
between plasma NQ( levels and circulating TNF-a and IL-2R positive lymphocytes were
present. NOx was the most predictive parameter of a rejection episode. Measuring
plasma levels of NOx may be useful in the assessment of acute allograft rejection.
Improved pharmacological control of rejection should reduce graft failures. The 
efficacy and safety of FK506 immunosuppression was compared to conventional CyA 
based regimens in 50 recipients transplantated for fulminant hepatic failure. FK506 
treated patients had an improved post-transplant outcome with higher survival 
figures, lower rejection and reduced intensive care stays. Toxicity was similar to 
conventional regimens. 1
Pre-transplant general clinical status plays a major role in determining early post - 
operative outcome and was given a separate category in the proposed classification. This 
effect may be especially important in patients transplanted for acute liver failure 
where systemic critical illness is severe. In patients transplanted for non-paracetamol 
induced ALF (n=79), no static variable on admission other than aetiology was 
predictive of 2 month patient survival. Fulminant Wilsons disease and idiosyncratic 
drug reactions had significantly better and worse outcomes respectively. At 
transplantation, of 4 dynamic variables significant univariately (encephalopathy 
grade, Apache 111 and organ system failure scores, and serum creatinine) only the last
was an independent variable in a stepwise logistic regression for 2 month survival. In 
patients transplanted for paracetamol hepatotoxicity (n=21), ‘overdose to hepatectomy 
period' was the only significant static variable, with no parameter predictive of 
outcome present on admission. Of two dynamic variables which were significant at 
transplantation (serum bilirubin and Apache 111 score) oniy the latter parameter was 
an independent variable in the regression modei. Selection for transplantation in ALF
'::'îdepends on assessment of both the prognosis of the primary illness on admission and the Z
clinical status at the time of proposed transplantation.
Transplantation for HBsAg-positive patients is controversial in view of the frequency 
of disease recurrence foliowing transplantation. The roles of passive 
immunoprophyiaxis, a stricter patient selection policy and coexistent HDV infection on 
outcome was examined. HBsAg serological recurrence rate was halved by 
immunoprophyiaxis and was especially valuable if the recipients are HBV DNA - 
negative or had co-existent HDV infection. Patient survival has improved with HBIg 
particularly in HDV-negative or actively replicating recipients. Co-existent HDV 
infection is protective with survival figures comparable to elective non-HBsAg 
recipients. Graft injury following recurrence appears to be diminished in recent 
patients with a reduction in the rate of fibrosing cholestatic hepatitis. 
Retransplantation for HBV-related graft injury is not justified without anti-viral 
treatment.
Clinical tolerance, with absence of pharmacological immunosuppression, may improve 
the natural history of liver transplant recipients. Identification of a marker of 
tolerance to select appropriate patients is required. The relationship between complete 
immunosuppression withdrawal and microchimerism (a recently proposed marker of 
tolerance) and the resulting clinical outcome in a group of long-term liver recipients 
was examined. Chimerism (determined by genotypic examination for donor-specific 
HLA-DRB1 alleles) was demonstrated in 40% of patients with skin the optimal tissue 
for testing. Approximately one-third of patients (all transplanted for non-immune 
mediated disorders) were successfully removed from immunosuppression. However, no 
difference in the frequency of tolerance was demonstrated between chimeric and non - 
chimeric recipients. Finally, the potential hazards of immunosuppresion, especially in 
primary immune transplant indications, are highlighted in the report of severe 
recurrence of auto-immune hepatitis in the context of low immunosuppression.
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ABBREVIATIONS
AIH autoimmune hepatitis
AID alcoholic liver disease
ALF acute liver failure
AMA antimitochondrial antibody
ANA antinuclear antibody
ASGPR asiaioglycoprotein receptor
AST amino aspartate transferase
AUC area-under-curve
CBIR cyclosporin A based immunosuppression regimen
01 cardiac index
CT computerised tomogram
CyA cyclosporin A
DNA deoxyribonucleic acid
DQ2 oxygen delivery
EDTA ethylenediaminitetra-acetic acid
BSD early graft dysfunction
ELISA enzyme linked immunosorbent assay
ELTR European liver transplant registry
EVLWI extravascular lung water index
FCH fibrosing cholestatic hepatitis
FHF fulminant hepatic failure
FWD fulminant Wilsons disease
GVHD graft versus host disease
HAS hepatic artery stenosis
HAT hepatic artery thrombosis
HAV hepatitis A virus
HBV hepatitis B virus
HOC hepatocellular carcinoma
HCV hepatitis C virus
HDV hepatitis D virus
HBIG hepatitis B immunoglobulin
HLA human leukocyte antigen
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ICG 
I FN"Y 
igG 
igM
IL2(R )
INR
IV
IVG
LDH
LKM
LVSWI
LOHF
LSP
MHO
MLR
MOF
n
NfiC
NANB
NC
OLT
06F
PBC
PGR
PEEP
Pgi2
PGN
PNP
PSC
PTLD
RFLP
RIA
RRT
SD
indocyanine green 
interferon-gamma 
immunoglobulin class G 
Immunoglobulin class M 
Interleukin 2 (receptor)
International normalised ratio
Intravenous
Inferior vena cava
lactate dehydrogenase
liver-kidney microsomal
left ventricular stroke work index
late-onset hepatic failure
liver-specific membrane lipoprotein preparation
major histocompatibility complex
mixed lymphocyte reaction
multi-organ failure
number (of subjects)
n-acetylcystelne
non A-non B
nitric oxide
orthotopic liver transplant 
organ system failure 
primary biliary cirrhosis 
polymerase chain reaction 
positive-end-expiratory-pressure 
prostacyclin
primary graft non-function 
purine nucleoside phosphorylase 
primary sclerosing cholangitis 
post-transplant lymphoproiiferative disorder 
restrictlon-fragm ent-length-poly morphism 
radio-immune-assay 
renal replacement therapy 
standard deviation
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SEM standard error mean
SLC sinusoidal lining cell
S90 sequence-specific oligonucleotide
SSP sequence-specific primer
TISS therpaeutic intervention scoring system
TNF-a tumour necrosis factor-a
UKTSSA United Kingdom Transplant Support Service Authority
UNOS United Network Organ Sharing
UW University of Wisconsin
VBDS vanishing bile duct syndrome
VO2 oxygen consumption
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:SECTION A. BACKGROUND AND INTRODUCTION
CHAPTER 1 
LIVER TRANSPLANTATION
1.1 HISTORY AND DEVELOPMENT
The first human liver transplants were performed by Starzl in 1963 (Starzl et al 1963).
These whole organ orthotopically placed homografts were possible following the technical 
achievements in the animal laboratory pioneered by Cannon and Moore in Boston |î
(Cannon et al 1956, Moore et al 1959). However despite the success achieved 
expeiimentally, it was a further 4 years before there was a long-term human survivor 
(Starzl et al 1968). These initial poor results predominantly reflected the limitations 
imposed by poor donor organ preservation with accompanying severe ischaemic injury, 
inadeqaute pharmacological control of rejection and the occurrence of systemic air 
embolism resulting from poor graft perfusion techniques (see sections 1.3 and 1.4).
Following refinement of operative technique and anaesthetic care, initial survival post - 
operatively was regularly achieved which encouraged other centres in Cambridge, United 
Kingdom (UK), Hannover, Germany and Groningen, Netherlands to develop Iprogrammes in the late 1960’s and early 70’s (Caine et al 1968). Initial candidates were 'I
limited to those experiencing hepatic malignancy with later experience restricted to patients 
experiencing severe decompensation of chronic liver disease. Subsequent improvements
•Sin preservation and rejection control over the decade 1970-80, focused increasing attention f
onto selection of appropriate transplant candidates. The unacceptable results intially 
attained alerted transplant surgeons and physicians to the risks of operating on patients 
where the pretransplant clinical status was so unfavourable. Survival rates consistently 
less than 50% at one year were standar d until the early 1980’s.
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During the decade 1980-90 following several advances discussed below, liver 
transplantation became established as the optimal treatment in a range of acute and chronic
end-stage liver disorders. Patient survival rates of 80-90% at one year can now be 
achieved in low-risk elective recipients. Even in acute liver failure (ALF), despite the 
critical state of tlie patient, survival figures as high as 70-75% at one year are possible. As 
a result of these successes transplantation programmes have expanded rapidly such that 
annual totals now exceed those for heart recipients. In the United States, the annual 
increments have been the largest observed in solid-organ transplantation with the total 
number of liver transplants performed increasing from 62 in 1982 to approaching 3000 in 
1992. Substantial increases in Europe have also occurred with an annual increase in 
transplants performed in the UK of between 15-20% per year. Such rapid expansion in 
liver transplantation is unlikely to continue over the next few years as the number of donor 
organs available is appearing to plateau. This is already stimulating debate on the 
appropriate allocation of organs, which have to be regarded as an increasingly scarce finite 
resource. Limitations in organ availability are particularly acute in the paediatric age group 
despite the recent innovative techniques of reduction and ‘split’ grafts. In the adult 
population, unless wider use is made of elective ventilation procedures or non-heart 
beating cadaveric organs - leaving aside possible changes in organ donation legislation - 
waiting lists for liver transplants can be anticipated to grow further (Roy First et al 1992). 
In the USA, reflecting the serious organ procurement problems, 23.2% of patients listed 
for liver transplantation died on the waiting-list in 1989 with the majority of these less 
than 45 years old (Annual report of UNOS 1991, UNOS Liver allocation data examined 
1991). Latest reports indicate that the waiting-list mortality is increasing annually.
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1.2 ORGAN VIABILITY AND PRESERVATION
In the pioneering days of clinical transplantation, the consequences which followed from 
the limitations imposed on donor organ retreival and preservation were soon evident. 
Organ procurement was only permitted following cardiac arrest i.e. from non-heart 
beating donors. As the risks of normothermic preservation (Goodrich and Welch 1956) 
were appreciated from animal experiments, hypothermic storage using rapid cooling of 
donor organs with a rudimentary electrolyte (lactated Ringers) solution was employed 
which limited viability to a matter of minutes rather than hours. Improvements, albeit 
marginal, to the preservation qualities of this solution followed from the introduction of 
dextran and tlien later buffered plasma. Of greater importance, the introduction of brain­
stem death criteria (Diagnosis of brain death 1976, Definition of irreversible coma 1968) 
allowing organ retreival from an intact circulation, in addition to the use of either 
extracorporeai or ex-vivo organ perfusion with a modified heart-lung machine, extended 
viability significantly (Brettschneider et al 1968, Marchioro et al 1963).
It was later recognised that the use of hypothermic organ storage results in several 
detrimental biochemical and physiological effects to the liver graft which include 
development of intracellular acidosis, depletion of ATP and ADP and injury from reactive 
oxygen intermediates (for review see Blankensteijn et al 1991). The introduction of 
Collins solution was an attempt to counter these effects. However, perhaps the most 
significant present advance in liver preservation awaited the work of Belzer who, 
following documentation of the effects described above, systematically devised a new 
preservation solution addressing the specific biochemical injuries. The clinical 
introduction of the University of Wisconsin (UW) solution which followed his 
endeavours has extended the period of organ viability and improved early graft function 
(Belzer and Southard 1988). The wider significance of preservation injury has also come
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.to be recognised. In addition to the obvious insult to early graft function, increased 
rejection frequency, development of non-anastamotic bile duct strictures and vascular 
thrombosis have been implicated as consequences of preservation damage (Adam et al 
1992, Campbell et al 1991, Howard et al 1990, Sanchez-Urdazpal et al 1992).
In contrast to programmes better knowledge and application of organ preservation 
techniques, there remains controversy over selection of suitable donor candidates. As 
Starzl pointed out in 1969 “an accurate picture of the quality of the donor liver may be 
difficult to obtain during the terminal phases of life”. Certain absolute contraindications to 
donation such as HBsAg or HIV positivity, septicaemia and a recent history of 
malignancy are normally enforced. However, increasing relaxation over the donor clinical 
history with use of organs from donors with previously considered unfavourable 
characteristics (such as increasing age, obesity, vasopressor requirements, presence of 
renal failure, prolonged ITU admission) has apparently resulted in acceptable recipient 
clinical outcome in some centres (Mirze et al 1994). The use of in-vivo measurements of 
donor liver function employed prior to retrieval in an attempt to refine organ selection has 
not found widespread clinical application. Donor management, which may play an 
important part in organ viabihty, has not been properly addressed (Wijnen et al 1991).
Despite these advances, a note of caution is required in view of recent data from the 
European Uver transplant ægistiy (ELTR). As previously refeixed to, annual increments in 
both transplant numbers and patient survival in the registry reports have come to be 
expected. However the most recent report from the ELTR has for the first time not only 
demonstrated a minimal increase in the annual total but additionally a small reduction in 1 - 
year patient survival in elective recipients (1992 [80.5%, n=1782] versus 1991 [81.7%, 
n=1764]) (ELTR 1992). The latter may reflect the recently perceived greater usage of 
inferior donor organs as demand for grafts outstrips supply.
28
; ','L- ■ L . . ■
1.3 SURGICAL AND TECHNICAL CONSIDERATIONS
The present surgical procedures which form the basis of modern clinical transplantation 
reflect the distillation of considerable experimental and clinical experience since the first 
documented liver transplant performed on a dog by Welch in 1955 (Welch et al 1955). 
This initial heterotopic approach, which foundered because of portal venous delivery and 
drainage problems, was quickly superceded by orthotopic graft placement in 1956 by 
Cannon and in 1958 by Moore (Cannon et al 1956, Moore et al 1959 and 1960). 
Progression from these canine to porcine models quickly occurred reflecting the unique 
venous drainage problems of canine grafts and the closer anatomical (and as it turned out 
immunological) similarity of the pig liver and vasculature to humans (Starzl et al 1965). 
Within a decade of these innovations, the first human liver graft had been transplanted 
(see section 1.1).
Several major advances improving the operative procedure have evolved since that era. 
Splenectomy at the time of transplant, which in retrospect was not only unnecessary but 
indeed further predisposed to post-operative infection, has been abandoned in routine 
procedures. Severe intra-abdominal haemorrhage also resulted in a large proportion of 
technical failmes in the early series. The introduction of veno-venous bypass, introduced 
to offset the circulatory derangements in the systemic and portal circulations present 
during the anhepatic phase, has also probably reduced intestinal congestion, abdominal 
infections, post-operative renal failure and bleeding secondary to portal hypertension 
(Papas et al 1971). This condition and associated hypersplenism alongside the 
coagulopathy of poor hepatic synthetic function, contributed to the severity of peri­
operative bleeding. The more recent use of rapid transfusion lines and cell-savers 
(reducing the harmful effects from massive transfusion of stored blood) has also made a 
significant contribution to the management of intra-operative bleeding. Vascular graft
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Following these advances in intra- and post-operative care and the consistent achieval of 
early survival, surgical innovation has more recently centred on strategies to either 
increase organ allocation or avoid continued immunosuppression. In particular, the
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complications were also identfied early in the clinical transplant series as potentially 
catastrophic events. Devasculaiisation of the graft from hepatic artery thrombosis (HAT) 
in the early post-operative period often progressed to liver failure as was predicted from 
the experimental experience. The increased prevalence of this complication in paediatric 
recipients was recognised in the Denver experience. Biliaiy tract complications were also 
recognised as a common cause of major graft complications (Maitineau et al 1972). 
Reconstruction of the biliary system has evolved from a cholecystoduodenostomy to 
gallbladder conduits and is presently standardised (in the absence of extra-heptic biliary 
disease) on a direct choledocho-choledochostomy. The major historical causes of biliary 
pathology were due not to surgical limitations (these were rare in dog and pig transplants) 
but to a combination of the tenuous vascular supply of the human biliary system 
promoting breakdown of the anastamosis and the corrosive effects of retained bile salts 
after storage resulting in sludge and obstruction. Shortening the donor common bile duct, 
improved storage techniques and irrigation of the biliary system at retrieval with 
preseiwation solution have abrogated both these problems (McMaster et al 1979a).
Other causes of technical transplant failures in the early series included overwhelming 
sepsis, air embolism and g astro-intestinal (particularly oesophageal) bleeding. 
Administration of anti-bacterial and anti-fungal prophylaxis and the introduction of 
improved immunosuppression regimens (see section 1.5) has reduced to a more 
acceptable level the eaiiy morbidity and mortality from sepsis. In contrast, the latter two 
problems have now been virtually removed by improvements in organ perfusion 
methodology and gastric antacid prophylaxis.
I
imbalance between the potential population of paediatric recipients and the pool of 
optimally sized donor organs has directed development to increase organ supply in this 
age-group. Reduced-size grafts including ‘splits’ are now regularly employed in 
experienced centres. The use of auxiliary grafts has also recently undergone renewed 
vogue. First employed in 1964, this approach had been attempted with consistently 
unsuccessful results until a 5 year survivor was reported in 1977. The attractiveness of 
this approach which can offer temporary liver support and thereby allow a period of native 
liver regeneration which may finally permit withdrawal of maintenance 
immunosuppression and atrophy of the donor graft is considerable (Moritz et al 1990). 
Initial attempts at heterotopic placement of auxiliary grafts have on the whole yielded 
unsatisfactory results due to vascular drainage and portal vein supply problems. 
Presently, there is increasingly widespread use of auxiliary partial liver orthotopic liver 
transplants (APOLT) which are technically more simple and have been successfully 
employed in correcting üver-specific metabolic defects and in patients experiencing acute 
liver failure.
1.4 DISEASE INDICATIONS AND PATIENT SELECTION
Patient selection is crucial in deterrnining the outcome following transplantation. Selection 
of appropriate candidates is based on a careful clinical judgement of both the individual’s 
prognosis and life expectancy with regard to the primary illness, as well as the effects of 
the iUness on their quality of life; additionally and more controversially there is a difficulty 
of balancing the former with the optimal timing of the procedure which will bring a 
successful outcome. These principles were learned by trial and err or in the early transplant 
series where the choice of candidates (see section 1,1) was so unfavourable to a 
satisfactory long-term outcome.
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The need for accurate assessment of prognosis in liver disorders - which can be the basis 
in evaluating the need for transplantation or other therapy - has led to number of landmark 
studies in the development of clinical prognostic models (Powell and Klatskin 1968, 
Dickson et al 1989, Wiesner et al 1989, Parr ant et al 1991, Weissberg et al 1984), Of 
these the natural history of primary biliary cirrhosis (PBC) is the best validated and the 
model has also been used to examine the important principle of disease severity at the tme 
of transplantation in relation to outcome. Studies have examined the effect of referral 
patterns, disease severity at transplantation and subsequent outcome in terms of survival, 
morbidity and financial cost (Neuberger et al 1990, Markus et al 1989, Cooper et al 
1990). In the UK, late referrals associated with higher serum bilirubin levels and a raised 
prognostic index were reflected in lower post-transplant survival. Stratification for risk 
scores, using the Mayo Clinic model, in PBC patients makes it possible to delineate 
outcome in different severity categories in relation to morbidity and costs (Wiesner et al 
1992). Reduced hospitalisation and costs were demonstrated in those transplanted with 
lower risk scores i.e. earlier in the natural history. This sort of clinically relevant data, 
which is poorly characterised in other chronic progressive parenchymal disease categories 
which proceed to transplantation such as primary sclerosing cholangitis (PSC) or 
alcoholic liver disease (ALD), cannot presently be applied to malignant or viral disorders.
Transplantation for hepatic malignancy results in survival rates at least 20-30% lower than 
other disease groups. These unfavourable results in liver tumours were recognised in the 
early transplant series where a large proportion of the recipients where patients 
experiencing unresectable hepatocellular carcinomas (HCC). Transplantation for 
cholangiocai'cinoma (either central or peripheral) and large, multifocal HCC is associated 
with inevitable disease recurrence (Iwatsuki et al 1985). Detection of extra-hepatic 
malignancy, with the possible exception of haemangioendothelioma and carcinoid / 
apudomas, remains an absolute contraindication to proceeding with a transplant.
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Worldwide, hepatitis B vims (HBV) and hepatitis C virus (HCV) -related liver disease 
represent the commonest potential indications for elective transplantation. The natural 
history of unmodified HBV infection after transplantation is one of rapid serological 
recurrence and graft injury (O’Grady et al 1992). Following isolation, cloning and B
development of serological assays for the detection of HCV, the patterns of reinfection 
and graft damage from this vims after transplantation ai’e being quickly elucidated.
IIt was probably not anticipated in the early years of developing liver transplantation that ij
ALD would quickly rise to be the largest single indication accounting for 15.4% of 
recipients in the US and increasing yearly. The surprisingly good results currently being 
obtained in ALD is dependent in most centres upon a very careful psychosocial 
assessment of the alcoholism quite apart from other important medical aspects which can 
affect the results of transplantation.
Given the success achieved with elective transplantation for chr onic Hver disorders, it was 
inevitable that emergency hver replacement with restoration of hepatic function would be 
attempted as a management option in ALF. Although renewed attempts are being made to 
develop artificial liver support with extra-corporeal circuits / columns and hepatocyte 
ti'ansplantation which may radically change physicians approach, at present ti'ansplantation 
has to be regarded as the optimal procedure for selected patients. Current surgical methods 
are centred on whole organ orthotopic transplantation with the role of APOLT and of 
hepatectomy prior to organ retrieval for earlier and very late cases respectively remaining 
to be defined. With survival rates reported for some centres in Europe as low as 46%, the 
need for adequate back-up in liver intensive care and medical aftercare in obtaining good 
results with transplantation is increasingly evident. Clinical and biochemical indices have 
been developed and are now available on which to reliably base the selection of patients 
whose prognosis is other-wise very poor (O’Grady et al 1989, Bernuau et al 1990).
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Selection of transplant candidates must take into account measures to prevent disease 
recuiTence. In addition to the viral and malignancy related liver disorders already refened 
to, recurrence of ALD, PBC, PSC, Budd-Chiari syndrome and autoimmune hepatitis 
(AIH) has been reported. The extent of graft injury following recurrence is variable and 
may be modified by the anti-rejection regimen used, for instance cyclosporin A (CyA) 
may affect recurrence of PBC whereas corticosteroids will promote replication in HBV 
and probably HCV viral reinfection.
1.5 REJECTION AND IMMUNOSUPPRESSION
The liver allograft is immunologically priviledged. This fundamental tenet went 
unrecognised in the initial canine transplants which normally underwent brisk rejection, 
although there were occasional long-teim survivors in pharmacologically unmodified graft 
animals. It was not until the observations of Gamier in porcine grafts, which were 
confiimed later by the Bristol and Cambridge groups, that rejection was often abrogated 
or even spontaneously reversed that the unique nature of the liver allograft was suggested 
(Gamier et al 1965, Caine et al 1967, Peacock and Terblanche 1967).
When it came to human transplantation, the expediency of allocating liver grafts to 
transplant recipients on the basis of clinical need, irrespective of donor-recipient tissue 
matches, allowed the observations that human liver grafts could successfully transcend the 
normal allogeneic bati'iers of the human leukocyte antigen (HLA) and even occasionally 
the ABO antigen systems (Markus et al 1988, Donaldson etal 1993, Fischel et al 1989). 
Immunological hver graft failures aie lower than other solid organ transplants reflecting 
the reduced frequency and severity of all forms of rejection. Why the liver is resistant to 
the “unrelenting incompatibility of the homograft” as described by BiUingham stiU remains
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speculative (for review see Wood et al 1993).
Despite this lower host-versus-graft response to liver transplants, inadequate control of 
rejection contributed to the poor outcome in early human transplantation. Pharmacological 
modification of the liver allograft response relied upon the immunosuppression regimens 
employed in renal transplantation by 1963 which comprised schedules of corticosteroids 
and azathioprine. Corticosteroids had been shown to possess immunosupppressive 
qualities by BiUingham and Medwar in 1951 (BiUingham et al 1951). The 
immunosuppressive qualities of purine analogues had previously been demonstrated by 
Caine in canine renal homografts in 1961 with clinical introduction a year later in view of 
a valuable synergistic action when administered alongside corticosteroids (Caine et al 
1961, Star zl et al 1963). The clinical introduction of azatliioprine undoubtedly contributed 
to the early attempts at human liver transplantation. Despite the promising results in 
human renal grafts, all the early liver recipients who were administered this dual therapy 
regimen under Starzl died from a variety of causes including irreversible rejection and as 
he noted "'overwhelming bacterial, fungal and viral infection"'. Problems with azathioprine 
overdosage and accompanying marrow suppression further contributed to these infectious 
problems. These early results, with non-specific immunosuppression resulting in global 
inhibition of natural immunity, highlighted the marginal balance between rejection and 
infection which has remained the Achilles tendon of liver transplantation.
Further attempts at clinical transplantation only proceeded following the introduction of 
anti-lymphocyte serum (ALS) or globulin (ALG) as an adjunct to the immunosuppression 
armamentarium alongside corticosteroid and reduced azathioprine schedules (Abaza et al 
1966). However, this regimen also proved inadequate and even the use of ancillary 
measures to treat presumed rejection employing local graft irradiation, cyclophosphamide, 
actinomycin and thoracic duct drainage were unsuccessful. It was not until the clinical
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introduction of CyA by Caine,, following elucidation of its immunosuppressive properties 
by Borel, that adequate conti'ol of rejection was regularly achieved (Borel et al 1977, 
Caine et al 1978, McMaster et al 1979b). This agent has considerably improved patient 
and graft survival rates allowmg significant reductions in corticosteroid and azathioprine 
dosages. Refinement of the use of CyA in the early post operative period and tailored as 
part of a triple therapy regimen alongside azathioprine and prednisolone to reduce toxicity 
has been the preferred maintenance immunosuppression regimen employed in most liver 
transplant programmes over the last decade.
1.6 RESULTS AND LATE OUTCOME
The establishment of liver transplant central registries in the USA (Pitt-UNOS Liver 
transplant registry) and the ELTR in Europe provide the best documentation on the current 
status of liver transplantation, allowing accurate determination of outcome in large 
numbers of subjects in relation to a range of clinical and demographic characteristics 
(Belle et al 1991, Belle and Dette 1993, ELTR 1992). In addition to the primary disease 
(published survival rates vary by up to 50% in different liver disorders as discussed in 
section 1.2) and the technical considerations outlined above, other factors such as general 
medical condition, nutritional status, presence of renal failure, age, race and 
retransplantation can significantly influence outcome (Williams et al 1987, Belle and Detre 
1993, Cuervas-Mons et al 1986a).
The impact of pretransplant functional clinical status (as assessed by the six-point United 
Network for Organ Sharing [UNOS] score which can be applied to all liver candidates) 
has also been shown to correlate with post-transplant outcome. This pattern was also 
found in the earlier study by Williams et al 1987 on hospital length of stay and total costs
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1of transplantation using a similar scale of pretransplant functional clinical status. The latest 
Pitt-UNOS registry data demonstrates a one-year patient survival of 84.4% versus 60.1% 
between recipients in tlie best and worst categories of this scale respectively. Significant 
differences in patient suiwival have also been shown by the registry in relation to 
demographic characteristics. Inferior survival rates were noted with respect to age (young 
paediatric and older adult recipients), race (black and oriental recipients fared worse) in 
addition to nature of primary liver disease. Extremes of age were until recently considered 
relative contraindications to hver transplantation. In many programmes however, older 
patients are now being transplanted with the mean age of ah recipients rising consecutively 
in the ELTR from 35 years in 1985 to 43 years in 1992. An early report from Pittsburg 
encouragingly reported no significant difference in survival in a cohort of 92 patients 
between 50 to 77 years compared to a group of adults 18-49 years old as well as a similar 
return to domestic activities (Starzl et al 1987). More recent data from both the Pitt-Unos 
and the European registries are less optimistic with reductions in survival noted for 
patients greater than 60 yeai's old. The differences aie compaiatively modest in the first 
few years post-tiansplant (approximately 5% or less) although they increase with time 
perhaps reflecting the contribution from natural mortality in this elderly population. 
Overall, children have survival rates marginally higher than adults although those less than 
1 years old fare less favourably due mainly to a higher rate of technical complications.
Considerable experience and data is now available documentmg the early outcome of liver 
transplant recipients with the clinical factors which influence patient and graft suiwival in 
the post-operative period and the initial years following ti'ansplantation well described (see 
above). In contrast, limited experience has been reported concerning the clinical status and 
natural history of long term liver transplant survivors with no detailed clinicopathological 
reports. In a recent analysis, the prevalence of systemic and graft complications in 
recipients beyond 5 years post-transplant was described from tins unit (Slapak et al 1995).
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Histological and biochemical abnormalities of the graft were unexpectedly common and 
could be broadly classified pathologically into seven main groups: a hepatitis-like picture, 
rejection, recuirent disease, sinusoidal damage / nodular regenerative hyperplasia, chronic 
cholangitis, scarring or cin'hosis. Normal biopsies were present in a minority of patients 
only.
Despite the potential pitfalls awaiting liver recipients at all stages following 
transplantation, as outlined above, the present populations are experiencing an 
enhancement of quality of life and often a return to employment (Lowe etal 1990, Tarter 
et al 1988).
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1.7 OBJECTIVES OF THESIS
1. Identification of the present major aetiological categories of giaft failure and death
following liver transplantation,
2 . Examination of the influence of novel epidemiological, clinical, biochemical and
immunological factors in identifying and monitoring recipients at risk of these 
disorders.
3 . Assessment of new therapeutic strategies in the prevention and management of
selected graft and systemic complications.
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CHAPTER 2
AETIOLOGY OF LIVER TRANSPLANT FAILURE
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2.1 BACKGROUND AND INTRODUCTION
Over 6000 liver transplantations are presently performed annually with approximately 20 - 
30% of procedures failing within the first post-operative year. A liver transplant can either 
fail from inadequate graft function necessitating regrafting or a graft or systemic 
complications which results in death. Unlike renal or cardiac transplantation, where 
rejection of the graft is the predominant pathological process leading to transplant failure, 
the circumstances which result in graft loss following hver transplantation are much more 
varied. This heterogeneity in the absence of a recognised system for classifying the 
various processses hinders proper analysis of factors involved as well as clinical and 
scientific communication in this field.
I
The two major studies on early mortality and graft failure in the current Hteratuie were 
reported from the Pittsburgh programme and are based on historical experience between 
1981-84 and 1984-88 respectively (Cuervas-Mons etal 1986b, Quirogaet al 1991). The
latter analysis performed in graft failures included only those transplant events which
:
proceeded to retransplantation and accordingly only identified those pathological 
mechanisms which primarily affected the graft and resulted in loss of function. A 
classification scheme based around such ‘allograft failures’ would provide only hmited 
and selected information on the total pathological events which liver recipients am exposed 
to, since the majority of transplant failures are in the context of patient death. A further 
study, from the Nebraska group, attempted to stratify the causes of post-transplant
I
mortality on the basis of an analysis of 44 deaths between 1985 and 1988 (Shaw et al 
1989). In that systematic examination, the authors divided the causes of all deaths into 
four categories - deaths related to pre-transplant condition, failure of the allograft to 
provide adequate early function, failures of immunosuppression and finally a 
miscellaneous group. However, similar to above, a classification based on the clinico - 
pathological events which led to a death or graft loss is more mfoimative than one centred 
around the immediate cause of death. The terminal event is often in the context of sepsis 
and multi-organ failure and such terms provide no infoimation on the major underlying 
pathology.
A standardised classification of the clinico-pathological causes of hver transplant failures i
is required. Such a scheme would promote interpretation and comparison of the results
emerging from both individual transplant programmes, registries and large multi-centre
trials. A consensus use of nomenclature should also facihtate internal and external audit #
and permit easier identification of changing clinical patterns which accordingly could serve
as a basis for directing clinical and research resources to those areas of particular need.
In this investigation, a prospective analysis of chnico-pathological events recorded in 126 
consecutive primary transplant failures over a recent three year period in the Kings 
College Hosptial liver transplantation programme was performed. On the basis of the 
precise clinical syndromes which were considered the primary and predominant morbid 
event leading to transplant failure, a classification encompassing the observed clinico - 
pathological processes was proposed. This investigation, by identifying the present major 
causes of transplant failure, serves as a basis for the subsequent studies in this thesis 
which examines strategies in the identification, assessment and modulation of serious 
graft injury.
41
2.2 SU BJECTS
2.2.1 Patients
126 consecutive primary graft losses either requiring retransplantation or leading to death 
which occurred in liver transplant recipients between 1/1/90-31/12/93 were determined 
and examined. This study cohort was derived from the population of primary liver 
recipients who were transplanted in this centre since its inception as an independent 
transplant centre in 1988. AH patients transplanted within the combined Cambridge-Kings 
College transplant programme were excluded from this analysis (data incomplete in a 
significant proportion).
2.2.2 Methods
The primary and predominant aetiological syndrome which contributed to the transplant 
failure was determined following a combined clinicopathological examination. 
Specifically, a review of the clinical events leading up to the graft loss and 
histopathological examination of the explanted graft (where retransplanted) or perimortem 
percutaneous biopsy specimens was performed. Post-mortem reports were available in the 
majority of deaths. All laboratory and imaging investigations were taken into account in 
allocating the major cause of failure.
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2.3 RESULTS
2.3.1 Clinical description
3
The study population comprised 65 males and 62 females with a mean age of 36.8 ± 1.8
A.'!
years (range 0.1 - 67 years). The aetiological categories of the primary transplant 
indications were PBC 19, PSC 8, HBV 11, HCV 6, non A non B (NANB) 9, biliary
atresia 9, ALF 23, AIH 8, ALD 6, hepatic malignancy 4 (HCC 1, metastatic carcinoid 1, 
cholangiocarcinoma 1, haemangioendothelioma 1), cryptogenic cirrhosis 2, disorders 
with a co-existing hepatic malignancy 9 (cirrhosis and HCC [8], PSC and 
cholangiocarcinoma [1]), and miscellaneous causes (13).
From the 127 transplant failures, 100 resulted in patient death and 27 from 
retransplantation. The majority of these losses occurred within the first post-operative 
month with greater than 50% by the 60th post-operative day. Transplant failures beyond |
one year were rare in this cohort (figure 2.1),
On the basis of the clinical syndrome and accompanying pathological features of the graft 
(where appropriate), the antecedent disorder(s) which were directly related to the graft 
losses aie summarised in table 2.1. Allograft rejection was the largest single aetiological 
category with significant variations in the contributions from the different rejection 
syndromes. Hyperacute rejection did not account for a single case of graft failure with the 
proportion of losses attributable to intractable acute cellular rejection also low at 4 cases 
only. All of these latter cases occuned in the first month post-transplant. In contrast, graft 
failure secondary to development of chronic allograft rejection was experienced by 26 
(20%) patients. The mean post-transplant period for chronic rejection resulting in graft
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loss was 251 days (range: 20-854 days). Technical complications resulted in transplant 
failure much earlier in the post-transplant phase with hepatic artery thrombosis / stenosis a 
common proceeding event to graft failure accounting for 18 (14%) cases (12 of whom 
died subsequently) at a median of 53 post-operative days (range: 1-288 days). The other 
major technical complication present in this series was abdominal bleeding which led to 
death in 9 patients. Systemic or graft sepsis leading to death or retransplantation as a 
primary event was present in 16 patients, with this complication particularly common in 
those recipients tiansplanted for acute liver failure. Disease recunence leading to death or 
regrafting was, in this present series, restricted to viral or malignant piimaiy transplant 
indications. The other major causes of transplant failure arose unexpectedly in specific 
organ systems. Cardiovascular events (myocardial infarction 2, cardiac failure 3, 
pulmonaiy hypertension, pulmonary embolism and tamponade) led to death in 8 patients. 
Fatal cerebral complications comprised cerebral coning in 2 patients, cerebrovascular 
accident 2, intracerebral haemonhage 3 (mycotic embolism 1), accounting for death in aU 
7 cases in the eaiiy post-operative phase. Gastrointestinal bleeding and bowel perforation 
was a comparatively rare cause of death (2 cases each). The development of any of these 
organ-system complications precluded retransplantation. Miscellaneous events which 
caused transplant failure included acute graft-versus-host-disease in 2 patients, non - 
thrombotic graft infarction (massive haemorrhagic necrosis) 2, pulmonary heamorrhage 
and Stevens-Johnson syndrome in 1 case each. De novo malignancy was a rare 
complication accounting for 2 deaths only (both post-transplant lymphoproiiferative 
disorders).
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Figure 2.1 Timing of transplant failures. Majority occurring in the early 
post-operative period usually before the firs t hospital 
discharge.
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Table 2,1 Clinical diagnoses leading to death or retransplantation 
(transplant failures) in 127 consecutive cases
Transplant failure
D iagnoses Deaths Retransplants Total
Rejection 14 16 30
intractable 2 2 4
chronic 12 14 26
Primary graft non-function 8 3 11
Sepsis 13 3 16
Hepatic artery thrombosis/stenosis 15 3 18
HaemoiThage 9 0 9
Gastrointestinal 5 0 5
bleeding 2 2
petforation 2 _ 2
torsion 1 1
HBV recurrence 4 1 5
Malignancy recuiïence 8 0 8
hepatocellular carcinoma 3 3
cholangiocarcinoma 3 3
haemangioendothelioma 1 1
carcinoid 1 1
De novo malignancy 2 0 2
Cardiovascular 8 0 8
myocardial infarction 2 2
cardiac failure 3 3
pulmonary hypertension 1 1
tamponade 1 1
pulmonary embolism 1 1
Cerebral 7 0 7
cerebral oedema 2 2
cerebrovascular accident 2 2
intracerebral haemorrhage 3 3
Graft-versus-host disease 2 0 2
Massive haemon'hagic necrosis 1 1 2
Miscellaneous 4 0 4
Stevens-Johnson syndrome 1 1
pulmonary haemorrhage 1 1
de novo HCV 1 1
unclassified 1 — 1
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2.3.2 Stratification of Transplant failure TGraft failure and death)
From the description of the underlying causes of transplant failures described above, a 
classification on the basis of the predominant underlying clinico-pathogenic mechanism 
can be proposed: This classification has 8 categories: 1) Pretransplant clinical status of the 
recipient n=14, 2) Primaiy graft dysfunction n=12, 3) Technical complications n=25, 4) 
Immunological n=34, 5) Disease recunence n=13, 6) Immunosuppression-related n= 12, 
7) Primary organ system failure n= ll and 8) Miscellaneous n-6 (figure 2.2).
The general medical status of the recipient immediately prior to transplantation was 
considered to have predisposed directly to the graft loss in a significant proportion (11%) 
of recipients. This category essentially comprised 3 separate patient groups. Those in 
whom there was unrecognised cardiovascular or cerebral pathology (coronary artery 
disease 2, pulmonary hypertension 1, inadequate cardiac reseive 2, aortic dissection 1, 
cerebral oedema 2). A second group was made up of patients where there was 
unrecognised infection at the point of transplantation (typically patients undergoing 
emergency transplantation for ALF). A final group were characterised by mahiutrition and 
general debility who typically had prolonged intensive care admissions terminating in 
death. The second category of primary graft dysfunction is a term which could be 
employed to encompass those recipients in whom impaired donor organ viability leads to 
either primary graft non-function (PGN) or early graft dysfunction and which proceeds 
eventually to graft failure. Technical graft failures is a third category which comprises 
those events directly attributable to the surgical procedure and would predominantly be 
made up of vascular events or post-operative haemonhage. Immunological graft failure 
would be a term to encompass all forms of transplant failure attributable to rejection and 
graft-versus-host-disease processes. Recurrence of the primary transplant indication
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remains a major cause of graft damage and loss and merits a separate category. Those 
primary events which are either initiated or aggravated significantly by I
immunosuppression and which would include de novo infection and malignancy and 
direct toxicity are categorised as immunosupression-related transplant failures. Events not 
directly attributable to either graft pathology or any of the other categories listed above and I
which primarily affect systemic organs could be classified under the umbrella tenn ‘organ - 
system’ transplant failure. Finally, there are causes of graft failure or death which cannot 
be readily placed in any of the above categories and require a final ‘miscellaneous’ 
grouping. The time following transplantation when these categories accounted for the 
transplant failures are shown in figure 2.3.
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2.4 DISCUSSION
This investigation reports a large and modern series of consecutive liver transplant 
recipients in whom the primaiy transplant failed resulting m either death or regrafting. As 
such, it identifies and provides data on the contributing roles of the disparate pathological 
processes which can result in failure of a liver transplant. The transplant registries 
although providing accurate data on the influence of demographic variables on outcome 
are less valuable when determining the precise causes which lead to a transplant failing. In 
this regard, single-centre data and experience should be more accurate with documentation 
of all losses based on caieful assessment of the clinico-pathological course.
From the data, it is clear that the early post-transplant period remains the most hazar dous
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Figure 2.2. Proportions o f the 8 clinico-pathological categories which are 
associated with transplant failure
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Systemic or graft sepsis, as a primary cause of transplant failure (normally death), was 
also a common event in this period and most likely reflects the combined 
immunodeficiency which results from impaired liver function and introduction of high - 
dose induction pharmacological immunosuppression. Finally, organ failures (the majority 
of which were unexpected) arising from the cerebral, cardiovascular and gastrointestinal
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with this phase being exposed especially to the major risks of either inadequate organ 
viability or technical complications. Primary graft dysfunction remains a difficult event to 
predict and thereby avoid. Clinical and histological evaluation of the donor liver is not 
sufficiently sensitive to exclude those organs which will not provide adequate function.
Although several dynamic measurements of hepatic function prior to organ retrieval have |
been proposed as adjuncts in improving organ selection (see section 3.1), these have not 
been widely employed in current clinical practice. The increasing waiting lists and 
plateauing of donor numbers (see section 1.2) is enforcing increased use of what were 
previously considered inferior livers. Despite this expediency, the rates of this ïï
complication are presently not increasing in this unit. These results contiast distinctly from 
the previous report of allograft failures from the University of Pittsburgh. In that report 
(experience from 1984-1988), PGN accounted for 53 (30%) of 177 primary graft losses.
Although these studies are not directly comparable (since the present investigation 
examined all transplant failures), PGN accounted for only 12 cases from the total of 126 
transplant failures. In the Pitt-UNOS registry, prhnary graft failure accounted for 13.5% 
of deaths within 1 week of transplantation (Belle and Detre 1993). Technical 
complications resulting in transplant failure were in this series predominantly related to 
graft ischaemia secondary to hepatic artery thrombosis or post-operative bleeding and 
predictably were associated with transplant failure when occurring in the early post - 
transplant phase. Several of the patients in the above 2 groups ultimately died from a 
terminal infection episode which was considered secondary to the initial complication. %
systems led to a signficant proportion of early transplant failures. These complications 
caused mortality rather than primary graft failure with liver function usually intact at the 
time of death. In the later phases following transplantation, the major pathological event 
causing graft failure was rejection with smaller contributions from primary disease 
recurrence and complications secondary to immunosuppression. The sharp decline in 
transplant failures beyond the first 2-3 months is in keeping with the data from the 
transplant registries. They also show that chronic rejection (which was amenable to 
regrafting in 50% of cases in this series) accounts for the largest proportions of second 
transplants (Belle et Detre 1993).
No formal and standardised classfication scheme exists for stratifying liver transplant 
failures. In this study, an attempt to devise a scheme based around the recent experience 
of this unit has been performed. This 8-point classification takes into account all the 
clinico-pathological factors identified from this investigation which predisposed to 
ultimate transplant failure. The placement of a transplant failure in a specific category of 
this classification should be based on all available investigations and await the post - 
mortem findings where performed. Specifically, all 4 of the categories in the classification 
proposed by Byers-Shaw for post-transplant mortality have been included in this new 
scheme, i.e: a category reflecting the pre-transplant clinical status, surgical / technical 
complications, rejection (under immunological graft failure) and also a miscellaneous 
group. Of these, the pre-transplant clinical status is perhaps the most subjective category 
to place individual cases. The importance of the general medical status with respect to 
nutritional and functional status, age and the presence of specific conditions such as renal 
failure is well-recognised (Belle and Detre 1993, Cuervas-Mons et al 1986). If these or 
other parameters are considered to represent the predominant underlying cause of death or 
retransplantation, then this should be the preferred category. Allocating transplant failures
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to this group is easier if investigations reveal specific pre-transplant pathology which led 
directly to death (e.g. presence of sepsis or cerebral oedema present immediately 
pretiansplant causing death post-operatively). Technical events and immunological failure 
(rejection or graft-versus-host disease) are self-explanatoiy categories. In addition, 4 new 
categories are proposed which take into account the larger and more recent experience 
now available and the recognition of new post-transplant syndromes since the early report 
from Nebraska. A separate category of primary graft dysfunction is proposed which 
would include the spectrum of impaired initial hepatic function secondary to organ 
viability and storage. At one extieme this would result in PGN or in less severe cases an 
impainnent in function which ultimately and directly leads to either a requirement for graft 
replacement or in death (the latter event often in the context of multi-organ failure and 
sepsis within the first 2 post-operative weeks). Diagnosing and placing transplant failures 
under disease recurrence should be comparatively simple for vh al and malignant disorders 
but more problematic for immune or biliaiy disorders where such a diagnosis may be 
contentious. A new category for immunosuppression-related complications is justified to 
reflect the considerable morbidity and occasional mortality secondary to de novo infection 
episodes and late malignancies (especially post-transplant lymphoproliferative disorders 
and others) which are attributable to the phaimacological inhibition of natural immunity.
In this classification, no separate category for sepsis as a cause of transplant failure is 
included. Systemic infection episodes normally either reflect impaired graft function (and 
accordingly would be classified under an appropriate category) or, especially in the 
presence of normal liver function, are directly attributable to immunosuppression. 
Similarly, isolated sepsis of the graft which is a rare clinical finding in this unit’s 
experience is restricted to either grafts which either are ischaemic or have biliary drainage 
disorders or finally affects recipients transplanted for acute liver failure (i.e reflects pre­
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transplant clinical status). AU of these predisposing pathologies can be placed in categories 
within the proposed classification. A separate category of transplant failures secondary to 
primary organ-system failures is proposed. In this series, many of these complications 
were attributable to disorders present at the time of transplantation and accordingly should 
be classified under pre-transplant clinical status (e.g. coronary artery disease leading to 
myocardial infarction). Certain transplant failures cannot be placed in the other proposed 
categories and are of sufficient number to justify this individual category. A final and 
potentially small category is proposed to place those patients who experience a transplant 
failure from miscellaneous aetiologies and which are not readily placed in those listed 
above. For example, the cases of non-thrombotic graft infarction have been placed in this 
category. This complication, which was a common cause of retransplantation in the 
Pittsburgh series (termed ischaemic graft injury), is characterised by initially adequate 
early graft function followed by severe deterioration without major vesssel insufficiency 
around the 4-10 post-transplant day. As such it appears not to represent an organ viability 
/ preservation problem and it is also presently not possible to attribute the graft failure to 
rejection or possibly disease recurrence in those recipients transplanted for NANB 
hepatitis. We also placed a case of de novo HCV infection which progressed to graft 
failure in this final category.
As with any proposal for a classification with respect to clinicopathological events, a 
potential for overlap between the different categories exists e.g. a patient with chronic 
rejection is managed with increased immunosuppression and eventually dies of CMV 
pnuemonia. In such an instance the cause of the transplant failure would primarily be 
rejection (an immunological transplant failure). If programmes wish to record the 
aetiology of the terminal cause of death, then the same categories could be used for 
stratifying causes of mortality rather than as transplant failure (so in the above instance the
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transplant failure would be immunological but the cause of immediate death would be 
immunosuppression-related).
The proposed terminology and classification should enhance clinical data management and 
communication as well as directing programmes to areas of clinical deficiencies.
Investigative strategies and protocols to reduce liver transplant failures should standardise
'on nomenclature in the design of the study and subsequent reporting of results. New large 
multicentre trials of immunosuppressant agents where patient and graft survival are 
principal end-points should address the aetiological categories of transplant failure within |
a system such as the one proposed.
The categories devised in the present classification serve as a basis for the general areas 
examined in relation to assessment and modulation of post-transplant complications 
examined in this thesis. Assessment and management of primary graft dysfunction is I
examined in chapter 3 and 10 respectively. Rejection, which remains the major cause of 
late graft injury, is examined with respect to identifying a high risk category in chapter 6, 
a novel immune marker in chapter 5 and finally the potential value of the new 
immunosuppressant agent FK506 (tacrolimus) in controlling the process in chapter 8. The 
importance of pretransplant clinical status is investigated in a high-risk group of 
emergency recipients transplanted for ALF in chapter 7 and the potential for modulation of 
HBV-related disease recurrence in chapter 9. A subgroup of technical complications 
(vascular complications) are assessed in chapter 4. Finally, the potential for alleviating 
immunosuppression-related transplant failures is examined through the ultimate step of |
withdrawal of the pharmacological agents in chapter 11.
CHAPTER 3
RELATIONSHIP BETWEEN EARLY LIVER GRAFT VIABILITY AND
ENZYME ACTIVITIES IN EFFLUENT PRESERVATION SOLUTION
3.1 BACKGROUND AND INTRODUCTION
Immediate and early graft function following Hver transplantation is largely detennined by 
the quality of the donor organ at retrieval and the secondary influences of hypothermic 
preservation, flush and reperfusion injury. These processes, as outlined in section 1.2, 
may also play a role in several post-operative complications including frequency of 
rejection, the development of vascular and biliaiy complications and overall graft survival. 
As was demonstrated in the previous chapter, graft failure secondaiy to deficient organ 
viability and storage injuiy is a major cause of retransplantation and mortality.
Attempts to predict graft viability based upon assessments of the donor liver prior to 
retrieval have the potential advantage of being clinically useful in the process of graft 
selection (Oellerich et al 1989, Yamaoka et al 1992). However, in clinical practice a 
reliable and readily performed parameter has not been identified, with donor organ 
assessment still based upon loosely defined clinical and, in some centres, histological 
criteria (D Alessandro et al 1991). Markers of donor liver status prior to retrieval are also 
of limited and mdeed diminishing value due to the cuiTent clinical requirements which are 
enforcing increased utilisation of previously considered inferior quality grafts. This 
practice reflects the widening gap between organ donation rates and recipient waiting-lists 
present in many programmes. Hence, markers of graft viability which reflect not only the
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donor organ status but also the injuries sustained following procurement may be of more 
practical value. Accordingly, a measurement of graft injury performed at the end of the 
ischaemic period should provide, by incorporating most of the post-procurement phases 
of injury, a more sensitive guide to viability than if performed on the donor. Such a 
measurement, albeit performed once the transplant is irretrievably underway, could well 
serve as a useful clinical parameter in the prediction of early graft function and additionally 
could be employed to examine the effects of experimental strategies in donor management 
and new retrieval and preservation / flush protocols.
In this investigation, liver enzyme activities present in the organ preservation solution 
washed out from the graft at the end of ischaemic storage and prior to reperfusion were 
examined. It was postulated that release of enzymes into this fluid over the ischaemic 
period may reflect the functional integrity of the graft. Two standard laboratory indices of 
hepatocellular damage, aspartate aminotransferase (AST) and lactate dehydrogenase 
(LDH) were examined. These enzymes were chosen because of their different localisation 
in the hepatocyte (LDH - cytoplasmic predominantly, AST - mitochondrial and 
cytoplasmic). Additionally, because of evidence indicating the importance of 
micro vascular integrity in early graft function and the particular damage to sinusoidal 
lining cells (SLC) during hypothermic preservation, two recently proposed markers of 
sinusoidal cell damage, (purine nucleoside phosphorylase (PNP) and an isoenzyme of 
creatine kinase (CK-BB) were also evaluated (Rao etal 1990, VaubourdoUe et al 1991). 
PNP is reported to be primarily localised in the cytosol of hepatic endothelial and Kupffer 
cells and is postulated to represent a good index of oxidative injury to the liver 
particularly following reperfusion.
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3.2 SU BJECTS
3.2.1 Patients and samples
Effluent preservation fluid was collected from 53 randomly selected (34 consecutive) 
primary elective adult hver recipients following gravity flushing of the graft, with 0,15M 
NaCl at room temperature, after completion of the suprahepatic inferior vena cava (IVC) 
anastomosis and immediately before that of the portal vein. Samples were collected at 1 
minute intervals from the infrahepatic IVC over a five minute period into plain tubes and 
centrifuged (2000g for 10 minutes) to remove cell debris and stored at -2Q0C prior to 
assay. Donor organ retrieval was performed in the standard manner with UW solution at 
40c  used for organ cooling and preservation. Immunosuppression in the study population 
was standardised to a conventional CyA based triple therapy regimen. All transplants were 
ABO isocompatible. Recipients in whom the pretransplant clinical status is recognised as 
significantly influencing early post-operative outcome were excluded (emergency 
transplantation for acute hver failure, presence of significant preoperative renal failure or 
retransplantation). Two patients in whom post-operative technical complications were 
considered to have significantly influenced early graft function were also excluded (HAT 
1, hepatic artery stenosis (HAS) 1).
3.2.2 Biochemical measurements
Total AST and LDH activities were assayed using the automated Spotchem SP-4410 
analyzer (BioMen Ltd., Croydon, UK). PNP activities were determined as previously 
described (Hoffee et al 1978). Total CK was determined using the optimised standard 
method recommended by the Deutsche GeseUschaft fur Khnische Chemie performed on a 
Cobas Bio analyzer (Roche Products, Welwyn Garden City, UK) at 3Q0C. CK
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isoenzymes were separated by agarose electrophoresis using the Helena REP automated 
electrophoresis system (Helena Laboratories, Gateshead, UK). The resulting bands were 
reacted with the substrate creatine phosphate and in a coupled series of reactions a change 
from NAD to NADH occurs which can be scanned densitometrically under UV light to 
obtain a percentage for CK-MM, CK-MB and CK-BB. The CK-BB activity was then 
calculated from the total CK. Enzyme activities in the effluent fluid are presented as area ~ 
under-the-curve [AUC] totals derived from the 5 serial one minute samples.
3.2.3 Assessment of early graft viabilitv
Early graft viability was assessed by measurement of standard laboratory indices of liver 
function for the first 5 days following transplantation (daily serum AST and total 
bilirubin, prothrombin time: international normalised ratio [INR]) and graft survival at one 
month post-transplant. Correlation coefficients were calculated to examine what 
relationships existed between activities of the different effluent enzymes and whether these 
activities were related to the post-transplant serum liver function tests and / or the presence 
of impaired graft function. This latter condition was defined as being present in patients in 
whom the serum AUC AST totals during post-operative days 1-3 exceeded the population 
mean activity plus one standard deviation. Enzyme activities were also examined in 
relation to the period of graft cold ischaemia in addition to the circulating platelet count 
(AUC totals of post-transplant days 1-5) and frequency of rejection in the first month. The 
combined cold and rewarming (poïkilothermie) ischaemic time was defined as the interval 
from donor aortic cross-clamp until recipient portal vein unclamping.
Results are expressed as mean ± standard error mean (SEM). Differences were calculated 
for statistical significance by the t-test or non-parametiic (Mann Whitney U) test where 
appropriate. P values less than 0.05 were considered to be statistically significant.
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3.3 RESULTS
3.3.1 Effluent preservation fluid enzyme activities
The first sample retrieved during initial graft rinsing contained between 79-94% of the 
total content for all four enzymes measured. Insignificant amounts of the enzymes were 
present in the wash-out fluid collected from the later 3 -5  minute sample time-points. The
mean (SE) [range] AUC activities of the 2 markers of hepatocellular damage (AST 1440 
(295) [35-10800] lU/L and LDH 4540 (739) [500-31700] lU/L) in the five samples were 
considerably more elevated tlian the two enzyme markers of sinusoidal cell damage (PNP 
119 (30) [0-521] lU/L and CK-BB 53 (18) [0-473] lU/L). Large variations in enzyme
:.ï:activities between patients were present and are reflected in the standard errors and ranges.
The ratio between the AST and LDH activities in washout fluid was similar to tlie ratio of 
reference ranges in serum (-  1:4), The CK-BB assay, as performed in this study, was 
unable to detect this isoenzyme in a significant proportion of patients (n=9, 18%) with 
other samples having activities at the lower end of the assay sensitivity. The PNP assay 
did not detect any significant activities m the wash-out fluid of 5 patients.
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ICorrelations between the effluent enzyme activities were examined. Strong correlates existed between the two hepatocellular enzymes ([ASTeffiuent (e)] vs [LDHe] r=0.75, 
p<0.001). Unexpectedly, similarly sti'ong relationships were also found between tliese 2 
enzymes and PNP activities (where detectable): [ASTJ vs [PNPg] 1-0.906, p<0.001 and 
[LDHe] vs [PNPg] r==0.833, p<0.001. No correlation between ASTe or LDHe and CK- 
BBe was present and unexpectedly, no relationship between the 2 proposed markers of 
sinusoidal cell injury could be demonstrated ([PNPe] vs [CK-BBg] r=0.16, ns).
3.3.2 Relationship between effluent enzyme activities and early graft viability
In those transplants where graft loss occurred within the first post-operative month 
(n=10), analysis of the effluent fluid enzyme activities demonstrated that the median ASTe 
concentration was significantly elevated in these recipients compared to those in whom the 
graft survived (1840 vs 695 IU/1, p<0.05) (table 3.1). Median LDHg and PNPg activities 
were also higher in graft non-survivors but did not achieve statistical significance. With 
respect to patients where there was a significant impairment of early graft function (see 
definition above) (n=9), none of the enzyme activities in the effluent fluid were 
significantly elevated compared to those recipients with non-impaired graft function.
A statistical correlation was found between the effluent ASTe activity and the post - 
operative ASTserum (s) activity (r=0.32, p<0.05). The post-operative ASTg activity was 
significantly more related to the AST© activity than the other measured effluent enzymes 
(LDH r=0.26, PNP r=0.18, CK-BB r=0.04).
When the effluent ASTe and LDHe activities were examined in quartiles, relationships 
with graft outcome and ischaemia were demonstrated (table 3.2). Those patients in the 
lowest effluent fluid ASTg quartile had the shortest period of cold and rewarming 
ischaemia and experienced only one graft loss (92% one month graft survival). Whereas 
those patients in the highest ASTe quartile group also had the highest ASTg activities and a 
significantly inferior early graft survival (62% one month graft survival, p<0.05). No 
relationship between effluent ASTg activities and the prothrombin time / INR was present. 
With respect to effluent fluid LDHe activities, a similar relationship between increased 
activities and prolonged ischaemia and high post-operative ASTg activities was noted. 
Those patients in the higher effluent AST quartile groups had a progressive tendency to 
increased rejection frequency in the first month post-transplant (group 1, 4 of 13 (31%),
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group 2, 4 of 13 (31%). group 3, 7 of 13 (54%) and group 4, 8 of 12 (67%), No 
relationship between activities of the four enzymes in the effluent fluid and early post - 
operative platelet count was shown. For example in relation to the AST quartile groups, 
no significant difference in the median AUC platelet count of the day 1-3 totals between 
the quartiles was shown (189, 173,90 and 192 xlQ9/L in groups 1-4 respectively).
3.4 D ISCU SSIO N
Determination of changes in the biochemical composition of the solution preserving a 
donor organ is an obvious but neglected source of information regarding the processes 
which occur during hypothermic storage. In this study, significant release of several hver 
derived enzymes into this fluid was demonstrated. Moreover, the activity of AST was 
found to be a discriminative marker for post-operative graft viability providing further 
evidence for the importance of donor organ quahty and preservation in determining early 
liver graft function. That an enzyme released from hepatocytes was valuable is notable 
given the general belief that these cells are spared the effects of preservation injury as 
compared to non-parenchymal ones (Blankensteijn et al 1991, Clavein et al 1992). 
Whether other measurements performed in effluent preservation fluid, such as 
determination of lactate and ammonia levels which have been shown to be useful 
discriminants of allograft viabihty in an animal model would be of superior value clinicahy 
to the hver-derived enzyme is unknown (Shimada et al 1993).
With respect to the two different hepatocellular enzymes, the activities of effluent AST 
were more closely related to post-transplant graft function than those of LDH. This result 
is consistent with a previous study performed in an isolated rodent liver perfusion model 
which similarly demonstrated the superiority of AST activities in the circulating perfusate -
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Table 3.1. Enzyme activities in the effluent preservation flu id  collected 
from recipients with severely impaired graft function within 
the first 5 days following transplantation and in those who 
experienced graft loss by I  month.
GRAFT FUNCTION GRAFT SURVIVAL
normal
(n=42) impaired(n=9)
p value survivors
(n=41) non-survivors(n=10)
p value
Effluent* ,■
hepatocellular
AST 866 1300 0.13 695 1840 <0.05LDH 3122 3670 0.2 2730 3150 0.2
sinusoidal
PNP 69 93 ns 64 89 nsCK-BB 24 34 ns 35 46 ns
Serum **
AST 746 2800 <0.05 1200 2300 <0.05INR 3.8 5.6 0.1 4 3.9 ns
*area-under-curve totals, **area-under-curve totals post-transplant day 1-3
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Table 3.2 Effluent flu id  enzyme activities presented in quartile groups 
in relation to graft function and survival.
Graft Outcome
Effluent Enzyme Activities Graft survival 
(1 month)
AST*
(lU/L)
bilirubin**
(umol)
INR*
Effluent AST (W/L) 
Quartile: mean [range] 
125 [30-175] (n=13) 12 (92%) 788 538 4.9
440 [188-866] (n=13) 12 (92%) 624 628 4.1
1267 [867-1564] (n=13) 11 (85%) 1130 912 3.8
2817 [1654-10820] (n=12) 7 (58%) 1340 901 3.6
Effluent LDH  
Quaitile
855 [500-1322] (n=13) 13 (100%) 695 507 3.9
2271 [1444-3145] (n=13) 9 (69%) 788 584 4.6
4707 [3309-6331] (n=13) 11 (85%) 764 938 3.9
10650 [6866-31762] (n=12) 9 (75%) 2060 853 4.1
* median area-under-the-curve post-transplant day 1-3 totals
** median area-under-the-curve post-transplant day 1-5 totals
6 4
- as a discriminative test of liver viability compared to LDH (In et ai 1987). Whether the 
cellular localisation of AST, which is located in both the cytoplasmic and mitochondrial 
compartments, in contrast to LDH which is cytoplasmic only, explains the superior 
predictive value is speculative. However, this may be an important difference in view of 
the previous demonstration that the sensitive test of hepatocyte mitochondrial function 
(arterial ketone body ratios) is of value in discriminating donor organ viability prior to 
retrieval (Yamaoka et al 1992). Moreover, a close relationship between loss of 
mitochondrial function and hypothermic preservation was found in a rodent model (Kim 
et al 1992). Further studies evaluating the mitochondrial fraction of total AST or of other 
mitochondrial markers in effluent UW fluid may be valuable. The closest relationship 
between AST activities in this fluid was with serum activities of this enzyme and 
marginally less with semm bilirubin. The absence of a relationship with prothrombin time 
probably reflects the variable loss and administration of coagulation factors peri - 
operatively.
PNP is not a specific marker of sinusoidal cell function with variable release from both 
parenchymal and non-parenchymal cells (Mochida et al 1992, Brass and Mody 1995).
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Several previous studies have demonstrated the functional importance and particular 
susceptibility of sinusoidal Iming cells (SLC) to hypothermic preseiwation and reperfusion 
injury (for reviews see Blankensteijn et al 1991, Clavein et al 1992, CaldwelLKenkel et al 
1989, Currin et al 1990). It was therefore surprising to find no clear relationship between 
early post-operative graft function and the markers of SLC damage evaluated. These 
results do not necessarily contradict the previous findings referred to as technical 
limitations for those markers exist. The close coirelation which was found between PNP 
activities and the hepatocellular enzymes would suggest that this enzyme may be also 
released from hepatocytes and not just from sinusoidal and Kupffer cells as had originally
been suggested (Rao et al 1990). Indeed, more recent reports have also suggested that
Activities of CK-BB also turned out to be a disappointing method of assessment of SLC 
damage with activities often being undetectable. Whether levels of hyaluronic acid would 
be a better index of sinusoidal damage or early graft viability as has been shown in a study 
of small bowel preservation is unknown (Mueller et al 1993). Since SLC are especially 
sensitive to reperfusion injury, it is perhaps not surprising that markers of this cell damage 
were low in the particular samples chosen to study which were collected prior to 
reperfusion.
Since enzyme activities present in the liver preservation fluid were evaluated at a single 
time point, it is difficult to draw conclusions as to the contributions to the total measured 
amounts of enzymes from the various processes which could have caused cellular release 
following organ procurement. To determine the influences of graft flushing, hypothermic 
preservation and rinsing, an examination of serially collected preservation fluid samples 
would be required. Such a study could not be performed clinically except in the context of 
redundant or rejected donor livers. From the present data, although a relationship between 
enzyme activities and the period until portal vein unclamping (i.e cold and rewarming 
ischaemic periods) was demonstrated, it is clear this is not the only variable to account for 
the significant differences in activities noted between patients. Graft quality at retrieval is 
probably the most significant variable in determining susceptibility to storage and of 
subsequent enzyme release into the preservation solution. Another potential source of 
enzyme release into the preservation fluid is the effect of the initial in-situ flushing of the 
liver during retrieval and of course the rinsing at the end of preservation the efflux of 
which was collected in this study. Suggestions that UW fluid used for initial flushing is 
superior to other solutions has presently not been substantiated and it remains unclear 
whether variations in this protocol would play a major role in enzyme release over the 
preservation period (Adam et al 1991, Morgan et al 1990). Similarly, various physical 
characteristics of the graft rinsing solution may be important in determining early organ
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viability through effects on mitochondrial function (Takei et al 1991). Saline rinsing, as 
performed in this study, has significant limitations with this solution having no oncotic or 
antioxidant properties. Carolina rinse may have advantages as a flush solution (Currin et 
al 1990, Sanchez-Urdazpal e ta l 1993). A significant limitation to the determination of 
effluent fluid composition is that no information on the impact of isolated cold or in 
particular warm ischaemia can be assessed, with the latter period increasingly recognised 
as playing a significant role in early graft function (Dunne et al 1994)
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CHAPTER 4
ASSESSMENT OF VASCULAR COMPLICATIONS BY ANGIOGRAPHY 
AND RELATIONSHIP TO GRAFT DYSFUNCTION AND SURVIVAL
4.1 BACKGROUND AND INTRODUCTION
From the data presented in chapter 2 and other recent reports, one of the major persisting 
causes of graft loss is an arteriopathic process either involving major vessels or the 
microvasculature of the liver graft. In addition to the lesions caused by HAT or HAS, 
vascular injury has been demonstrated in such serious graft complications as EGD and 
both acute and chronic allograft rejection. Devascularisation of a liver graft in the early 
post-operative period usually results in catastrophic graft dysfunction progressing rapidly 
to death unless surgical or thrombolytic recanalisation or preferably retransplantation is 
performed. Similar but normally less severe graft dysfunction results from segmental 
HAT or anastomotic stenosis. Vascular insufficiency from a major vascular event beyond 
the first few months post-transplant may be tolerated following development of collateral 
circulation, but complications such as non-anastomotic biliary strictures and graft 
abscesses can develop.
EGD is an umbrella term used in the present investigation to describe serious liver 
dysfunction occurring within the first seven days after transplantation and includes both 
PGN and graft function which deteriorates rapidly after an initial period of stability. This 
latter condition may result from identifiable clinical complications such as severe acute
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cellular rejection, HAT or ABO incompatibility but in many instances no clearcut 
precipitating cause can be identified, although graft ischaemia, systemic sepsis, 
preservation / reperfusion injury, viral disease recurrence and unrecognised rejection have 
been suggested as possible aetiological factors (Carithers et al 1988, Fagan et al 1992,
Hubscher et al 1989).
The vascular component to liver allograft rejection is underestimated. Histological 
assessment of a percutaneous biopsy specimen from a rejecting graft, in which few 
arterioles will be present, often does not recognise the arterial-directed element of the 
rejection process. Terms derived by histopathologists such as ‘vanishing-bile-duct - 
syndrome’ which infer damage to the biliary epithehal cells alone to describe chronic hver 
rejection reflect this limitation (Vierling and Fennel 1985). In acute cellular rejection, an 
arteritis is a poor prognostic sign but rarely recognised (Snover et al 1987). Similarly in 
chronic rejection, the presence of an obhterative arteriopathy, which is the hallmark of 
other vascularized solid organs undergoing chronic rejection, may go unnoticed in 
rejecting Hvers. This histological phenomenon normally indicates an irreversible process 
in heart, lung and renal allografts.
The diagnosis and significance of the vascular pathologies outlined above have not been 
systematically evaluated in a single study. In this investigation, a retrospective analysis of 
the findings using hepatic angiography, which is presently the optimal tool for detecting 
vascular pathology was performed. This study attempted to define the role of arteriopathic 
processes and the value of angiography in monitoring and assessing graft dysfunction in a 
series of 50 consecutive patients undergoing this examination.
i
4.2 SUBJECTS
4.2.1 Clinical groups
Fifty (50) consecutive patients undergoing hepatic angiography following orthotopic hver 
transplantation in the Kings College Hospital and Cambridge transplant programmes 
between July 1987 and March 1991 completed the study, this population representing 
9.7% of the total transplant activity of four hundred and sixty four (464) patients over this 
period. All donor livers during this period were harvested in the UW preservation fluid 
and only two patients received a graft from an ABO-incompaUble donor. The study 
population had serial hver function tests performed and most underwent assessment of the 
hepatic arterial tree with duplex doppler ultrasonography prior to angiography.
The patients could on the basis of the chnical syndrome be divided into the following three 
groups: Group A comprised eighteen patients with a chnical diagnosis of EGD — 11 
patients with PGN and 7 with delayed graft dysfunction. In each patient the peak serum 
AST activity exceeded 2000 IU/1 and the prothrombin time was greater than three times 
the control within the first seven days following transplantation. Group B were made up 
of 16 patients with chnically suspected hepatic artery obstruction, either HAT or HAS 
who presented with either biliary leakage / stricture n=5 (median time 50 days) or 
relapsing bacteraemia / hepatic abscess(es) n=6 (median time 72 days) or deteriorating 
graft function with a liver biopsy suggestive of ischaemic damage n=5 (median time 40 
days). Group C had 16 patients in whom histological features of chronic allograft 
rejection as evidenced by an absence of interlobular or smah septal ducts in 50% or more 
of portal tracts with or without an associated foam cell arteriopathy in addition to 
biochemical evidence of deteriorating graft function were present (Portmann et al 1988).
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4.2.2 Angiographic investigations
Arterial access for angiography was via the transfemoral route, an abdominal flush 
aortogram was performed initially in all patients followed by selective injections of the 
hepatic artery when an abnormality was suspected. Indirect portography by superior 
mesenteric artery injection was carried out to evaluate the portal vein if this failed to 
opacify in the flush angiogram. Imaging was performed by digital subtraction 
angiography (General Electric) and the radiographs were reviewed at a joint clinico - 
radiological conference (JK - see acknowledgements).
4.3 RESULTS
Group A : Angiograms in this group with EGD were performed at a median time of
three days (range 1-7 days). In nine of the 18 patients the angiograms were normal. Of the 
nine with abnormal angiograms anastomotic HAS and HAT were seen in two patients and 
one patient respectively. In the remaining six patients with early graft dysfunction in this 
group angiography demonstrated a characteristic appearance of delayed filling of the 
donor hepatic aitery in association with narrowing of the main recipient and donor arterial 
vessel and pruning of the peripheral intra-hepatic arterial tree. There were no apparent 
significant differences in the biochemical profile of those with and without abnormal 
angiographic appearances — normal angiogram mean AST 2186 lU/L, INR 3.6, arterial 
obstruction mean AST 2574 lU/L, INR 4.2 and arteriopathic group mean AST 2668 
lU/L, INR 3.6. All patients in this group with the exception of the three patients with 
arterial obstruction were treated empirically for acute cellular rejection with supplemental 
steroids (hydrocortisone Igram b.d. for three days, 1 gram o.d. for a further two days 
and if there was no response following this regimen, methylprednisolone Igram/day for
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three days was added). A satisfactory response to anti-rejection therapy was accepted on 
the basis of a reduction of the AST level to below 100 IU/1 and a prothrombin time not 
greater than three seconds of the normal control. This response was obtained in six 
(66.7%) of the nine patients with normal angiograms and two (33.3%) of six patients 
with diffuse arterial changes. Retransplantation was achieved in only one of the patients 
with evidence of a diffuse arteriopathy and the longer-term graft and patient survival in the 
sub-group with angiographicaUy determined changes was 33% as compared to 78% in the 
nine patients with normal angiograms. Histological evaluation of liver biopsies, obtained 
either at retransplantation or early postmortem in 12 patients, revealed a common pattern 
within the group of a severe coagulative necrosis often with a mixed but predominately 
polymorphonuclear (PMN) cell infiltrate. In those with arteriopathic changes there was 
evidence in three of the five available biopsies of acute cellular rejection in addition to 
severe graft infarction. Those patients (n=5) with a dense PMN cell infiltrate had clinical 
evidence of severe systemic sepsis.
Group B In this group with clinically suspected HAS or HAT the angiograms were 
performed at a median time of 4 weeks (range 17 days to 14 months) after transplantation. 
Either thrombosis, n=10, (figure 4.1) or stenosis, n=6, (figure 4,2) was confirmed in all 
cases at angiography. Screening duplex doppler ultrasonography performed in all patients 
had suggested the presence of arterial blockage or narrowing in only 10 of the 16 patients. 
All the stenotic lesions were present at the site of anastomosis of donor and recipient 
artery. Patients with confirmed thrombosis were listed for retransplantation, 6 of the 10 
patients undergoing the procedure, and those with clinically significant stenosis 
underwent balloon angioplasty. There was a marked disparity in prognosis within this 
group with graft and patient survival being only 10% and 30% in the HAT group 
respectively compared to 100% survival for the HAS group.
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Figure 4.1 Hepatic artery thrombosis. Absent filling o f the hepatic artery 
demonstrated on selective angiography.
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Figure 4.2 Hepatic artery stenosis. Significant anastomotic arterial 
stenosis demonstrated on selective hepatic arteriography 
(above) and relieved by percutaneous angioplasty (below).
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Group C The sixteen patients with chronic rejection in this group had angiograms 
performed at a median time of 11 months following transplantation (range three months to 
three years). Patients in this group were obseiwed for a mean follow-up period of three 
months following angiography, with regular clinical and histological review to detect any 
reversibility of the rejection process, prior to being listed for retransplantation. All patients 
in the group received a conventional maintenance triple therapy immunosuppression 
regimen of prednisolone, azathioprine and CyA. These latter levels were maintained at 
100-120 jO.g/1 {monoclonal RIA, Incstar) for the first six months following transplantation, 
hi the presence of histologically confmned chronic rejection levels were maintained at 120 - 
180 |xg/l. Two patients later in the series were switched to tacrolimus and low dose 
prednisolone as salvage therapy following clinical deterioration. A pattern of vascular 
abnormalities ranging from peripheral pruning of the intra-hepatic vasculature with 
diminished perfusion (figure 4.3A) to a constrictive sclerosing pattern of the intra and 
extrahepatic arterial tree with a beading appearance (figure 4.3B) was noted in 10 of the 
16 patients. There was evidence of a foam cell arteriopathy on standard histological 
criteria in only three of the group, all of whom also demonstrated arterial lesions at 
angiography. Graft survival in patients with radiographic changes was very poor with 
only one graft in 10 surviving, this latter patient showing a successful ‘rescue / salvage’ 
with tacrolimus. Two patients of the six with no evidence of arteriopathy either 
histologically or at angiographically spontaneously reversed the histological pattern of 
chronic rejection and now have normal graft function.
75
Figure 4.3A D evelopm ent o f  angiographie evidence o f  rejection  
arteriopathy in a patient over a four week time interval. 
Normal hepatic angiogram present at this stage.
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Figure 4.3B Chronic allograft rejection. Severe constrictive and beading 
appearances in the hepatic vasculature o f the same patient 
who now has established chronic rejection o f the allograft 
which developed over a 4 week interval.
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4.4 DISCUSSION
The findings using angiography in the present series show clearly the value of this 
investigation in the assessment and management of patients after tr ansplantation as well as 
in the prediction of outcome. In patients suffering from EGD, 33% of the patients had 
angiographic evidence of an aiteriopathic process involving both the recipient and the 
donor vasculature and this pattern was associated with reduced graft survival compared to 
those patients with anormal angiogram. The involvement of both the donor and recipient 
vasculature is fascinating and suggests a non-discriminant vasoactive process rather than 
one determined by tissue characteristics alone. EGD remains a poorly understood 
phenomenon. The descriptive pathological term, massive haemorrhagic necrosis, has been 
used in one centre to describe the histological picture of the allograft present in this 
condition (Hubscher et al 1989). In this programme, the term non-thrombotic graft 
infarction to emphasise the clinical and histological features of graft infarction in the 
absence of macro vascular hepatic arterial thrombosis is preferred. The pathological 
appearances of severe haemorihagic necrosis in the absence of major vessel obstruction, 
in conjunction with our angiographic evidence, leads to the hypothesis that 
microcirculatory failure is the common pathogenic pathway of different aetiological 
processes in this devastating complication. Acute cellular rejection has been considered by 
other groups to be the cause of early graft dysfunction and in our group there was 
supportive evidence of cellular rejection in 60% of patients as shown by histological 
examination of the graft at re transplantation or autopsy. In the 40% of patients with no 
evidence of acute rejection a common factor of severe systemic sepsis appeared to be the 
precipitating factor of the early graft dysfunction. In practical terms, from this data the 
hepatic arteriogram is the investigation of choice in this clinical situation and urgent
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Iretransplantation should be considered when an abnormal study is demonstrated.
A reduction in total hepatic arterial flow was first obseived in an experimental animal 
model of unmodified acute cellular rejection and confirmed recently in human 
transplantation using implanted doppler probes (Groth et al 1968, Payen et al 1989). 
Furthermore in a previous angiogram study, in which acute cellular rejection was 
histologically confirmed in the majority of cases, angiographic appearances were #
demonstrated similar to those above in 50% of patients (White et al 1987). The hepatic 
endothelial cell, which demonstrates increased expression of the class II major 
histocompatibility complex (MHC) antigens and may act as an antigen-presenting cell 
during rejection, is a probable target in the rejection process (Adams et al 1989). Indeed 
the presence of an arteritis on pathological assessment of liver biopsies, found in 2-5% of 
patients with other histological criteria of acute rejection, appears to be a marker for 
particularly severe acute rejection as described previously (Snover et al 1987). 
Administration of supplemental anti-rejection therapy in the group of EGD with 
aiteriopathic changes, to neat presumptive acute cellular rejection, appeared to confer no
benefit in either graft or patient survival. This suggests that the vascular pattern |
'
demonstrated on angiography represents either particularly severe, steroid resistant acute 
cellular rejection which, once established, is no longer reversible by controlling the |
rejection process or that this pattern is non-specific to rejection.
The need for angiography in the detection of laige aiterial vessel compromise was shown 
by the findings in the second group of patients with suspected arterial thrombosis or 
anastomotic stenosis. Although duplex doppler ultrasonography may be used as a 
screening investigation it’s sensitivity was only 60% as compaied to angiography. It may 
also give false-positive signals in the presence of collaterals and in the paediatric 
population (Kubota et al 1990). These results confinn the poor graft and patient survival
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in established HAT. Early recourse to angiography when this complication is suspected, 
even in the presence of a normal doppler ultrasound, is essential to obtain a definitive 
diagnosis and to expedite retransplantation where possible.
The results in patients with chronic allograft rejection demonstrate the superior sensitivity 
of angiography to routine histopathology in the detection of hepatic arterial lesions and 
suggest that the presence of arteriopathy may be an important determinant in graft 
survival. Chronic rejection arteriopathy primarily involves large septal or segmental 
hepatic arteiy branches and therefore often cannot be identified on histological assessment 
of needle liver biopsies which remains the standard method of assessing the severity of 
rejection processes. A recent paper has reported reversibility of the chronic rejection 
process in a small proportion of patients, and in this series 3 of sixteen patients 
demonstrated reversibility either by switching to tacrolimus or increasing conventional 
immunosuppression (Hubscher et al 1991). Two of these patients had entirely normal 
angiograms and the one patient with moderate aiteriopathic changes is on tacrolimus. The 
role of rejection arteriopathy in the pathogenesis of interlobular bile duct loss (a 
characteristic feature of chronic allograft rejection) is controversial, but there is increasing 
evidence of both ischaemic and immunological factors in this lesion (Oguma et al 1989), 
In the study by Oguma et ah, based on histometric analysis, the severity of bile duct loss 
was found to be proportional to the degree of obliterative arteriopathy. It remains 
unproven whether this biliary destruction is dependant on the arteriopathy or merely 
occurs in parallel. The well-described association of large biliary duct strictures with 
arterial insufficiency and chronic allograft rejection supports the hypothesis that graft 
ischaemia may be an important co-factor in intra-hepatic biliary duct destruction (O’Grady 
et al 1988a). In a recent clinical and histopathological review of chronic rejection it has 
also been argued that a sub-group of patients have a primarily vascular directed rejection 
which leads to an ischaemic hepatic injury and has a worse prognosis than biUary directed
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rejection. It is also well established in renal and cardiac allograft rejection that the |
microvascular supply to the graft is an impoitant deteraiinant in graft sumval and that the 
presence of an obliterative arteriopathy leads inevitably to graft loss (Rao et al 1988,
Chomette et al 1988). From these observations, it can be recommended that angiograms :
should be perfoiined routinely in patients with suspected chronic allograft rejection who i
do not demonstrate unequivocal aiteriopathic lesions at histopathology in view of the 
sensitivity of this investigation in detection of arterial lesions and its predictive value in 
graft survival.
The clinical limitations of the present recommendations primarily reflect the invasive 
nature of conventional angiography. However with the insensitivity of duplex 
sonographic assessment as shown in this study and others and the present clinical 
application of magnetic resonance angiography poorly characterised, clinicians for the i
foreseeable future will rely on this method as the gold-standard assessment of vascular 
graft pathology. Prospective evaluation of the place of angiography in assessing vascular 
pathology would be valuable, particularly in the area of vascular rejection which has 
previously been considered irreversible. Tacrolimus, on the basis of the isolated case 
presented herein, may modify the natural history of this process.
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CHAPTER 5
ASSESSMENT OF ACUTE LIVER ALLOGRAFT REJECTION BY 
NITRIC OXIDE GENERATION
5.1 BACKGROUND AND INTRODUCTION
Acute liver allograft rejection is traditionally diagnosed by histopathological assessment of 
a percutaneous biopsy specimen, a method which has several limitations. An inevitable 
risk of biopsy complications exists, a delay in diagnosis occurs and in certain patients the 
presence of a thrombocytopaenia or a coagulopathy contraindicates the procedure. Several 
novel techniques have been suggested to overcome these limitations. Pine-needle 
aspiration biopsies of the liver graft are technically safe and simple, but aie also limited by 
technical failures in sampling the relevant cell population and the laborious sample 
processing and interpretation. Immunological monitoring has also been proposed as an 
alternative method of assessing the rejection response. Phenotyping peripheral circulating 
lymphocytes, cytokine measurements and various other putative markers of 
immunological damage have been proposed. Difficulties arising from cost, assay 
complexity and reproducibility have limited the introduction of these methods into clinical 
practice.
The generation of nitiic oxide (NO) as an adjunct in monitoring of rejection is evaluated in 
this chapter. The synthesis of NO by the L-arginine / NO biosynthetic pathway mediates a 
wide spectrum of biological functions including roles in cytotoxic host defence 
mechanisms and in immunoregulation (Moncada et al 1991a). This pathway is induced in
8 2
inflammatory cells by various cytokines including interferon-y (IFN-y), tumour necrosis
factor-(X (TNF-a), interleukin-1 (IL-1) and interleukin-2 (IL-2), all of which have been 
shown to be involved in the pathogenesis of the in-vivo allograft response (Li et al 1991, 
Denis et al 1991, McCall et al 1991, Hibbs et al 1992, Vierling et al 1992). The induction 
of the enzyme which mediates this increased production of NO can be inhibited by 
therapeutic doses of glucocorticoids which may contribute to the anti-inflammatory 
mechanism of action of these agents (Moncada et al 1991b). In addition, NO appears to 
have an impoitant modulatory role in lymphocyte proliferation (Efron et al 1991, Fu et al 
1992). Increased production of NO in the allo-antigen response has recently been shown 
in a sponge allograft model and in an animal model of transplantation (Langrelir et al 
1991a, Langrehr et al 1991b).
In this investigation, the levels of the stable end-products of NO generation and their 
relationship with the allograft cellular response in liver graft recipients were studied. 
These levels have been coiTclated with cmculating TNF-oc, an important mediator in the 
allograft response and, interleukin 2 receptor (IL2R) positive lymphocytes as a marker of 
peripheral lymphocyte activation and proliferation. In addition, a comparison of NO 
production between primary transplant patients receiving a CyA-based 
immunosuppression regimen to a tacrolimus one was perfoimed.
5.2 SU BJECTS
5.2.1 Patients and controls
Samples were collected from 50 consecutive primaiy liver recipients prospectively entered 
into this study at the time of transplantation and a cohort population of 10 consecutive
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patients with established and histologically confirmed chronic allograft rejection. The 
primary recipients received either a triple therapy immunosuppression regimen of CyA 
(120-150 ng/ml whole blood, Incstar RIA), azathioprine (1 rag/kg/day) and prednisolone 
(0.4-0.8  mg/kg/day) (n=24), a dual therapy regimen of tacrolimus (0.10-0.15 mg/kg/day) 
and low-dose prednisolone (0.1-0.3 mg/kg/day) (n=22) or, in the presence of toxicity to 
either CyA or tacrolimus, a regimen of azathioprine and prednisolone (n=4). Treatment 
allocation was prospectively randomised as part of the European multicentre trial of 
primary tacrolimus versus CyA based immunosuppression which was being conducted 
during the period of this investigation. NO generation was compared in those with 
histologically confirmed rejection, whether or not clinically significant, to those with other 
post-transplant complications which included cytomegalovirus (CMV) infection (n=3), 
vascular* stenosis or thrombosis (n=3), significant renal impairment (n=3) and systemic or 
hepatobiliary related sepsis (n=4). Patients clinically well (absence of major graft or 
systemic complications) and with good graft function (AST and bilirubin levels less < x2 
upper hmit of noimal range) were considered as having a ‘stable’ post-operative course.
5.3 METHODS
5.3.1 Samples
Venous blood was collected serially, on a daily basis for the first two weeks and then 
twice weekly until day 28 after transplantation and whenever a liver biopsy was 
performed. Blood was collected on ice into endotoxin-free tubes (vacutainer) and plasma 
separated within 20 minutes by centrifugation at 200 g for 10 minutes. Aliquots were 
stored at “20® C until assay. Separate aliquots of whole blood were collected in EDTA for 
study of peripheral compartment lymphocytes.
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5.3.2 Determination of nitric oxide end-products
The stable end-products of NO generation were assayed by chemiluminescence, either 
directly or after reduction of nitrate (NO3 -) to nitrite (N0 2 ’) with nitrate reductase as 
described previously (figure 5.1) (Palmer et al 1987, Schulz et al 1992). Nitrate reductase 
(20 mu), FAD (120 mM), NADPH (14.4 mM) were added with phosphate buffer 
solution to the plasma samples and incubated for 1 hour at 37®C to derive total NO2 . 
Volumes ranging from 5-100 pi were then added to a reaction vessel refluxing 6 % 
aqueous sodium iodide and acetic acid under which conditions NO2 is reduced to NO 
which is then removed into a gaseous phase by a constant stream of nitrogen which also 
removes any contaminated oxygen (which reacts with the NO). The NO is then mixed 
with generated ozone to form a chemüuminescent product which is measured by a detector 
coupled to an electronic integrator. The area under the peak signal is proportional to the 
NO2 in the sample. The assay was calibrated using standard solutions of NaN0 2 - The 
direct assay measures NO derived from acid labile products (NO%), which include NO2 
and possibly some nitroso-compounds (co-efficient of variation 9-12%). After reduction 
this assay additionally measures NO3- which predominates by approximately 20 fold (co - 
efficient of variation 6-15%).
5.3.3 Measurement of TNF-g and IL2R-positive lymphocytes
TNF-a was assayed using a commercial ELISA kit (British Biotechnology Ltd. UK) with 
a threshold sensitivity 5 pg/ml. The proportion of IL-2R lymphocytes was determined 
using CD25 monoclonal antibodies (Dako Ltd., UK). Analysis was performed using 
FACS analyzer (Becton and Dickinson).
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Figure 5.1. Schematic representation of the nitric oxide end-product analysis
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5.3.4 Incidence and grading of acute allograft rejection
Percutaneous liver biopsies were performed at day 7 following transplantation and 
whenever an episode of rejection was clinically suspected (n=67). Three patients were 
excluded from analysis because a liver biopsy was contra-indicated during an episode of 
suspected rejection. Allograft rejection was graded by histological assessment into four 
categories on the basis of previously published criteria — none/grade 0 , mhd/grade 1 , 
moderate/grade 2 and severe/grade 3 by an independent pathologist (Snover et al 1987). 
Clinically significant rejection requiring a course of high dose supplemental 
glucocorticoids (hydrocortisone 1 g b.d. for three days and 1 g o.d. for two days) was 
defined as the presence of clinical and biochemical evidence of graft dysfunction 
accompanied by either grade 2 or 3 histological evidence of rejection. Recipients who 
experienced an episode of grade 1 rejection were not treated with anti-rejection therapy.
Results are expressed as mean (SEM) and compared by the students paired or unpaired t - 
test where appropriate. Regression analysis was performed to determine the relationship 
between variables and a logistic regression performed to determine the most 
discriminating variable in the prediction of an episode of acute clinical rejection.
5.4 RESULTS
5.4.1 Nitric oxide generation and allograft rejection
Twenty-eight recipients had 33 episodes of histologically confirmed acute rejection (grade 
1 18, grade 2 11, grade 3 4). AH but four of these episodes occurred during the first 5-10 
days of the post-transplant period. Plasma levels of NO% were higher in patients during an 
episode of acute clinical rejection (n=15) than patients with either stable graft function,
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other complications or chronic allograft rejection (figure 5.2). In contrast there was no 
significant correlation between plasma NO3 levels and the occurrence of rejection (table
5.1). There was a strong correlation between the histological grade of allograft rejection 
and the plasma NOx level. The mean concentrations for rejection grade 0 and 1 (0.58
5.4.2 Relationship between nitric oxide end-products and other circulating markers of 
rejection
In the first 30 consecutive patients in the study (which included 10 patients with 
significant chnical rejection), the relationship between plasma NOx levels and circulating 
TNF-a and peripheral IL2R positive lymphocytes was studied. There was a correlation 
with TNF-a (r=0.451, p<0.001) with this parameter showing marked elevations during 
complications other than rejection. There was also a coiielation between plasma NOx and 
IL2R positive lymphocytes (1-0.787, p<0.001). These three variables in addition to 
plasma NO3- were compared as predictors of rejection in a logistic regression analysis.
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pmol, 0.61 |imol respectively) were significantly less than those for grade 2 or 3 rejection
(mean level 2.28 |imol, p 0.001) (figure 5.3). In the patients developing clinically 
significant rejection, serial median concentrations of plasma NOx rose to a peak during the 
rejection episode and decreased with resolution. The mean increase in NOx concentration 
from pre-iejection (-3 days) 0.96 jimol to rejection was 1.44 fimol (p<0.01). Following 
administi'ation of supplemental glucocorticoids, plasma NOx concentrations were reduced 
to below the pre-rejection concentrations, with a mean reduction of 1 .8 8  pmol by seven 
days post-treatment (p<0.01) (figure 5.4). Levels began to decline by day 2 in all patients 
following supplemental steroids. Concentrations of NO3 were not significantly reduced 
by the supplemental glucocorticoids (p 0.07).
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Figure 5.2 Plasma N O x  levels during episodes o f c lin ica lly  
significant rejection were significantly elevated compared to 
recipients with ^stable  ^ graft function (p<0.0001), n o n - 
rejection complications (p<0.01) or chronic rejection 
(p < 0 .0 5 ).
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Figure 5.3 Peak plasma N O x levels related to histological grades o f 
rejection. These levels were significantly higher in grades 2 
and 3 than either group 0 or 1 (p<0.01 and p 0.001 
respectively).
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Plasma NOx was found to be the most discriminating variable in both univaiiate and 
multivariate analyses (table 5.1). An analysis of the predictive values of isolated 
measurements of these variables during an episode of rejection based on the median+SEM
values of the four parameters (NOx, NO3-, TNF-a and IL2R positive lymphocytes) on the
day of histological diagnosis was performed. All parameters were reliable negative 
predictors, with plasma NOx and IL2R lymphocytes additionally demonstrating high
positive predictive values for an episode of rejection. Representative examples of the 
measured parameters during graft rejection (case 1 ) and stable function (case 2 ) are 
presented in figure 5.5.
5.4.3 Relationship between nitric oxide generation and immunosuppression
Plasma concentrations of NO% and the proportion of IL-2R lymphocytes were
significantly lower in patients receiving tacrolimus-based immunosuppression than in
those on a CyA regimen in the early post-operative period (table 5.2). This difference in f
plasma NOx was consistent with the trend towards reduced frequency of an episode of 
.acute rejection in the tacrolimus versus CyA treated patients of both clinical (4/21) 19% 
versus (8/21) 38% respectively (p 0.18) and histological rejection (11/21) 52% and 
(16/21) 76% respectively (p 0.10). Those recipients (n=4) not receiving either CyA or 
tacrolimus had the highest levels of NOx the study period, in particular' dui-ing the first
10 days post-transplant (mean levels 1.84 pmol, p 0.05) with 3 of the 4 patients 
experiencing clinical rejection.
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Figure 5.4 Serial plasma N O x  levels in 12 recipients under either 
cyclosporin A or tacrolimus immunosuppression during an 
episode o f rejection. Levels rose significantly from  
prerejection (~3 days) to rejection (*p <0.010) and decreased 
fo llow ing administration o f supplemental anti^rejection 
therapy ( *  *p <0.01 ).
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Table 5.1 Comparison of the predictive powers o f the 4  parameters
( NOx)  N O 3 ", TNF-a, 1L2R lymphocytes [based on mean
+SEM on day o f histological diagnosis]) in detecting an 
episode o f clinical rejection.
positive predictive value %
negative 
predictive value %
univariate 
analysis p value
multivariate analysis p value
NOx 73 95 <0 .0 0 1 0.06
N03- 33 87 0.09 0.27
TNF 25 92 0.26 0.40
IL-2R 6 6 89 0.075 0.43
Table 5.2 Plasma NOx (mean) levels in the early post-operative period  
in recipients receiving either a tacrolimus (FK506) or CyA ~ 
based primary immunosuppression regimen.
Cyclosporin A Tacrolimus
DAY 3 0.606 0.681
DAY 5 0.924 0.534
DAY 7 1.260*+ 0.496
DAY 12 0.524 0.419
■•■ l^evels risen from early post-operative period (day 3) (p<0.001) 
levels higher in patients receiving cyclosporin A compared to tacrolimus (p<0.05)
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Figure 5.5 Representative examples of serial data during rejection [day  
7] (case 1) and stable graft function (case 2) (note different 
scale). An increase in NOx levels by post-operative day 5 in 
the rejection episode was detected (Le. levels were increased 
2 days prior to histological confirmation). In case 2, NOx 
levels were consistently low. Although the levels o f the 2 
other parameters studied were typically lower than during 
rejection unexpected fluctuations which were difficult to 
attribute to clinical events occurred.
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5 , 4  Discuss ion
The present study shows the potential value of immunological monitoring by 
measurement of NO generation in human liver allograft rejection. A close relationship 
between NO end-products and rejection was demonstrated. NO itself is very unstable, 
reacting with a variety of molecules to form NO2 , NO3- and other nitroso-compounds,
either directly or after decay of intermediates. In this study, a particular correlation 
between elevations in NOx (acid labile nitroso-compounds), rather than NO3 -, and 
rejection was shown. The reasons for this discrepancy are presently not clear, however it 
is likely that NO% is formed directly from a reaction with NO. In contrast NO3-, in
■Iaddition to being a product of NO, is derived predominately from the diet as previously 
reported (Knight et al 1987). Further work is required to identify the stable product that 
correlates with rejection and which may be either N O 2 " and / or stable nitroso -
compound(s).
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NO may contribute to the pathogenesis of rejection following activation of the immune 
system as a cytotoxic molecule. The absence of systemic hypotension in allograft rejection 
suggests that the systemic vasculature is not a source for this increased production of NO 
as it is m endotoxic shock. The source of this increased production is likely to be the graft - 
infiltrating cells and / or the hepatic vasculature and parenchymal cells, following 
induction of NO synthase by products of the infiltrating cells. The elevated local 
concentrations of NO in the allograft are likely to be directly injurious to target cells in 
rejection, mediating damage in liver rejection to vascular endothelium and inhibiting 
hepatocyte protein synthesis (Palmer et al 1992, Curran et al 1991).
Administration of exogenous IL-2 increases NO production in a clinical population (Hibbs 
et al 1992), The coirelation between NOx and IL-2R lymphocytes in this study suggests
I
that at least one of the factors involved in the production of NO is activation of 
inflammatory cells by IL-2. Hence the suppression of NO production with tacrolimus and 
CyA immunosuppression may be mediated through their inhibition of IL-2 production. 
The markedly reduced NO production in the tacrolimus group matched the lower 
frequency of rejection in these patients and is consistent with this agent’s superior 
immunosuppression (Stai'zl et al 1989). The rapid reduction in NOx production following 
supplemental steroids during allograft rejection, is consistent with previous studies 
showing that induction of nitiic oxide synthase in inflammatory cells can be inhibited by 
pharmacological doses of glucocorticoids, which may be a contributing mechanism of 
action in their ability to reverse cellular rejection (Moncada et al 1991b). The finding that 
NO3 - concentrations were not significantly reduced after supplemental glucocorticoids 
supports the superior validity of NOx as a measure of NO production. A recent study of 
urinaiy NO3- excretion in an expeiimental rodent model of acute cardiac allograft rejection 
has found virtually identical results to this clinical investigation (Winlaw et al 1994). In 
that study, an 8 -fold rise in urinaiy NO3- excretion (measured by the Greiss reaction) was 
detected during rejection in untreated animals whereas treatment with steroid and CyA 
immunosuppression abrogated these peaks. Whether differences in the assay and the 
compaitment which was measured explain the differences between the studies in relation 
to the particular value of NO3- measurements is speculative. Urinary levels were not 
measured in the study from this unit and the Greiss leaction is too insensitive to be used in 
clinical investigations (Archer 1993).
In addition to having a role in the pathogenesis of allograft rejection, NO production may 
also be important in regulation of the immune response. This molecule has been shown to 
be required for optimal DNA synthesis in human lymphocytes, although at higher 
concentrations it appears to have a species-dependent ability to inhibit proliferation 
following mitogenic or allo-antigenic presentation (Fu et al 1992, Langrehi* et al 1991b).
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Despite the potential value of immunological monitoring of allograft recipients, this is 
rarely employed clinically because of the expense and complexity of assay systems 
involving lymphocyte and cytokine preparations. Measurement of plasma NOx, a stable 
end-product of NO production, is a cheap measurement which is potentially available 
within minutes of sampling and which appears to give superior predictive values in 
detecting acute allograft rejection.
The limitations which confound all attempts at immunological monitoring in allograft 
rejection is the non-specific activation of the immune system in conditions such as sepsis.
This variable is not surmounted by measurement of NO, although this parameter did 
appear the best of the variables evaluated. Although there was a close correlation with 
activated lymphocytes, there is no definite evidence at present that these cells were the 
source of NO. Several other cells including Kupffer cells, hepatocytes and endothelial 
cells, which are known to produce NO, could contribute to the circulating levels. 
Immunohistochemical localisation of the inducible nitric oxide synthase in graft tissue 
during rejection would be one approach to determine the source of the circulating NO. | |
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CHAPTER 6
IDENTIFICATION OF RECIPIENT ETHNIC ORIGIN AS A RISK 
FACTOR IN CHRONIC LIVER ALLOGRAFT REJECTION
6.1 INTRODUCTION
Demographic characteristics have previously not been widely examined in relation to liver 
allograft survival. The age of the recipient, as discussed in section 1.6, is of some 
importance with, not unexpectedly, extremes of age being associated with inferior results. 
No effect of recipient gender is reported. Data on the influence of ethnic recipient 
background has been inadequately examined in liver transplant patients. In contrast in 
renal transplantation, it has been established that the ethnic origin of recipients is an 
important factor in determining allograft survival. Although there are variations between 
centres, data from the large renal-transplant registries both in the United States and Europe 
have demonstrated an inferior long-term allograft survival in recipients of black / Afro - 
Caribbean origin (Opelz et al 1989, Takemato et al 1989). Moreover, this ethnic 
background in separate multivariate analyses has been shown to be an independent risk 
factor for lenal graft survival (Sanfilippo et al 1986). There is limited data regaining the 
effect of racial origin of either donor or recipient on outcome in other ti ansplanted organs, 
with no published reports on pancreatic, heart or lung transplantation. In the one large 
study to date on liver recipients from the University of Pittsburgh, the 120 adult black 
recipients had a reduced two-year patient sumval as compared to non-black recipients in 
their programme, which they later attributed to a difference in pre-transplant clinical status 
(Teperman et al 1989).
In this investigation, an analysis of patient and graft survival, incidence and contiibution 
of chronic allograft rejection to graft loss and rate of retransplantation was performed.
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6.1.3 Statistical analysis
Actuaiial graft and patient survivals were calculated using life table analysis on BMDP-PC 
software and statistical significance estimated with the Mantel-Cox or Breslow test. The
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6.1 SUBJECTS
6.1.1 Patients and methods
The patient groups comprised all paediatric and adult patients undergoing primary 
orthotopic liver transplantation in the transplant programmes of Kings College hospital 
and Addenbrokes hospital, Cambridge between January 1,1984 and August 1, 1991 was 
performed. No exclusions were made except for multi-organ transplants and unavailability 
of ethnic origin data (n=8 ). All donors and recipients were ABO compatible except in 
exceptional urgent circumstances (0.7%). Patient selection for transplantation was 
standardised on clinical criteria and organ allocation was decided on the basis of ABO - 
compatibility and anatomical suitability with no consideration to the ethnic origin of the 
donor or recipient or HLA matching. Diagnosis of chronic allograft rejection was made 
by a single pathologist based on previously published and established criteria (Portmann 
et al 1988).
6.1.2 Ethnic and racial groups
The patients were divided into four groups based on ethnic origin — group 1 included 
those of north European origin (n=441), group 2 those of south European / mediterranean 
origin (n=121), group 3 those of middle east / central Asian origin (caucasoid n=83) and 
group 4 patients of Afro-caribbean / eastern Asian origin (non-caucasoid n=28).
statistical significance of differences in the demographic data, the incidence of 
retransplantation and chronic rejection were estimated with the chi-test (x2 ) or students t - 
test where appropriate. A multivariate Cox regression model to determine independent risk 
factors in graft survival within the four groups was performed with the primary liver 
disorders HCC, HBV and NANB viral hepatitis and chronic allograft rejection. A P value 
<0.05 was considered to be significant.
6.2 RESULTS
6.2.1 Demographic variations
Comparison of the demographic data showed significant differences between the groups f-
::(table 6.1). The average age of the patients making up groups 2, 3 and 4 (south European, 
mediterranean / central Asian and Afro-caribbean / eastern Asian patients respectively) was |
significantly less than group 1 (north European patients) (p<0.001). Groups 2 and 3 were 
male-dominated with group 1 having a majority of female recipients (p<0 .0 0 1  vs groups 
2, 3 and 4). The aetiology of the liver diseases vailed between the groups with groups 2,
3 and 4 having significantly less patients with PBC (p<0.001 vs group 1) and an 
increased proportion of recipients undergoing transplantation for post-hepatitic ciiThosis 
(p<0.001 vs group 1), this category of liver disease accounting for approximately 40% of 
transplants in these groups. In group 4, an increased proportion of patients were 
transplanted for piimaiy hver malignancy compared to the other groups (p<0 .0 1  vs total).
The proportion of recipients undergoing transplantation for FHF was approximately equal 
between the groups with the exception of group 2  who had a reduced proportion in this 
category.
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Table 6.1 Comparison o f the demographic data o f the liver transplant 
recipients according to the different groups (group 1 - north 
European^ group 2 - south European, group 3 - mediterranean 
/  central Asian and group 4 - Afro-caribbean ! eastern Asian).
1 2
GROUPS
: 3 4
n (%) 441 (65.5) 121 (17.9) 83 (12.3) 2E! (4.2)
Age
mean 3 5 .3 2 9 .6 2 3 . 8 2 7 .4
Sex
male 1 60 74 5 6 1 9
female 281 4 7 2 7 9
Original Liver Disease
primary biliary cirrhosis 101 (23) 17 (14) 6 (7) 1 (4)
post-hepatltic cirrhosis 34 (10) , 51 (42) 35 (42) 8 (29)
chronic active hepatitis 30 (6.7) 10 (8) 6 (7) 2 (7)
alcoholic liver disease 21 (5) 12 (10) 2 (2) 1 (4)
biliary atresia 53 (12) 2 (2) 4 (5) 2 (7)
a1-antitrypsin deficiency 20 (5) 2 (2) 2 (2) 0 (0)
Wilson's disease 15 (3) 1 (1) 3 (4) 0 (0)
primary liver malignancy 28 (6) 7 (6) 5 (6) 6 (21)
Budd-Chiarl syndrome 13 (3) 4 (3) 0 (0) 1 (4)
primary sclerosing cholangitis 32 (7) 3 (2) 7 (8) 1 (4)
fulminant hepatic failure 62 (14) 6 (5) 11 (13) 4 (14)
other 32 (7) 6 (5) 2 (2) 2 (7)
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6.2.2 Patient and graft survival
In the early post-operative period — defined as mean period of hospitalisation prior to 
discharge following transplantation for all the patients in the study (8  weeks) — there was 
no significant differences in either patient or graft survival between the groups (figure
6.1), At 1, 3 and 3.5 years following tiansplantation, group 4 had a significantly inferior 
patient suiwival than aU the other groups (p<0.05) (figure 6.2). There was no significant 
differences in patient survival rates between the other groups. Graft survival rates were 
similar for the European groups (groups 1 and 2) although there appeared to be a 
marginally inferior outcome in the south European group (e.g. 48.5% vs 53.5% at 3 
years n.s.). Groups 3 and 4 had inferior graft survival rates at 1 ,2  and 3 years post - 
transplantation with the non-caucasoid group having the worst outcome (p<0 .0 1  and 
p<0.001 respectively versus group 1 at 1,2 and 3 years) (figure 6.3).
6.2.3 Chronic allograft rejection and retransplantation
European recipients, either of northern or southern European origin, had similar incidence 
of chronic allograft rejection at just under 6 %. In the non-European groups 3 and 4 this 
complication was recorded in a significantly greater number — 1 2 .6 % of the population 
(p 0.002 vs groups 1 and 2) with a separate rate of 12.0% for group 3 (p<0.01 vs groups 
1 and 2) and 14.3% — the highest rate — in group 4 (p<0.05 versus groups 1 and 2) 
(table 6.2). In a multivariate analysis of independent risk factors in graft suiwival (analysis 
of chronic rejection, HCC and HBV-related ciiThosis), chronic rejection and HCC were 
found to contribute independently to graft loss within all the groups (p value 0 .0 2  and p 
value 0.05 respectively). Chronic allograft rejection was the single lai'gest indication for 
retransplantation in the groups, accounting for between 38 - 100% (table 6 .2 ).
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Figure 6.1. Early graft survival up to the mean period o f  hospitalisation 
follow ing transplantation (8 weeks) in patients from  the 
different ethnic groups.
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Figure 6.2 Actuarial patient survival in the different ethnic groups up to 
three years following transplantation.
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Figure 6,3 Actuarial graft survival divided by ethnic groups up to two 
years post-transplant. The non-European groups (groups 3 
and 4) have lower success rates.
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In the period between 1984 - 1987, the maintenance immunosuppression regimens 
comprised either CyA monotherapy or CyA in combination with low dose prednisolone 
(CyA levels maintained between 120-150 pg/1, monoclonal RIA). Subsequently from 
1987 to the present day, the patients are maintained on a triple therapy regimen 
(prednisolone 0.1 mg/kg/day, azathioprine 1 mg/kg/day and CyA levels maintained 
between 100-120 pg/1, monoclonal RIA) with the exclusion of twenty-six patients in the 
study population who were on a combined tacrolimus ± steroid regimen. There were 
significant differences in distribution of the groups between the two principal 
immunosuppression regimens with larger proportions of groups 2, 3 and 4 being 
distributed in the later triple therapy regimen compared to group 1 (p value 0.005) (figure 
6.4).
6.4 D ISCU SSIO N
The findings in this large study in liver transplantation supports the evidence from renal 
transplant programmes that the ethnic origin of the recipients is an important risk factor in 
graft loss mediated to some extent through variable rates of chronic allograft rejection. The 
recipients in the present study from a non-European and in particular a non-caucasoid 
ethnic background have inferior graft survival rates compared to an indigenous European 
population in a programme utilising donor organs retrieved from a predominately 
Caucasian population. The United Kingdom Transplant Support Service Special Authority 
(UKTSSA) estimates that greater than 95% of the multi-organ donor population pool in 
the UK are white, Caucasian and from either the UK or Ireland; unfortunately no data is 
available on individual donors preventing an analysis of specific donor-recipient pairings 
(personal communication UKTSSA) but the possibility of a spontaneous racial match 
between non-indigenous recipients to UK donors would be virtually negligible.
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Table 6,2 Frequencies o f chronic rejection and the contribution to 
elective retransplantation and graft loss between the different 
ethnic groups
1
GROUPS 
2 3 4
n,(%)
Chronic rejection 26 (5.9) 7 (5.8) 1 0  (1 2 .0 ) 4 (14.3)
Graft loss due to chronic rejection
23 (5.2) 7 (5.8) 1 0  (1 2 .0 ) 4 (14.3)
Retransplantation on account of chronic rejection (%) 4.8 5.8 1 2 .0 14.3
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Figure 6,4 Distribution (%) o f all the recipients, divided by ethnic 
group, as managed with the two im m unosuppression  
regimens over the study period.
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The influence of ethnic background on outcome is demonstrated clearly in groups 2 
(south European /  mediterranean origin), and 3 (middle east / central Asian origin), which 
although similarly matched demographically for age, gender and recipient disease 
categories had considerably different outcomes after transplantation. The variable 
incidence of chronic allograft rejection (a complication which alongside HCC is an 
independent risk factor in graft survival) contributes to and largely explains these ethnic 
variations in outcome. The comparative data above suggests that the variable rates of 
chronic rejection between ethnic groups cannot be explained by simple demographic 
features but is due to some inherent population differences as yet undetermined. To date 
the only risk factors for chronic rejection have comprised reactivation / reinfection of 
CMV, HLA match / mismatching and positive lymphocytotoxic crossmatching (O’Grady 
et al 1988b, Batts et al 1988). However the present results are consistent with the data 
emerging from the large American and European renal registries which, with the aid of 
large population groups, have demonstrated that the ethnic origin of transplant recipients 
is an important factor in graft survival, with a pattern of reduced graft survival secondary 
to chronic rejection in black recipients (Dunn et al 1989). There have however been no 
previous studies of this inferior outcome extending into other non-caucasoid populations 
or into recipients of a middle east / central Asian origin as has been demonstrated in the 
present study.
Several explanations have been proposed for the inferior outcome in black renal recipients 
which include non-compliance with immunosuppression therapy and higher rates of 
hypertension but the present consensus is that an immune-mediated mechanism leading to 
chronic rejection is more likely to be involved (Sanfilippo et al 1986). Although 
multivariate analyses have confirmed that ethnic origin is an independent risk factor for an 
inferior outcome following renal transplantation, there is no convincing evidence from 
these studies that HLA mismatching (a prime candidate for the increased risk of chronic
1 0 9
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rejection) contributes to this phenomenon (Sanfilippo et al 1986, Kondo et al 1987). This 
apparent lack of importance of HLA mismatching in renal allografts may be misleading in 
the light of the recently described disparity between clinical serological HLA typing and
Ifunctional HLA status and the heterogeneity of HLA antigens, as assessed by the newer 
techniques of polymerase chain reaction and oligohybridisation, in minority ethnic groups 
(Fernandez et al 1991). What were previously considered to be beneficial matches in a
ethnic minorities will have to be reconsidered with this functional disparity and the 
heterogeneity of these groups compared to the more homogenous white donor 
populations. The role of HLA matching / mismatching in liver transplantation remains 
controversial, as no attempt is made to beneficially match HLA antigens prior to organ 
allocation and in this units series spontaneous beneficial matching of either three / four 
HLA A / B antigens has only occurred in three patients in a series of four hundred patients 
(Donaldson et al 1991a). Other possible explanations for this increased rate of chronic 
rejection, independent of HLA status, is the higher immune responsiveness of black 
compared to white renal recipients which has been demonstrated in these patient 
populations (Kerman et al 1991). This observation may also explain why black recipients 
of both cadaveric grafts from black donors and live-related grafts also have an inferior 
outcome (Mügrom et al 1989), The possible effect of socio-economic status among non - 
Caucasian recipients and consequent non-compliance is not an appropriate explanation ■Iamong our patients. The great majority of non-caucasian recipients within the Kings 
programme are privately funded individuals from above average socio-economic status 
referred from around the world and in whom non-compliance is not recognised as a 
problem.
This present European study appears to reach different conclusions from the only 
previously published reports on this subject from two hver transplant programmes in the 
USA. The University of Pittsburgh which restricted analysis to outcome in black and %
hispanic americans demonstrated a reduced patient survival at 2  years in black compared 
to white recipients (less than 50% vs 70%, p 0.015). They concluded however that 
allowing for pretransplant clinical status as assessed by UNOS there was no significant 
difference in outcome although this scoring system was only applied to a relatively small 
number of the study group (Teperman et al 1989). A smaller study of 23 black recipients 
did not show any significant difference in outcome although there was a trend towards 
lower survival in this ethnic group (Gonwa et al 1991). In this study, pre-clinical status 
did not appear to explain the differences with similar frequencies of patients between the 
groups undergoing transplantation for fulminant hepatic failure and no differences in early 
peri-operative mortality. It is also noteworthy that higher proportions of the ethnic 
minorities groups were transplanted in the later part of this study when there had been 
additional immunosuppression in addition to improved patient selection and surgical 
technique.
The results of this study indicate that further prospective analysis of the role of HLA 
matching / mismatching and immunological responsiveness in stratified ethnic groups 
undergoing liver transplantation is required. A further study of donor organs retrieved 
from non-indigenous populations and transplanted into a uniform indigenous population 
may also yield important information on the effects of organ donation across ethnic 
groups.
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CHAPTER 7
IMPORTANCE OF PRETRANSPLANT CLINICAL STATUS IN 
OUTCOME OF EMERGENCY TRANSPLANTATION FOR ACUTE LIVER
FAILURE
7.1 BACKGROUND AND INTRODUCTION
Pretransplant clinical status is an important determinant of outcome in all liver recipients 
and was proposed in chapter 2  as meriting a specific category of clinico-pathological 
determinants causing graft failure. The inferior survival of elective recipients with poor 
nutrition, renal failure and advanced cirrhosis has already been established (Cuervas - 
Mons et al 1986). In contrast to this data, no infonnation is available on the influence of 
pre-transplant clinical status on the outcome of emergency transplantation for ALF where 
the recipients are often critically ill. Transplantation is now established as an important 
component of the overall care of patients with acute hepatic failure, although selection of 
the cases that need to be transplanted is difficult due to variability in both the prognosis of 
different aetiological / clinical categories and the accompanying effects of multisystem 
critical illness (O’Grady et al 1988c). One year patient survival rates following 
transplantation are around 50-60% and many recipients have a slow convalescence 
requiring prolonged periods of intensive care (Bismuth et al 1987, Schafer et al 1989, 
Emond et al 1989). Indeed it has been argued that liver grafts would be better used for 
elective cases where suivival rates of 80-90% can be obtained (Chapman et al 1990). In 
this centre, the decision to consider a transplant is based on certain clinical and laboratory 
indicators of prognosis found in a multivariate analysis of patients with fulminant hepatic 
failure (FHF) which identified a survival without transplantation of less than 10% 
(O’Grady et al 1989). Other groups use different criteria based around either factor V
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levels or serial assessment of liver size with CT scanning and liver biopsy (Bernuau et al 
1991, Van Thiel et al 1993). Following initial selection and listing for transplant, some 
patients deteriorate before a donor organ becomes available with the development of 
absolute contraindications which include severe haemodynamic disturbance, presence of 
uncontiolled cerebral dysfunction or systemic sepsis. As yet no detailed analysis of other 
par ameters of pretransplant clinical status which could have a significant influence on the 
post-operative course has been reported.
In this present study, the outcome of the first 100 consecutive adult patients who 
underwent emergency transplantation for ALF in relation to aetiology, severity of the liver 
failure and associated systemic critical illness was analysed. Additionally, an attempt to 
elucidate which clinical parameters or scoring systems of pretransplant status could be 
used in the prediction of early hospital outcome was performed.
7.2 SUBJECTS
7.2.1 Patients and clinical categories
Data from the first 100 adult patients who underwent emergency liver transplantation (98 
orthotopic and 2 auxiliary heterotopic transplants) for either FHF (n=79) or late-onset - 
hepatic failure (LOHF) (n=21) [standard classifications (Trey and Davidson et al 1970, 
Gimson et al 1986)] in this unit’s series between Januaiy 1984 and September 1992 were 
analysed. These 100 patients represented 13% of consecutive cases admitted with ALF 
(n=759) during the study period. Median age of those transplanted was 32 years 
[range: 11-63] with a predominant female sex ratio [F:M, 70%:30%]. Determination of 
aetiological category was based upon standard clinical, virological and laboratory indices 
with histological assessment of the explanted liver available in all cases. The number and 
proportion of all cases adm itted to this unit who underw ent
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transplantation were as follows: hepatitis A virus (HAV) 4/36 (11%), NANB / 
indeterminate 51/125 (41%), paracetamol hepatotoxicity 21/446 (5%), fulminant Wilsons 
disease (FWD) 9/14 (64%), idiosyncratic drug hepatotoxicity 7/26 (26%) and 
miscellaneous causes (which comprised HBV 1, halothane toxicity 2, fulminant 
presentation of autoimmune hepatitis (AIH) 2 and Budd-Chiari syndrome 1, 6/83 (7%) 
(table 7.1). To allow examination of potential pre-transplant risk factors in relation to 
outcome, the study population was additionally divided into 2  patient groups: 
non-paracetamol induced liver failure (n=79 [FHF n-58, LOHF n=21], group 1) and 
those with paracetamol hepatotoxicity (n=2 1 , group 2 ).
7.2.2 Patient selection and immunosuppression
Consideration for transplantation in FHF patients, since 1988, was based on the clinical 
criteria of O’Grady as already referred to (n=58; group 1 n=37, group 2 n=21). All 
patients with LOHF were considered for transplantation in view of the poor prognosis of 
this group (Gimson et al 1986). The presence of irreversible brainstem dysfunction, 
increasing inotrope dependence and culture-positive systemic sepsis resistant to 48 hours 
antimicrobial therapy were absolute medical contraindications to proceeding with 
transplantation. Additionally in patients who self-administered a deliberate paracetamol 
overdose, a history of a severe chronic psychiatric disorder or repeated suicide attempts 
were also contraindications. Immunosuppression schedules were based upon either a dual 
therapy prednisolone / CyA regimen [1984-1987] (n=23), CyA based triple therapy 
regimen [1987-1992] (n=69) or a tacrolimus / low dose corticosteroid schedule 
[1990-1991] (n=8 ). Modifications to induction immunosuppression regimens, in 
particular reduction or withdrawal of CyA, were often required due to the high incidence 
of postoperative renal and neurological complications. No anti-lymphocyte preparations 
were administered as induction immunosuppression. For donor organ preservation
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Eurocollins solution (n=ll) was used prior to 1987 and UW solution (n=89) thereafter.
7.2.3 Parameters examined in relation to post-transplant outcome 
Pretransplant parameters examined as risk factors were the static variables: age, gender, 
transplant year, aetiology, ‘time from admission to transplantation’ and in the case of 
paracetamol-overdose cases ‘time from overdose to transplantation / hepatectomy’. The 
latter variable was included as 3 patients underwent total hepatectomy as a ‘holding 
procedure’ prior to the eventual transplantation. On admission to the Liver Failure Unit 
and again immediately prior to transplantation dynamic variables examined comprised 
encephalopathy grade, presence of cerebral oedema, indices of systemic illness (organ 
system failure and apache 1 1 1  score) and standard serum biochemical and haematological 
parameters (bilirubin, AST, albumin and creatinine levels, INR; mean control 15s, total 
white cell and platelet count). In the paracetamol hepatotoxicity cases only, arterial pH 
was also evaluated. Multiple organ failure was quantitated using standard criteria with the 
addition of an episode of cerebral oedema or grade IV hepatic coma constituting 
neurologic failure during a 24-hour period (Knaus et al 1985). Apache 111 score was 
calculated as previously described with the additional adoption of a standardised scoring 
system for the assessment of hepatic encephalopathy dependent upon coma grade (grade 1 
- 3 points, grade 2 - 8  points, grade 3 - 1 3  points, grade 4 (without cerebral oedema) - 24 
points and grade 4 (with cerebral oedema) - 33 points (Knaus et al 1991). In patients who 
required mechanical ventilation (all paralysed and sedated according to established clinical 
practice) encephalopathy grade was later assumed to be that present at the time ventilation 
was commenced except when cerebral oedema developed which was equated to grade IV 
encephalopathy. Actuarial patient survival was calculated by life-table analysis and 
statistical differences estimated by the log-rank test.
Figure 7.1 Summary clinical data of transplanted liver failure patients 
divided into those experiencing non-paracetamol liver failure 
(group 1) and severe paracetamol hepatotoxicity (group 2). 
Significant variations in the clinical parameters, related to 
liver failure or systemic illness characteristics, are present 
between the aetiological categories.
NON-PARACETAMOL (1) PARACETAMOL (2) TOTAL
characteristic
NANB / indeterminate 
FHF LOHF (n=30) (n=21)
HAV
(n=6)
Wilsonsdisease
(n=9)
drug
(n=7)
other
(n=6)
paracetamol
(11=21) (n=100)
sexmale 6 7 3 4 1 4 5 30female 24 14 3 5 6 2 16 70
age 30mean 33 37 30 19 34 38 32(range) (11-54) (11-54) (12-63) (14-26) (19-50) (13-48) (17-50) (11-63)
apache 111 50(18) 50(25) 57(26) 46(29) 48 (25) 41(13) 74(21) 55 (24)
INR 6,9 (4.3) 3.8 (1.7) 7.0 (3.5) 4.6 (3.5) 9.5 (6.3) 6.0 (4.9) 8.2 (4.0) 6.5 (4.2)
AST (lU/L) 704 (1208) 245 (264) 316(171) 173 (212) 744 (666) 517(438) 2034(2058) 787(1317)
bilimbia (nmol) 410(140) 538 (174) 492 (93) 714(204) 427 (230) 369 (233) 146(81) 413 (223)
encephalopathy grade * (%) 3(10) 9(43) 0 (0) 6(68) 1(14) 1(17) 0 (0) 20 (20)II 6(20) 4(19) 1(17) 1(11) 2(29) 2(33) 0 (0) 16(16)III 9(30) 3(15) 2(33) 2(22) 1(14) 2(33) 8(38) 27 (27)IV 12 (40) 5(24) 3(50) 0 (0) 3(43) 1(17) 13 (62) 37 (37)
cerebral oedema
(%) 10(33.3) 2(10) 2(33) 0 (0) 2(29) 1(17) 10(48) 27 (27)
apache 111, INR, AST, bilirubin expressed as mean (standard deviation) 
encephalopathy grade and cerebral oedema are expressed as totals (%)
■I
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Other differences between the groups were estimated by the chi-square test. Those 
parameters significantly different by univariate analysis (Mann-Whitney U test) between 
survivor and non-survivors at two months were entered into a stepwise logistic regression 
model stratified for the two groups in the prediction of early [two-month] survival. 
Reasons for graft and patient loss were determined following combined clinical and 
pathological assessment with post-mortem reports available for all deaths. Results are 
expressed as median or mean (standaid deviation) [SD] where appropriate.
7.3 RESULTS
7.3.1 Pretmnsplant Characteristics
A significant deterioration in the majority of pai'ameters was noted during the inteival from 
admission to the time of transplantation (table 7.2). At transplantation, the median 
prothrombin time was greater than 100 seconds [INR 6.5] [SD 4.2]) and serum bilimbiii 
411 [223] umol (group 1: prothrombin time 62 s [INR 4.15], bilimbin 474 umol; group 
2: prothrombin time 122s [INR 8.2], bilirubin 109 umol). All patients had experienced 
hepatic encephalopathy with approximately two thirds of patients (64%) in either grade III 
or IV hepatic coma and a clinical episode of cerebral oedema occurring in 27%; those 
patients with paracetamol hepatotoxicity had significantly worse grades of encephalopathy 
and rates of cerebral oedema (table 7.1). At transplantation, the mean apache 111 score 
was 55 [24] with 32 patients requiring renal replacement therapy. In group 1, the mean 
periods [hours (range)] from admission and listing to transplantation were 132 (9-264) 
and 65 (7-216) hours respectively. In group 2, the median period from overdose and liver 
failure unit admission to transplantation / hepatectomy was 4 days (range 3-8 days) and 
40 hours (range 14-144 hours) respectively. Over the 8  year study period, an increase in 
the median apache 111 scores at the time of transplantation was detected (figure 7.1).
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7.3.2 Patientandgraftoutcome
Two month actuarial patient survival rates in the whole series was 67% (6 6 % in group 1 
[non-paracetamol] and 71% in group 2 [paracetamol]). Within those patients experiencing 
FHF who were selected for transplantation on the basis of the Kings College Hospital 
criteria for a poor prognosis since 1988, 38 of 58 (6 6 %) were alive at two months. In 
patients with non-paracetamol FHF, a significant variation in patient survival in relation to 
aetiology was noted (figure 7.2). AU patients transplanted for FWD were alive at two 
months in contrast to those with idiosyncratic drug reactions in whom only 1 from 7 
survived. For the other aetiological categories, no significant variations in outcome were 
seen. In patients with NANB / indeterminate FHF or LOHF, the two-month patient 
survival rate was 69% with no significant difference in outcome between fiUminant or late - 
onset presentations (67% and 71% respectively). Retransplantation was required in 9 
patients within the first 2  months, with only 2  of these patients surviving long-term. 
Reasons for graft and patient loss were determined following combined 
clinicopathological assessment with explant postmortem reports available for all cases. 
The indications for retransplantation (confirmed by explant pathological examination) 
were massive haemorrhagic necrosis [2], arterial thrombosis / graft size disparity [3], 
fungal graft sepsis [2], and intractable acute ceUular rejection [2]. The largest proportion 
of deaths were due to systemic sepsis developing as a primary complication (47%). This 
complication resulted in death at a median of 13 days post-transplant. Additionally, a 
number of other patients with other complications died with infection as a secondary 
terminal event. This complication usuaUy precluded retransplantation with the exception of
2  patients who had isolated fungal graft sepsis (see above).
aa
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Table 7.2 Clinical parameters on admission and at transplantation in 
both groups: (non-paracetamol liver failure [group 1] and 
severe paracetamol hepatotoxicity [group 2]), Deterioration in 
a range of important indices (particularly encephalopathy and 
multisystem illness) was apparent during this variable 
interval.
variable
Group 1 (n=79) Group 2 (n=21)
admission 
mean (SD)
nansplantation 
mean (SD)
admission 
mean (SD)
transplantation 
mean (SD)
bilimbin (|imol) 443 (190) 485 (193)** 104 (13.9) 146 (19)*
(mg/dl) 26.1 (1 1 .2 ) 28.5 (11.4) 6 . 1  (0 .8 ) 8 . 6  (1 .1)
AST (lU/L) 518(582) 470 (809) 3214 (1892) 2034 (2057)
prothrombin time (INR) 4.6 (3.4) 6.0 (4.1)*** 8.1 (3.3) 8.2 (4.0)
albumin (mg/dl) 3.0 (0.6) 3.3 (0.7)** 3.8 (0.8) 4.0 (0.7)
encephalopathy grade^ 1 1 4= ^
cerebral oedema (%) 4.2 2 2 ** 9.5
creatinine (jLtmol) 131 (8 8 ) 153 (122) 272 (148) 349 (176)
mg/dl 1.75 (1.17) 2.04 (1.63) 3.62 (1.97) 4.65 (2.35)
WCC (xl09) 12.4 (7.0) 12.4 (6.2) 17.2 (6 .6 ) 10.1 (5.5)***
platelets (x 109) 201 (132) 160 (162)*** 154 (98) 6 8  (52)***
organ system failures^ 0 0 2 **
apache 111 38 (18) 50 (22)*** 49 (23) 74 (21)***
ai'terial pH - - 7.28 (0.14) 7.35 (0.10)
^  encephalopathy grade and OSF expressed as median 
* p <0.05, ** p<0.01, **=*= p<0.001
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Figure 7,1 Distribution o f the study population o f the 100 recipients 
transplanted fo r  acute liver failure with regard to year o f  
transplantation (March 1984 to September 1992), The median 
apache 111 score at the time of transplantation is also shown. 
It is apparent that these are tending to rise annually probably 
reflecting the increased use o f emergency transplantation in 
severe paracetamol hepatotoxicity and lengthening delays in 
organ allocation.
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Fungal infection was detected in 8 patients and was associated with death in 7. Graft loss 
from rejection was found in 12 patients. Possible disease recurrence from viral graft 
reinfection (Fagan et al 1992) in 8  cases of NANB hepatitis was noted and usually led to 
death within the first 2 weeks post-transplant. Miscellaneous events leading to early 2 - 
month mortality were neurological complications in three patients (cerebral 
oedema/infarction [2], intracerebral haematoma [1]), GVHD [2], PGN [1], aortic 
dissection [1], myocardial infarction [1] and a gastrointestinal bleed [1].
?
7.3.3 Pre-transplant risk factors in earlv hospital mortality
In non-paracetamol-induced liver failure, no static variables other than aetiology (FWD) |
and idiosyncratic drug reactions as described above were significantly related to 2 -month 
survival. Of the dynamic variables examined on admission to the Unit, the serum 
creatinine (2.1 [1.6] mg/dl non-survivors vs 1.4 [0.6] mg/dl survivors, p 0.02) was the Ionly parameter significantly different in a univariate analysis. In contrast, by the time of 
transplantation, in addition to serum creatinine which remained significantly elevated in 
non-survivors, the two intensive care indices of systemic critical illness (organ system 
fahme and apache 111 scoie) also discriminated survivors from non-survivors (table 7.3).
When these significant parameters were entered into a stepwise logistic regression model 
to predict 2 -month mortality, serum creatinine at the time of transplantation was the only 
independent variable (r=0.33). A serum creatinine >2.7 mg/dl (200 pmol) at |
transplantation had a 42% sensitivity and a 92% specificity for 2-month mortality.
In paracetamol-induced liver failure, the ‘time from ingestion to transplantation / 
hepatectomy’ was the only static variable significantly different between survivors 4 [1]
■■■■day vs non-survivors 6  [1] days, p<0.01). No patient transplanted at day 7 or greater 
from the time of drag ingestion survived to two months.
Figure 7.2 Early actuarial patient survival following transplantation in 
the various aetiological liver failure indications. With the 
exception o f idiosyncratic drug reactions and fulm inant 
Wilson s^ disease (filled  sym bols), the outcome was 
independent of aetiology.
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The ‘time from admission to transplantation / hepatectomy’ also approached statistical 
significance with survivors waiting for a graft on average less than non-survivors, 41 [14] 
hours vs 67 [52] hours (p 0.09). With respect to dynamic variables on admission, no 
parameter examined could significantly distinguish survivors from non-survivors. 
However by the time of transplantation, total semm bilirubin and apache 111 score were 
significantly different in survivors vs non-survivors (table 7.3). Significant correlations 
between serum bilirubin and ‘time from overdose to transplantation / hepatectomy' existed 
(r=0.56) with a lesser association between the bilirubin level and apache 111 score 
(r=0.29). In a stepwise logistic regression of 2 month survival with the significant 
variables above entered, the apache 1 1 1  score at the time of transplantation was the only 
independent determinant (r=0.51). If one patient who died from a technical complication 
(severe post-operative bleeding) on day 3 was excluded from the analysis, arterial pH 
would have been the strongest parameter by a significant margin. In a univariate analysis, 
the mean (median) pH at transplantation in non-survivors was 7.21 (7.23) vs 7.38 (7.37) 
in survivors (p<0.001). A pH below 7.30 at transplantation had a sensitivity of 80% and 
a specificity of 94% for 2-month hospital mortality.
With respect to hepatic encephalopathy at the time of transplantation (whole population), a 
trend towards a reduction in patient survival was seen with increasing coma grade. The 2 - 
month survival rates were 80% in patients transplanted in grade 1 , 81% in grade 2 , 63% 
in grade 3 and 59% in grade 4. The prognosis for patients transplanted in grade IV coma 
is significantly worse than those in grade I in a univariate analysis (p<0.05). In those 
patients who experienced a clinical episode of cerebral oedema (usually with grade 4 
coma), the 2 -month patient survival rate was 6 8 %.
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■Table 7.3 Summary of clinical and biochemical data in group 1 and 2 
for survivors and non-survivors at 2 months post-transplant 
calculated at the time of transplantation.
Group 1 Group 2
variable survivors
(n=52) 
mean (SD)
nonsurvivors
(n=27) 
mean (SD)
survivors
(n=16) 
mean (SD)
nonsurvivors
(n=5)
mean (SD)
bilimbin (pmol) 504 (192) 443 (181) 121 (47) 233 (126)**
(mg/dl) 29.6 (11.3) 26.1 (1 0 .6 ) 7.1 (2.8) 13.7 (7.4)
AST (lU/L) 418 (354) 654(1315) 1782 (1593) 2791 (3292)
prothrombin time (INR) 5.8 (3.8) 6.7 (4.8) 8.9 (4.6) 7.9 (2.5)
albumin (mg/dl) 3.2 (0.7) 3.4 (0.7) 4.5 (0.9) 3.8 (0.6)
encephalopathy grade^ 2 3^ 4 3
cerebral oedema 23% 26% 44% 40%
creatinine (pmol) 117 (81) 190 (147)* 333 (167) 402 (214)
(mg/dl) 1.56 (1.08) 2.53 (1.96) 4.44 (2.22) 5.36 (2.85)
WCC (xl09) 11.6 (5.5) 12.0 (5.8) 9.1 (5.3) 13.1 (5.7)
platelets (x 109) 155 (116) 153(117) 67 (36) 74 (94)
OSF 0.5 1* 2 2
apache 1 1 1 48 (20) 58 (23)* 6 8  (19) 92 (16)*
arterial pH — — 7.36 (0.09) 7.26 (0.13)
* encephalopathy giade and OSF expressed as median
* p <0.05, ** p<0.01
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7.4 DISCUSSION
Pretransplant clinical status has a major impact on the outcome of transplantation in acute 
liver failure. Given that the selection of recipients, at least in this centre, is based on 
identification of the most severely ill (often greater than 90% expected mortality) it is not 
surprising that markedly deranged systemic and liver parameters influence the outcome. 
Several important observations emerge from this large study explaining the inferior 
survival figures. Graft loss and death in this series of transplanted ALF patients were 
predominately due to the development of systemic sepsis. This susceptibility to infection, 
present in patients with ALF from an early stage, is continued and possibly initially 
aggravated in the early post-transplant period with the introduction of immunosuppression 
regimens which include high dose corticosteroids (Kusne et al 1988, Canalese et al 1982, 
Rolando et al 1990). In addition, conventional strict criteria applied to graft assessment 
may through necessity be set aside m the emergency transplant situation when there is a 
desperate need for an organ. Early graft dysfunction following use of inferior organs is 
likely to further predispose to sepsis. The high incidence of fungal infection post - 
transplant associated with death is in keeping with previous findings from this unit of the 
frequency of this complication in patients with ALF managed conservatively (Rolando et 
al 1991). Antifungal prophylaxis regimens, although never tested at clinical trial, have 
been incorporated clinically in the later series at this unit.
Patients with ALF aie usually so critically ill that they are unable to undergo the normal 
rigorous pretransplant assessment of cardiorespiratory status which may explain why 
normally avoidable postoperative complications ensued with one patient dying from 
myocardial infarction, in the presence of coronary artery disease, and another from aortic 
dissection (present at the time of transplantation). Possible disease recurrence may also
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have been a significant cause of early giaft failure in patients transplanted with fulminant 
NANB hepatitis (Fagan et al 1992). Graft dysfunction and sepsis presenting at the end of ,1the first week with a rapid deterioration to graft failure and characterised by ‘massive 
haemorrhagic necrosis’ on histological examination may represent recurrence (Hubscher 
et al 1989). Viral particles were demonstrable in the explanted graft in a proportion of Icases in the study by Fagan. The low mortality rate related to cerebral complications 
including cerebral oedema was encouraging and may reflect both the patient selection 
policy and peri-operative monitoring with intra-cranial pressure transducers in high-risk 
patients adopted at this centre (Potter et al 1989). The results of retransplantation were 
poor when carried out within the first two months post-transplant, probably reflecting the 
patients very poor clinical condition at that time.
With respect to identification of pretransplant clinical parameters which may predict post­
transplant outcome, surprisingly, clinical characteristics of the primary hver disease were 
poor discriminators of survival. The various aetiological categories had similar outcomes 
with the exception of idiosyncratic drug reactions (poor outcome) and FWD (100% 
survival). Liver failure from idiosyncratic drug reactions managed conservatively is f
similarly associated with a high mortality, a phenomenon which is presently not explained 
(O’Grady et al 1988c). The excellent results achievable in FWD recipients confirms the 
suitability of these patients for emergency transplantation and is probably a reflection of 
their less rapid downhill clinical course. Additionally, these patients may benefit from 
usually being fit and young and a decision to list can be taken as soon as the diagnosis is
made reflecting the dismal outcome of this condition if managed conservatively (Stemleib
,et al 1984). In relation to the two largest aetiological groups, no significant difference in 
patient survival between NANB / indeterminate liver failure and paracetamol 
hepatotoxicity was detected despite this latter group having the worst indices of both fiver
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damage and systemic critical illness (apache 111 scores). The similar outcomes may 
reflect the use of a prognostic scoring system which identifies patients in these groups 
with a similarly poor prognosis - approximately 1 0 % survival - if managed conseiwatively 
(although the criteria are different) and whose prognosis might be expected to improve 
equally following transplantation. The 2 month patient suiwival rate of approximately 6 8 % 
in patients with FHF who were selected for transplantation on the basis of these criteria 
represents a considerable improvement on that achievable with medical management.
No relationship between outcome and the year the transplant was earned out (8  year study 
period) was noted. This initially surprising result is in line with the recent plateauing of 
outcome, as yet not adequately explained, reported for all recipients by the lar ge tr ansplant 
registries as previously referred to in section 1.1 (Belle and Detre 1993, ELTR et al 
1992). The apparent lack of improvement in overall results in these patients is probably 
best explained by the significant increases in apache 1 1 1  scores over time i.e. sicker 
patients, as indicated by multisystem illness, are being transplanted. An increasing use of 
sub-optimal organs is also likely to prevent further improvements in outcome in this 
par ticular' clinical population where the rapid restoration of adequate hepatic function is so 
crucial.
In the non-paracetamol liver failure group, the critical illness scores at the time of 
transplantation and the presence of renal dysfunction were the most significant parameters 
cort'elating with outcome. Both renal impair-ment and development of systemic sepsis (an 
association recognised in both acute and chronic liver disease), are known to be associated 
with an inferior outcome in patients experiencing FHF managed conservatively (O’Grady 
et al 1988c, Bismuth et al 1987). It would appear that transplantation does not entirely 
remove this deleterious effect with these results supporting previous reports which have
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found that renal dysfunction is an important pretransplant clinical variable in determining 
outcome after transplant for cirrhosis (Cuervas-Mons et al 1986a, Arroyo et al 1993). In 
terms of clinical decision-making, the serum creatinine / renal impairment identifies a sub - 
group of liver failure patients whose prognosis would appear to be only moderately 
improved by transplantation.
In patients with paracetamol hepatotoxicity, the effects of the multi-system illness (as 
reflected in the highest apache 1 1 1  scores in the study) was a more important factor in 
outcome than the severity of the liver failure which indeed is often improving at the time 
of transplantation. The prognostic significance of high apache 111 score reflects the 
widespread effects of severe liver failure. Determination of the apache 111 score, as part 
of the clinical review at the time of proposed transplantation, would appear to allow a 
subjective appraisal of post-transplant outcome. Although critical illness scoring systems 
are not widely applied in liver failure / transplant programmes, adoption of these scores in 
general intensive care units has considerably improved the accuracy of clinical judgements 
on likely patient hospital mortality. Serum bilirubin levels, which rise with time after 
paracetamol overdose in the severe cases considered for transplantation, were also 
associated with a poor outcome and predictably strongly correlated with the period from 
overdose to hepatectomy / transplantation. Prolongation of this interval leading to a greater 
opportunity to develop serious complications not surprisingly led to an inferior outcome 
and reinforces the superurgent requirement for early graft allocation. The indicative value 
of arterial pH in this group is not surprising as the onset of acidosis in multisystem failure 
(not explained by other causes) reflects critically low tissue oxygen extraction / tissue 
hypoxia, a marker of severe often preterminal illness.
This study has focused selectively on the role of pretransplant parameters which are
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probably the most important variables influencing outcome where the patients are so 
critically hi at the time of transplantation. However, other variables such as donor organ 
quality, ischaemia times, intra-operative events and control of rejection all contribute to 
eventual outcome. Excellent early graft function can be expected to reduce the influence of 
the pretransplant parameters described here.
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It is apparent from this data that the final decision to proceed to transplantation, when a 
donor liver becomes available, needs to be a separate decision from the initial selection of 
potential candidates, a policy previously expressed by the French group who recently 
evaluated the Kings criteria for FHF (Pauwels et al 1993). With greater delays in organ 
avahability likely, definition of risk factors at the time of transplantation may permit a 
more informed basis for deciding which patients are too ill to have a successful outcome.
In the initial report on liver transplantation for paracetamol hepatotoxicity from this unit, 
the authors described the ‘window period’ of opportunity for a successful outcome which 
this study emphasises and shows can be applied to other acute liver failure aetiologies
à(O’Grady et al 1991).
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CHAPTER 8
TACROLIMUS (FK506) IMMUNOSUPPRESSION MODIFIES 
REJECTION AND SYSTEMIC COMPLICATIONS FOLLOWING 
TRANSPLANTATION FOR FULMINANT HEPATIC FAILURE
8.1 BACKGROUND AND INTRODUCTION
The outcome of liver transplantation when carried out for FHF remains inferior to elective 
recipients as described in the previous chapter and previously reported (Belle et al 1991, 
see previous references). Selection of patients with liver failure for transplantation is on 
the basis of biochemical or clinical prognostic criteria which indicate an extr'emely low 
probability of survival if tr*eated medically (Bernuau et al 1991, O’Grady et al 1989). As 
shown in chapter 7, these critically ill patients are at high risk of bacterial and fungal 
infection despite prophylactic antimicrobial therapy and close infection surveillance 
(Rolando et al 1990, 1991). Patient loss in these high-risk patients in the early 
postoperative period is often related to the development of severe systemic sepsis and 
multiorgan failure (Quiroga et al 1991). The risk of these complications in all liver 
recipients, but particularly in those patients transplanted for FHF, is probably modified by 
the immunosuppression regimens used (Ascher et al 1988, Kusne et al 1988). 
Conventional regimens based upon CyA and azathioprine include administration of 
high-dose corticosteroid dosage schedules in the early postoperative period. Patients 
experiencing liver failure should be considered to be immunodeficient. Accordingly, they 
are at particular risk from the non-specific immunological effects mediated by high dose 
corticosteroid schedules which constitute a major component of conventional induction 
immunosuppression regimens in the event of a rejection episode (Cupps et al 1982).
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Tacrolimus, a potent immunosuppressant agent recently the subject of controlled clinical 
trials, has been proposed to allow withdrawal of azathioprine and considerably reduce 
maintenance and supplemental corticosteroid schedules through improved control of 
rejection. These modifications in immunosuppression may represent major advances in 
post-transplant care with the early uncontrolled clinical trials of tacrolimus based regimens 
demonstrating both reductions in sepsis and improved patient and graft survival (Starzl et 
al 1989). The advantages of such a regimen may be most readily appreciated in the high 
risk patients transplanted for liver failure.
In this investigation, the outcome of the patients transplanted for FHF who were entered 
into the controlled, European multicentre trial of tacrolimus versus a conventional CyA - 
based immunosuppression regimen (CBIR) from this centre are analysed in relation to the 
clinical course of the early post-transplant period. To put these patients in context, the 
efficacy data of all 50 recipients entered from the participating centres is initially reported 
(unpublished data used with permission of Fujisawa GMBH).
8.2 SU BJECTS
8.2.1 Patient population
50 liver recipients transplanted for FHF (as defined by Trey and Davidson) and who were 
entered into a multicentre, open, prospectively randomised, parallel-group study 
comparing primary tacrolimus immunosuppression (n=22) to a CBIR (n=28) in liver 
transplantation were studied. Randomisation was performed separately in this sub-group 
before surgery using a 1:1 randomisation schedule. Data is presented on a minimum 
follow-up for six months. 17 patients (34%) from this total number were entered in this 
trial from this unit and have been examined in considerably more detail with respect to 
efficacy and safety.
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8.2.2 Immunosuppression protocols
In the first part of the trial, the initial intravenous (IV) dose of tacrolimus of 0.075 mg/kg 
(four hour infusion) was administered within six hours after closure of the abdominal 
wall. This dose was repeated every 12 hours for three days and followed by oral 
tacrolimus therapy at a dose of 0.30 mg/kg day in two divided doses. Subsequently, this 
regimen was modified to 0.03-0.05 mg/kg (12 hour infusion) repeated every 12 hours for 
three days with the same oral dosing schedule. Dose modifications on the basis of graft 
function, efficacy, drug monitoring and drug-related toxicity were performed. Plasma 
levels in the first phase of the trial were maintained initially between 1 - 2  ng/ml with later 
trial protocol dose reductions allowing levels below this range based on clinical 
parameters (assay method: Sep-pak, room temperature separation, ELISA). Corticosteroid 
administration in this treatment group was standardised with initial doses of prednisolone 
(or equivalent) commenced at 2 0  mg/day with reductions as clinically indicated. 
Azathioprine was not routinely administered in this group except if desired during |
tacrolimus interruption or withdrawal.
The CyA based regimens were centre-specific, with each programme maintaining their 
preferred optimal immunosuppression regimen at the time of protocol design (1989) 
throughout the study period. All induction maintenance regimens included CyA (2-6
■'U
mg/kg day), azathioprine (1-3 mg/kg day) and corticosteroids (0.2-10 mg/kg day) with f
anti-lymphocyte globulin administered in induction schedules additionally in three centres.
In this centre, this regimen in the early post-operative period comprised a triple therapy 
schedule of CyA (target whole blood levels 120-150 ng/ml, monoclonal RIA, Incstar), azathioprine 
(dosage: 1 mg/kg/day) and prednisolone 60 mg/day. Maintenance immunosuppression was 
similarly based, in the absence of drug-related comphcations, on a tiiple therapy regimen 
with CyA levels maintained between 100-150 ng/ml and prednisolone dosage at 
0.08-0.10 mg/kg/day.
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Supplemental anti-rejection protocols were similarly centre-specific with this regimen in 
this centre comprising an initial course of hydrocortisone 1 g twice daily IV for two days 
followed by 1 g once daily for three days. Rejection episodes resistant to this regimen 
were treated with an additional course of methylprednisolone 1 g once daily IV for three 
days.
8.2.3 Efficacy and safety pai’ameters
Patient and graft survival was analysed using Kaplan-Meier methods and the survival 
times compared between the treatment groups using the generalised Wilcoxon test. As a 
large proportion of clinical events were in the early post-transplant period this test was 
employed which is more sensitive for early events in life-table analysis. Patients who died 
or undeiwent retransplantation weie defined as having graft failure. The same conventions 
were employed for the time to first rejection / intractable rejection with distribution of 
events between the study groups compared with the Cochran-Mantel-Haenszel procedure. 
Protocol liver biopsies were performed on day 7 and whenever a rejection episode was 
clinically or biochemically suspected. In the detailed analysis of patients from this unit, 
outcome of the study population was detemiined by measurement of routine clinical and 
biochemical parameters, in addition to prognostic scoring systems (apache 1 1 1  and 
therapeutic inteiwention scoring system [TISS]) used in the assessment of critically ill 
patients (Knaus et al 1989, Knaus et al 1991). These results are expressed as median 
[mean] and compared using chi-squared methods or Fishers exact test where appropriate.
I
3
133
8.3 RESULTS
8.3.1 Patient and graft survival
From the complete series of fifty (50) patients, survival at six months in the tacrolimus 
recipients was 72.7% compared to 60.7% in the CBIR treated patients (ns). A consistent 
trend towards improved patient survival was detected in favour of tacrolimus treated 
patients with this pattern apparent from week 1 (95.5% versus 82.1%) (figure 8.1). A 
similar benefit was also noted for primary graft survival in the tacrolimus group with a 
survival at six months of 72.7 % compared to 53.6% in the CBIR group (ns).
8.3.2. Rejection and graft function
A significant reduction in the cumulative rate of a first acute rejection episode was 
demonstrated in the tacrolimus group compared to the CBIR patients at one week (19,3% 
versus 59.1%) with considerably lower rejection frequency in the early post-operative 
period (figure 8.2). Similarly, there was a marked reduction in the intractable rejection rate 
between the groups. The intractable rejection rate of 22.6% in the CBIR group by six 
months with a rate of 6.2% in the tacrolimus treated patients (table 8.1). Notably, the rates 
of rejection and in particular intractable episodes were considerably higher in fulminant 
patients than elective recipients irrespective of immunosuppression, although these rates 
were always lower in the tacrolimus treated patients.
134
1.0
13 0.8>
0.6
0.4
W 0.2
%!
0.0
tacrolimus
CBIR
0 2 3 4
post-transplant (months)
Figure 8.1 Cumulative actuarial patient survival to 6 months following 
transplantation in the patients transplanted fo r  fulm inant 
hepatic failure who were administered either a tacrolimus 
(ii=22) or CyA (n=28) based immunosuppression regimen 
(C B IR ).
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Figure 8.2 Lower cumulative risk of acute allograft rejection in those 
patients administered tacrolimus compared to conventional 
CyA based regimens (CBIR) following transplantation fo r  
fulminant hepatic failure.
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Table 8.1 Cumulative incidence of acute (including intractable) rejection 
rates at 6 months in both emergency and elective patient 
groups in the 2 immunosuppression groups
Tacrolimus (%) CBIR (%)
recipients rejection
acute 65.5 73.2
FHF(n=50)
intractable 6.2 22.6
acute 40.5 53.7
Elective (n^490)
intractable 3.1 9.4
acute 42.0 54.7
All (n=540)
intractable 2.9 10.1
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8.3.3. Kings College Hospital Experience
The clinical characteristics of the two treatment limbs of the study population were not 
significantly different in the treatment groups with a similar pretransplant status and donor 
organ characteristics (table 8.2). All donors and recipients were ABO compatible. The 
median grade of encephalopathy in the tacrolimus (2.5) and the CyA recipients (3) was 
similar, with evidence of cerebral oedema present in 2 of 8  and 3 of 9 patients 
respectively. Renal replacement therapy was required in 3 of 8 of the tacrolimus recipients 
and 4 of 9 CyA recipients prior to transplantation. The actuarial one-year patient and graft 
survival at six months post-transplant or at retransplantation was 87% (7 of 8 ) in the 
tacrolimus group and 53% (5 of 9) in our CyA treated patients (ns). Current follow-up of 
the population reveals an actuarial patient survival of 75% (6  of 8 ) in the tacroHmus and 
44% (4 of 9) in the CyA group (ns). The causes of the two deaths in the tacroUmus 
recipients was segmental hepatic infarction leading to retransplantation and subsequent 
sepsis / multi-system organ failure (MOF) and primary sepsis / MOF. In the CyA treated 
patients, patient loss (n=5) was due to graft versus host disease / MOF, chronic rejection 
requiring retransplantation and subsequent development of haemorrhagic pancreatitis /  
MOF and primary sepsis / MOF (3 cases).
Apache 111 and TISS scores were lower in the tacrolimus recipients particularly in the 
first post-transplant week and 5 of 8 (63%) tacrolimus-treated patients were discharged 
from the ICU by the end of the first week compared to 3 of 9 (33%) of the CyA-treated 
recipients (table 8.3). The median period to self ventilation in survivors was 3 days in the 
tacrolimus group and 5 days in the CyA recipients (ns). Early graft function was superior 
in the tacrolimus hmb as assessed by routine clinical measurements of serum levels of 
aspartate aminotransferase (AST) and bilirubin (table 8.4).
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Table 8.2 Clinical and demographic data o f the 17 patients entered into 
the European tacrolimus primary liver transplant study from  
this unit prior to transplantation with donor organ ischaemia 
times and intra~operative blood loss.
Tacrolim us
(n=8 )
Cyclosporin A
(n=9)
age (yr)
median 34 35
range 18-53 17-64
sex
MIF 2 \ 6 3\6
aetiology
paracetamol 2 2
nonA-nonB 3 2
hepatitis A/B 4
Wilsons 2
drug 1 1
apache 111
median 53 62
range 19-91 19-78
infection
suspected 318 419
confii-med 318 219
donor organ
total ischaemia 1 2 . 6 9.5
time (hrs) 
surgery
intra-operative 2617 3250
blood loss (mis)
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Table 8,3 Critically ill prognostic scores (Apache 111 and TISS) in the 
early post-transplant period in the Kings College Hospital 
patient series.
APACHE 111 TISS
post-Tx day cyclosporin A tacrolimus p value cyclosporin A tacrolimus p value
1 71 58 ns 37 35.5 ns
3 67 55 0.05 37 28 0 . 0 2
7 53 45 0.08 14 7.5 ns
14 46 40 ns 8.5 4 N/A
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In the tacrolimus treated patients, levels of AST were significantly reduced in the first 
week following transplantation in comparison to those on CyA with the largest difference 
between the regimens noted on the seventh postoperative day (78 vs 326 IU/1, p<0.05). 
Similarly, the serum bilirubin did not rise significantly in the tacrolimus patients in 
comparison to the CyA ones with levels lower in tacrolimus recipients throughout the 
early post-transplant period (e.g. post-operative day 7: 188 vs 352 pmol, p<0.05). 
Reflecting the chnical parameters above, the median intensive care unit admission (either 
discharge or death) was lower in the tacrolimus group compared to the CBIR group 
(median period: 6  vs 11 days).
Thirteen episodes of acute rejection proven histologically occurred in the CyA recipients 
with aU patients experiencing at least one episode (1.38 episodes per patient). Control of 
rejection was achieved following one cycle of supplemental corticosteroids in nine 
episodes with a further four episodes requiring an additional cycle of steroids. Two 
patients developed intractable rejection and were switched to rescue therapy with 
tacrolimus. In one, rejection was successfully reversed with the other patient requiring 
retransplantation. In the tacrolimus limb, only four episodes of rejection were documented 
all of which were reversed by one cycle of supplemental corticosteroids in four patients 
(0.5 episodes per patient) (p 0.02). The total steroid requirements in the first thirty days 
following transplantation (prednisolone equivalent dose/day graft survival) was 150 
mg/day in the CyA treated patients as compared with 69 mg/day in those administered 
tacrolimus (p 0 .0 1 ).
A higher mcidence of infection episodes in the CyA limb (2 [2.11 per patient]) compared 
to the tacrolimus limb (1 [0 . 8 8  per patient]) (p <0 .0 1 ) was noted with sepsis a major 
contributing factor to all deaths in the study population. The majority of these infection 
episodes were either of confirmed or suspected bacterial sepsis with the number of viral 
infections insufficient for analysis.
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Table 8.4 Early graft function as assessed by serial liver function t e s t s  
(serum bilirubin and amino aspartate transferase [AST]) in the 
first month following transplantation.
A ST (lU /L) Bilimbin (jxmol)
day CyA Tacrolimus P CyA Tacrolimus P
3 303 (106) 152 (40) <0.05 193 (31) 184 (64) ns
7 326 (100) 78 (23) <0.05 352 (64) 188 (48) <0.05
14 105 (17) 70 (31) ns 357 (60) 182 (77) <0.05
28 119 (43) 74 (20) ns 70 (10) 35 (7) <0.05
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Two patients in the CyA limb additionally developed systemic / cerebral nocardiosis at 6  
and 8 months post-transplant. There were no protozoal infections in the tacrolimus-treated 
group.
Major neurological complications were infrequent in this study population despite the 
severity of pre-transplant hepatic encephalopathy. There were no episodes of seizures in 
either group with one patient in the tacrolimus group experiencing a possible episode of 
central nervous system toxicity (aphasia persisting until the second post-transplant week). 
No significant psychiatric or confusional episodes were seen. Renal impairment was 
common in these patients with dialysis required in 3 of 8  tacrolimus recipients and 4 of 9 
CyA recipients (the same patients who required pretransplant dialysis) with calculated 
creatinine clearance rates similar between the groups. The clearance rates were 53 ml/min 
at seven days, 70 ml/min at three months and 82 ml/min at 12 months in the tacrolimus 
group with the rates of 58 ml/min, 81 ml/min and 85 ml/min in the CyA group 
respectively (ns).
8.4 D ISCU SSIO N
This present study demonstrates the potential benefits available with a tacrolimus-based 
immunosuppression regimen in those high-risk recipients transplanted for FHF compared 
to conventional schedules. In tacrolimus recipients, an improvement in a range of standard 
clinical and biochemical parameters in relation to both graft function and systemic illness 
was demonstrated. Easier control of allograft rejection and a reduction in the prevalence of 
severe systemic sepsis are the main explanations for the superior graft function and 
outcome in the tacrolimus recipients. The potent immunosuppression available with this 
agent permitted a substantial reduction in total steroid requirements which will have been a
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major contributing factor to the reduction in systemic sepsis. The reduction in steroid 
exposure is mainly derived from a decrease in the frequency of rejection and hence high - 
dose supplemental corticosteroid schedules (which in this centre comprise 
methylprednisolone Ig daily for three days).
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Liver function can be severely affected by systemic sepsis with the development of a 
prolonged cholestatic syndrome, and it is therefore interesting to note the lower level of 
bilimbinaemia in the tacrolimus-treated compared to the CyA-treated patients (Carima et al 
1982), Other possible explanations for the differences in graft function may be the 
hepatotoxic and hepatoti'opic profiles of these major immunosuppressants. CyA has well - 
documented cholestasis effects, a phenomenon not reported under tacrolimus (Kahan et al 
1987). This latter agent also appears to have significant hepatotropic properties with an §
early report suggesting that this may be considerably superior to CyA (Francavilla et al |
1991).
Excellent long-term graft function in those recipients immunosuppressed with tacrolimus 
monotherapy supports the withdrawal of corticosteroids and azathioprine from 
mahitenance regimens and thereby removing the serious long-term complications of these 
agents. There would not appear to be a major hazard to this undertaking in patients 
transplanted for FHF in whom there is no evidence that primary disease recunence would
be promoted by removal of these agents. One notable exception to this principle would be #!?■
the small number of patients transplanated as an emergency for a fulminant presentation of 
AIH. Disease recurrence in this group may be reduced by continued immunosuppression 
with steroids and azathioprine (see section 11.5.1). The attendant hazards from long-term 
azathioprine administration, particularly in relation to hepatotoxicity, which are avoided 
with a tacrolimus monotherapy schedule were discussed in chapter 2. It is not clear 
whether tacrolimus has any advantage over a CyA-regimen when it comes to a steroid - 
sparing effect. Experience from the programme in Birmingham, UK, would appear to 
indicate that early steroid withdrawal may be possible in both treatment schedules without
a deterioration in graft function (Draitiewski et al 1994).
The absence of any major neurological complications or long-tenn renal impairment in 
these patients was reassuring. These patients who were all encephalopathic and had a high 
prevalence of renal dysfunction were at particular risk from immunosuppressant related 
neurotoxicity and / or nephrotoxicity. In this present study, no significant difference in the 
toxicity profile of the major immunosuppressants was detected.
As a separate obseivation, it is interesting that the rates of rejection (including intractable) 
were higher in the patients in this population of FHF transplanted patients compared to 
elective recipients emphasising the requirement for potent immunosuppression in this 
group. The mechanisms underlying this phenomenon require to be deteiinined.
The importance of immunosuppression in affecting outcome in the early post-operative 
period is probably best examined in high-risk patients where the benefits and pitfalls of 
regimens are amplified and readily detectable. This may explain why the benefits of 
tacrolimus immunosuppression are more obvious in these patients with ALF than in the 
elective recipients where the benefit in survival is less than 10% at one year. An improved 
control of rejection should deliver not only reduced immunological graft failures (which is 
dramatic with tacrolimus) but also reduced deaths from sepsis which this separate analysis 
would tend to support. The paiticulai' trial from which the study population was entered 
suffered from a number of major design deficiencies which included major positive and 
negative biases to the trial agent. Centres had the option of converting patients 
experiencing intractable acute and chronic allograft rejection from CyA to tacrolimus 
which inevitiably artifically supported the survival figures in the control limb. 
Additionally, the influence of the major dose reduction in the tacrolimus schedule may 
significantly alter the efficacy and toxicity profile.
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CHAPTER 9
IMMUNOPROPHYLAXIS AND IMPROVED PATIENT SELECTION 
REDUCES DISEASE RECURRENCE FOLLOWING ELECTIVE 
TRANSPLANTATION FOR HEPATITIS B SURFACE-ANTIGEN
POSITIVE PATIENTS
9.1 BACKGROUND AND INTRODUCTION
Disease recurrence following transplantation was identified in chapter 2 as a major cause 
of graft damage and loss. In particular, the recurrence of hepatic malignancies and of 
primary viral transplant indications were most problematic. Improvements in patient 
selection for malignancy with exclusion of cholangiocarcinomas and large multifocal HCC 
has reduced the recurrence rate in this indication. Alongside these improvements, 
increased awareness of the predisposing features for recurrence of HBV infection 
following transplantation and the clinical availability of hepatitis B immunoglobulin 
(HBIG) should allow improvement in the outcome of HBsAg-positive recipients. End - 
stage liver disease from HBV infection remains the largest potential population of liver 
recipients worldwide. The natural history of this infection after liver transplantation has 
previously been described from this unit in a cohort of HBsAg positive patients in whom 
selection for transplantation was not determined by pre-transplant viral serology and who 
did not receive long-term passive immunoprophylaxis (O’Grady et al 1992). Following 
serological recurrence, a significant proportion of patients go on to develop either 
cirrhosis or the distinct syndrome of fibrosing cholestatic hepatitis a condition which is 
characterised by a unique histological pattern in the presence of a rapidly progressive 
deterioration in graft function (Davies et al 1991). The outcome of this clinical group
146
serves as important control data in the assessment of possible improvements in patient 
selection and the use of immunoprophylaxis in modifying disease recurrence and the 
nature and severity of associated graft injury. Considerable uncontrolled data suggests that 
HBV DNA-negative recipients have a lower rate of serological recurrence and that 
long-term passive immunoprophylaxis regimens further reduces the recurrence rate 
(Samuel et al 1991). Co-existent hepatitis delta virus (HDV) infection has also been 
described as delaying serological recurrence of HBV and diminishing graft injury (Samuel 
et al 1992).
In this study, this units experience in a group of HBsAg-positive recipients transplanted 
for related chronic liver disease and who have received systematic and prolonged 
immunoprophylaxis alongside a stricter patient selection policy (HBV DNA-negative or 
HDV-positive candidates preferred) was compared with the previous experience in 
historical untreated controls as reported above. Additionally, in this present series of 
patients a rapid steroid withdrawal schedule was initiated as a modification to our triple 
therapy immunosuppression regimen to offset the potential role of corticosteroids in 
promoting HBV replication (Tur-Kaspa et al 1986). The consequences of co-existent 
HDV infection in relation to both serological and disease recurrence and overall patient 
survival have also been examined.
9.2 SUBJECTS
9.2.1 Patients and methods
The study series comprises 56 HBsAg-positive elective liver transplants who survived 
beyond the early postoperative period ( 2 1  days) and who were divided into two groups 
based upon the introduction of immunoprophylaxis and a rapid steroid withdrawal 
regimen in April 1989. The earlier cohort (group 1) comprised 29 HBsAg-patients who
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9.2.2 Immunoprophvlaxis with hepatitis B immunoglobulin
underwent transplantation between December 1975 and April 1989 (24 male, 5 female, 
median [range] age 37 [23-63] years). With the exception of the three earliest patients, 
immunosuppression was based upon a CyA triple therapy regimen with no modification 
made because of the presence of HB V infection. One patient received a short-term course 
of polyclonal anti-HBsAb in the early post-transplant phase. The median (minimum) 
follow-up in this group was 5.9 (4) years. The second cohort (group 2) was made up of 
27 HBsAg-patients who were transplanted between May 1989 and May 1992 (23 male, 4 
female, median [range] age 43 [29-60] years). All patients in this group, were 
immunosuppressed in the early phase with this units conventional CyA triple therapy 
regimen and underwent a rapid corticosteroid withdrawal regimen (prednisolone 40 mg at 
week one, 30 mg at week two, 20 mg at week three and 10 mg at week four with 
discontinuation where possible by three months). The median (minimum) follow-up of 
group 2 was 2.2 years and 10 months. No patients with HBV-related fulminant liver 
disease were included in this study.
HBIg (polyclonal anti-HBs immunoglobin, United Kingdom Blood Transfusion Service, British 
Products Laboratory, Ltd.) was administered to the group 2 patients in a standard regimen 
based upon a modification of the schedule recommended by the Paris group. In the 
anhepatic phase of the transplant, 5(XX) lU of HBIg was administered intravenously and 
in the early post-operative phase 2000-5000 lU administered intramuscularly on 
consecutive days until clearance of HBsAg was demonstrated. Further administration was 
determined by circulating anti-HBs titres with the object of maintaining levels above 100 
IU/1 indefinitely (2000-5000 lU per dose) [Paris group administered 10000 lU  daily for the first 
week with additional 10000 lU  when anti-HBs titres approached 100 IU/1]. If HBsAg persisted or 
recurred in serum further immunoprophylaxis was withheld.
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9.2.3 Pre-transplant hepatitis B. C and D virus status
HBV status prior to transplantation was determined by standard commercially available 
kits. Radioimmunoassay or microparticle capture enzyme immunoassay was used to 
measure HBsAg, HBeAg, anti-HBs and anti-HBe (Ausria II, Abbott HBe (rDNA), 
Ausab, Abbott, North Chicago, IL). Total anti-delta antibody was tested by 
radioimmunoassay or enzyme immunoassay (Sorin Biomedica, Italy). HBV DNA was 
detected in group 1 by a quantitative dot-blot technique as previously described and in 
group 2 detected and quantified by the Hepatitis B viral DNA assay (Abbott, North 
Chicago, IL) (Fagan et al 1985). Hepatitis C antibody (HCVAb) was determined 
retrospectively by second generation enzyme immunoassay (United Biomedical. Inc., 
Lake Success, N.Y., U.S.A). Based upon the pre-transplant serological profile, the 
patients in the two groups were divided into three sub-sections: (a) non-replicative HBV 
infection (HBV DNA seronegative), (b) replicative HBV infection (HBV DNA 
seropositive or HBeAg positive where HBV DNA unavailable) and (c) HBV infection 
(irrespective of replication status) with co-existent HDV infection (tables 9.1 and 9.2).
Actuarial rates of HBsAg recurrence and patient survival were calculated by life-table 
analysis and statistical significance compared with the log-rank test. Circulating HBV 
DNA titres were compared with the Mann-Whitney U test with other differences in 
frequencies between groups estimated with the chi-square test (with continuity correction 
where appropriate).
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Table 9,1 Pretransplant hepatitis B serology in the historical control 
patients who were selected for transplantation on clinical need  
and did not receive immunoprophylaxis (group 1).
Case HbsAb HbeAg HBeAb HBVDNA A n t i -H D V
(a) HBV alone without viral replication
1 - N.D. N.D. N.D.
2 - - - - »
3 - - + - -
4 “ - + - "
5 + - + - -
6 - - + - -
7 - “ + - -
8 - - - - ”
9 - - + - -
(b) HBV alone with viral replication
1 0 - - + 1 1 -
1 1 - " + 1 0 -
1 2 - - + 1 0 -
1 3 - - + 76 -
1 4 - + - N.D. -
1 5 - + - 21 "
1 6 - - + 98
1 7 - + - 131
1 8 - + - N.D. -
1 9 N.D. + N.D. N.D. "
20
(c) HBV and delta
+ 1 1
21 - - - - +
22 - - + - +
23 - - - “ +
24 - - -t- - +
25 - - + 1 2 +
26 - - + 1 5 +
27 - - + 9 +
28 - - + - +
29 + +
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Table 9.2 Pretransplant hepatitis B serology in the latest patients who 
underwent a more rigorous selection procedure and who were 
administered long-term passive immunoprophylaxis (group
2h
Case HBeAg HBeAb HBVDNA A n ti -H D V HCVAb
(a) HBV alone without viral replication
2 4- - - -
3 + - - ND
4 + - - +
5 weak + - - -
6 + - - -
7 + - ”
8 n/a n/a - -
9 n/a n/a - " -
(b) HBV alone with viral replication 
1 0 +  - +
1 1 + + -
12 + + - -
1 3 + + -
1 4 + + - -
15 + + - r-
(c) HBV and delta 
16 -  + +
1 7 + - + «
1 8 ND ND - + ND
1 9 + - + -
20 + + + 4-
21 + - + «
22 + - + ■f
23 + - + 4-
24 + - + 4"
25 + + +
26 + - +
27 + “ + •*
precore mutant
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9.3 RESULTS
9.3.1 Serological recuiTence
In the earlier group of patients, 9 (31%), 11 (38%) and 9 (31%) patients were in the non - 
replicative, replicative and HDV-positive sections respectively prior to transplantation and 
9 (33%), 6  (22%) and 12 (44%) patients in group 2. The six HBV DNA-positive 
recipients in group 2  had been recruited early during the second series as they were 
otherwise good candidates for an elective transplant. Comparison of rates of serological 
recuixence in the two groups shows a significant reduction since 1989, with one-year 
actuarial recuixence rates of 90% in group 1 and 48% in group 2 (p<0.05) (figure 9.1). In 
addition, the median time to recurrence has also been significantly extended (group 1 one 
week [0-34 weeks] and in group 2 10 weeks [0-32 weeks]) (p<0.05). When considered 
in relation to the state of pretransplant repHcation, virtually all patients as assessed by the 
presence of HBV DNA experienced serological recurrence of HBsAg irrespective of 
whether or not they were administered HBIg (11/11 in group 1 and 5/6 in group 2 ). 
Immunoprophylaxis appealed to have more beneficial effects in the subsections of non - 
replicating and HDV-positive patients. Within the HBV DNA-negative recipients, 
recuixence was significantly reduced at one-year from 7 of 8  patients (78%) in group 1 to 
3 of 9 (33%) in group 2 (p<0.05). Similarly in the HDV-positive recipients, a beneficial 
effect from immunoprophylaxis was apparent with the one-year recuixence rate in group 1 
89% as compared to 33% in group 2 (p<0.05) (table 9.3).
9.3.2 Hepatitis B serological findings and HBV DNA levels
Following initial detection of serum HBsAg, levels of serum HBV DNA rose steadily in 
all patients, becoming detectable at a median of 2  weeks.
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Figure 9.1 Reduced HBsAg recurrence in those patients selected more 
rigorously fo r  transplant and who received long-term  
immunoprophylaxis
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Table 9.3 HBsAg serological recurrence in relation to pretransplant
HBV and HDV recipient status
H B V  s ta tu s Actuarial HBsAg recurrence (%)
6 months 12 months 18 months
G ro u p  1
HBV DNA positive (n=ll) 91 91 91
HBV DNA negative (n==9) 57 78 78
HDV positive (n=9) 89 89 89
G ro u p  2
HBV DNA positive (n=6 ) 84 84 84
HBV DNA negative (n=9) 2 2 33 33
HDV positive (n=12) 25 33 33
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The median titre of HBV DNA rose from 58 pg/40pl prior to transplantation to a 
maximum level of greater than 800 pg/40pl (dot-blot assay) following recuiTence in the 
replicating recipients (11/ 1 1 ) in group 1 and from a median pretransplant level of 45 pg/ml 
to 843 pg/inl (768-1282 pg/ml) (Hepatitis B viral DNA assay) in this category of patients in 
group 2 (5/6). A difference in the levels of maximum HBV DNA titres attained in relation 
to pretransplant HBV status was noted with the median titres amongst group 1 patients 
[insufficient recurrence in group 2] being 800 pg/40|ll in non HDV-positive patients compared 
to 181 |ig/40pl in the HDV-positive recipients (p<0.05).
Following recurrence, those patients who were HBeAg-negative prior to transplantation 
invariably developed HBeAg positivity with loss of anti-HBe if this had been present 
previously. Of the 6  patients who have become HBV DNA-negative following HBsAg
-',-Crecurrence (4 patients in group 1, 2 in group 2), 5 had coexistent HDV infection. In 3 of 
these patients, clearance of HBV DNA has been associated with seroconversion of I
HBeAg positivity with the development of anti-HBeAb. Of a total of 6  patients who have 
cleared HBsAg, 4 patients were HDV-positive with the remaining two being HBV DNA - 
negative prior to transplantation. No HBV DNA-positive patient in the series has 
seroconverted HBeAg or cleared circulating HBV DNA.
9.3.3 Patient survival
Actuarial patient survival was significantly improved in the most recent patients compared 
to the earlier group 1 cases with one and two years survival of 62% and 48% [group 1] 
and 8 6 % and 80% [group 2] (p<0.05) (figure 9.2). A comparison of actuarial patient |
survival in the recipients classified by their pre-transplant status demonstrated that since 
(1989) there has been an improvement in survival of the pre-transplant HBV DNA - 
positive patients at current follow-up (1/11 [9%] group 1 vs 4/6 [67%] group 2, p 0.05)
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(table 9.4). In the non-replicating recipients, there is no significant difference in patient 
survival. Taking aU the non HDV-positive patients together in group 2 irrespective of pre - 
transplant replicative status, current survival is 11/15 (73%) versus 5/20 (25%) in group 1 
(p<0.05). A comparison of those patients who experienced recurrence in group 1 (25/29) 
and in group 2  (12/27) reveals that HBV directly led to death of the patients in 12/29 
[41%] and 4/27 [15%] respectively (p<0.05). The median period to patient loss in group 
1 was 9.5 months and 7 months in group 2. The better patient survival in HDV-positive 
recipients in group 1 (89% one-year survival) has been maintained in the group 2 series 
(92%). Taking the two groups together, HDV-positive patients have a one-year patient 
survival of 90% (19/21) versus 45% (16/35) in the HDV-negative patients (p<0.05). The 
current one-year survival in all HDV-positive recipients and patients in group 2 is similar 
to a consecutive cohort of 100 cirrhotic HBsAg-negative patients who underwent elective 
transplantation from (1989)-(1991) (8 6 % versus 89%, ns) and who survived beyond 3 
weeks.
9.3.4 Graft injury
In the recent series there appears to have been a reduction in the graft injury associated 
with serological recurrence. Amongst the 12 patients in group 2 who have experienced 
recurrence, fibrosing cholestatic hepatitis (FCH) has occurred in 3 (11%) patients (3, 9 
and 1 2  months respectively) with subsequent patient loss despite retransplantation in two. 
This is to be compared with 7 (24%) patients with FCH in group 1 (median onset 6.5 
months) leading similarly to rapid death (a clinical suspicion of FCH was also present in a 
further 3 cases but no tissue was available for histological confirmation).Thus the 
development of confirmed FCH has accounted for 10/16 [63%] of the total HBV 
recurrence-related deaths. In the remaining 9 patients in group 2 experiencing HBV 
recurrence, one patient died 4 months post-transplant with massive hepatic necrosis 
present in the peri-mortem biopsy, chronic active hepatitis (CAH) is currently present in 
five (fibrosis is present in three), and minimal or mild chronic hepatitis in four.
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Figure 9.2 Im proved patient survival in recipients (group 2) who 
underwent the new selection and treatment policy.
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Table 9 .4 Patient survival in relation to pre-transplant H BV and HDV
recipient status
HBV status Actuarial patient survival (%)
6 months 12 months 18 months
Group 1
HBV DNA positive (n=ll) 87 45 9
HBV DNA negative (n=9) 89 56 56
HDV positive (n=9) 89 89 89
Group 2
HBV DNA positive (n=6) 80 80 67
HBV DNA negative (n=9) 89 78 78
HDV positive (n=12) 92 92 92
•Ï.,
I
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There have been no deaths in the recent patients from hepatic decompensation 
consequent on development of chronic active hepatitis or cirrhosis. All together there 
were seven patients [5 in group 1, 2 in group 2] who underwent retransplantation for 
severe graft injury following HBsAg recunence at a median post-operative period of 24 
weeks (8-56 weeks). Circulating serum HBV DNA in those patients immediately prior 
to retransplantation was greater than lOBOpg/ml in all cases measured. Six of these 
patients died either from rapid HBsAg recurrence or early multi-organ failure with four 
of this group developing a post-transplant course characterised by rapid HBV 
serological recurrence and early graft failure despite administration of laige prophylactic 
doses of HBIg in three patients. Four patients died within one week, and one patient 
each in the fourth and twenty-second week after retransplantation.
9.4 D ISCU SSIO N
Recuixence of HBV following liver transplantation is the main reason for the restriction 
of this management option in HBV-related end-stage liver disease. Recurrence is 
presently one of the commonest causes for transplant failures beyond the early post - 
operative period and has resulted in several centres declining to transplant ah HBsAg - 
positive patients. However, long-term passive immunoprophylaxis appears to 
significantly modify HBV recuixence and associated graft injuiy. The benefits are clearest 
in those HDV-negative recipients in whom, with a moderate reduction in the frequency of 
recurrence, there is a significant improvement in patient survival. Within this sub-group, 
immunoprophylaxis appears to reduce serological recurrence especially in the non - 
replicating recipients, whereas in the replicating recipients although recurrence is not 
prevented thei'Q is also an improvement in patient survival. This data on the benefits of 
immunoprophylaxis, in relation to HBV DNA status, is similar to those results obtained 
from the other large published series by Samuel et al (1991). In their HBV DNA-
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negative recipients with chronic liver disease, 2 year actuarial HBV recurrence rate was 
reduced to 29% whereas in the replicating recipients the rate remained high at 96% (33% 
and 83% in our comparative groups). Similarly, there was no significant difference in 2 
year patient survival between replicating and non-replicating recipients (52% vs 60% 
respectively, ns [67% and 78% respectively in our patients]). These data do not justify 
the exclusion of HBV DNA-positive patients from consideration for elective 
transplantation.
In addition to decreasing the frequency of HBsAg serological recurrence, HBIg may 
modify graft injury in those recipients who do experience recurrence. Amongst the i
possible explanations for this effect of HBIg, the timing of HBV recurrence (delayed 
with immunoprophylaxis) may be crucial if there is a graft susceptibility factor or if the 
level of concuiTent immunosuppression is playing a substantial role in the pathogenesis 
of graft injury. In the early post-transplant phase, the graft which is often already 
compromised by the common post-transplant complications (which include other viral 
infections) may be at particular risk of further insult in the form of HBV recurrence. An 
analogy exists with the increased graft susceptibility to vascular complications in the 
early post-operative period. A major arterial thrombosis is often tolerated at least in the i
medium-term as a late-onset complication but has disastrous sequelae if occurring in the 
early post-operative period as discussed previously. Delaying recurrence beyond the 
early post-operative period also avoids the potential additive risk of a high level of i
immunosuppression in enhancing viral replication and antigen load in liver cells due to 
the glucocorticoid-responsive element of HBV. Steroid requirements as part of both 
maintenance and supplemental regimens are maximal in this period due to the level of 
immunosuppression required to control the rejection process. The precise effects of 
other immunosuppressant agents, which inhibit T-cell activation, on HBV replication 
require to be determined. Severe rejection problems were not experienced with the rapid 
steroid withdrawal regimen. Indeed there is some evidence that HBsAg-positive patients
may be at lower risk of allograft rejection than other recipients which could permit 
further reductions in maintenance immunosuppression (Adams et al 1991).
The value of pretransplant anti-viral therapy with a-interferon in all HBsAg-positive 
patients and in particular with the replicating candidates requires to be defined. Attempts 
to elicit seroconversion and / or inhibition of HBV replication prior to transplantation 
with administration of a-interferon is often accompanied by significant morbidity in 
these patients who have end-stage chronic liver disease and at present there is no 
evidence that this treatment reduces the HBV reinfection rate following transplantation 
(Marcellin et al 1992). However a range of new anti-viral agents are becoming available 
(such as Lamuvidine and gancyclovir) which will require clinical assessment as will the 
use of concurrent anti-viral chemotherapy with immunoprophylaxis regimens.
These results demonstrate a reduced frequency of HBsAg recurrence in HDV-positive 
recipients receiving immunoprophylaxis. The presence of HDV also appears to modify 
the severity of graft injury with patient survival in HDV-positive recipients comparable 
to HBsAg-negative recipients. Successful use of HBIg in post-HBV / HDV hepatitis 
recipients appears to prevent graft injury although HDV RNA can still be detected by 
reverse transcriptase-PCR in the first post-transplant year (Samuel et al 1991). Although 
there is no difference in current patient survival in HDV-positive recipients whether they 
received HBIg or not, the rate of serological recurrence is lower in the treated group and 
this may translate into a difference in patient survival with longer follow-up. The 
beneficial effect of co-existent HDV infection is likely to be a reflection of this agents 
ability to inhibit HBV replication and our data which indicates lower peak HBV DNA 
levels after viral recurrence in these patients and a high proportion of patients who have 
subsequently either cleared HBV DNA or HBsAg also being HDV-positive supports 
this hypothesis (Genesca et al 1987).
There appears to be no current clinical role for re transplantation following the graft
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damage consequent on HBsAg recurrence. We have had no survivors in this situation 
irrespective of further immunoprophylaxis and a recent series has reported only one
,.■1survivor from a study population of twenty patients (Crippin et al 1992). As shown by 
the findings in this present study the poor outcome may reflect the veiy high HBV DNA 
levels present in the recipients prior to retransplantation.
The anti-HBs Ig regimen which was followed is based upon the schedule recommended a
by the Paris group with HBIg being given in dosages sufficient to maintain anti-HBs ttitres greater than 100 IU/1 without discontinuation in the absence of recurrence. The 
requirement for indefinite immunoprophylaxis is based upon the identification of HBV 
DNA by PCR in extra-hepatic sites which serves as a basis for graft reinfection (Feray 
et al 1990). With late graft reinfection reported one year beyond transplantation and the |
absence of data based upon PCR in relation to the persistence or clearance of extra - 
hepatic foci of HBsAg following prolonged HBIg, we currently follow an indefinite 
immunoprophylaxis regimen. Although our total recurrence rate in HBIg-treated patients 
is similar to non-fulminant HBV patients from the Paris group, our median period to 
recurrence was significantly shorter which may reflect a lower dosing schedule in the #
yearly post-operative period. Furthermore, three-year serological recurrence rates of less
than 10% have recently been reported by Gugenheim et al (1992). in non-rephcating
recipients where polyclonal HBIg was administered to maintain anti-HBs titres above
500 IU/1. If, as appears likely, a dose-response effect to immunoprophylaxis does exist, 
there are considerable implications with respect to the long-term costs of high dose 
regimens.
Î
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CHAPTER 10
N-ACETYLCYSTEINE IMPROVES INDOCYANINE GREEN 
EXTRACTION AND OXYGEN TRANSPORT DURING HEPATIC 
DYSFUNCTION INCLUDING THAT FOLLOWING LIVER 
TRANSPLANTATION
10.1 BACKGROUND AND INTRODUCTION
Morbidity and mortality in the immediate post-transplant phase is commonly related to 
primary graft non-function or ischaemia as discussed in section 2.3. These graft 
complications which are associated with reduced hepatic blood flow often result in 
systemic critical iUness requiring intensive care. Although urgent retransplantation is often 
the prefeixed management option in this situation, maximal medical treatment is required 
to prevent the development and reduce the severity of multi-organ failure which if 
established can preclude regrafting and ultimately lead to death. Pharmacological 
haemodynamic intervention in this period of critical illness is directed at improving both 
systemic and splanchnic circulations.
It has previously been established that inadequate systemic oxygen delivery (DO2) and 
consumption (V0 2 ) with accompanying tissue hypoxia is associated with the development 
of multi-organ failure and a reduced patient survival following major surgery and during 
critical illnesses (Bland et al 1985). This phenomenon may in part reflect impairment of 
regional ciiculation and particularly hepatic-splanchnic 0 % and nutrient delivery which, as 
assessed by low gastric intramucosal pH and indocyanine green (ICG) extraction, are 
associated with a poor clinical outcome (Gutierrez et al 1992, Gottlieb et al 1984, 
Kholoussy et al 1984). Although the relationship between systemic oxygen transport =1
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parameters and regional indices of tissue oxygenation are poor, strategies achieving 
supranormal oxygen transport to both these circulations can improve survival (Shoemaker 
et al 1988, Boyd et al 1994).
In liver disease, the only systematic studies of systemic haemodynamics and oxygen 
transport have been performed in FHF, a condition which is also haemodynamically 
characterised by a ‘supply dependent’ oxygen consumption, multi-organ failure and tissue 
hypoxia (Bihari et al 1987). In contrast, the functional importance of impairment in the 
hepatic-splanchnic circulation has been well described in a range of liver disorders 
including those following transplantation (Yamanaka et al 1992, Frenette et al 1994).
Phaimacological modulation of haemodynamics in severe illness would ideally employ an 
agent which would improve both systemic and regional DO2 and not stimulate cellular 
aerobic metabolism. Concern is mounting that those agents presently administered to 
modulate systemic oxygen transport may paradoxically promote hepatic-splanchnic 
ischaemia or increase oxygen requirement through stimulation of tissue metabolism 
(Ruokonen et al 1993, Giraud et al 1984, Reinhait et al 1994). In the particular experience 
of liver intensive care, potent ai-agonists are associated with reductions in VO2 despite 
their undoubted inotropic effects, a phenomenon which most probably reflects the 
increasingly intense regional vasoconstriction present at increased dosages (Wendon etal 
1990). Novel pharmacological agents which improve systemic and regional circulations, 
without a penalty m relation to direct stimulation of tissue metabolism or a deterioration in 
gas exchange, require to be identified.
Previous studies from this unit have previously shown that infusion of N-acetylcysteine 
improves systemic haemodynamics and oxygen supply and consumption in FHF, a 
property which may account for this agents beneficial effect on survival in this disorder
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(Harrison et al 1990, Hanison et al 1991). It is presently unknown what effect this agent 
has on either systemic haemodynamics or the deranged hepatic circulation found in most 
fonns of acute or decompensated chronic liver disorders including those present following 
transplantation. This present study was designed to evaluate and compare the 
haemodynamic effects of N-acetylcysteine and prostacyclin infusions on systemic and 
hepatic circulatoiy disturbances present in both liver recipients with normal graft function 
and those experiencing complications following liver transplantation in the early post - 
transplant period. Since this studied was also extended to non-transplant disorders and the 
same effects were observed, the combined results are presented for the interest of the 
reader.
10.2 SUBJECTS
10.2.1 Patients
15 patients (9 M, 6  F, median age 36 years, range; 16-62) with liver dysfunction and 
accompanying critical illness, who were haemodynamically stable, entered this study. The 
population comprised eight liver transplant recipients who were either studied on the first 
post-operative day (n=5) or later (post-operative day 2-8) at the time of a critical 
complication (n=3). Graft function was within the normal post-operative range in 3 of this 
group, primaiy graft dysfunction was present in 2 , severe acute rejection in 2  and septic 
shock in 1. The remaining 7 patients were either experiencing sepsis syndrome as a late 
complication in the convalescent phase of FHF (n=3) or had critical decompensation of a 
chronic liver disorder (n=4; alcoholic hepatitis 2, AIH 1, PSC 1). Four patients were 
receiving inotropic agents during the couise of the study. All subjects required mechanical 
ventilation (Siemens Servo 900C; volume conti’ol mode with a PEEP of 4 cm H2O). No 
alteration in ventilator settings, pai*alysis or sedation infusions was permitted during the
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study period. A stable inspired oxygen requirement, and normalisation of the pulmonary 
capillary wedge pressure were present at least 2  hours prior to study commencement. 
Crystalloid and vasoactive drug infusion rates were unchanged and no colloid 
administration was permitted during the investigation.
10.2.2 Measurement of haemodvnamics and gas exchange
Placement of a systemic arterial cannula and a conventional thermal dilution pulmonary 
artery flotation catheter (Edward Laboratories 7 French, Irvine, California) had been 
perfoimed as part of this units routine clinical practice. These catheters were connected to 
electronic pressure transducers which in turn were connected to a physiological monitor 
(Marquette Series 7005; Marquette Electronics Inc, Milwaukee, WI, USA ) from which 
heart rate, central venous, pulmonary capillary wedge, mean systemic and pulmonary 
artery pressures were determined. A 5F fibreoptic thermistor catheter (PV-2025 
Pulsiocath 5FTL, Pulsion Medizintechnik, Munich, Germany) was inserted into a femoral 
artery and connected to an integrated fibreoptic physiological monitoring system (COLD Z - 
02 system. Pulsion Medizintechnik). The pulmonary arteiy catheter was connected to the 
standard physiological monitor for conventional determination of cardiac output by 
thermodilution and thereafter to the COLD Z-02 system for the measurements available 
from thermal dye double indicator methodology (Pfeiffer et al 1991). Conventional 
haemodynamic measurements and calculations were performed to standard protocols 
(Varon and Civetta 1990, Harrison et al 1992). Radial arterial and distal pulmonary artery 
samples were analysed for oxygen tension (AVL 995; AVL Medical Instruments UK Ltd, 
Stone, UK) and for haemoglobin content and saturation (AVL 912). Following 
determination of these measurements, ICG (0.5 mg per kg) dissolved in 10 mis of ice 
cold (4-lOOC) 5% dextrose was injected into the proximal port of the pulmonary artery 
catheter and derived measurements recorded from the COLD-Z-02 system.
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10.2.3 Admimsnation_Qf N-acetylcvsteinc and prostacyclin
Following determination of baseline values, prostacyclin (Flolan; Burroughs Wellcome, 
Crewe, England) was administered at a continuous infusion rate of 5 ng/kg/min for 60 
minutes at which time measurements were repeated. A 60 minute interval was then 
allowed to wash-out the effects of this agent before repeating a second baseline 
measurement. Thereafter, N-acetylcysteine was administered (Parvolex; Duncan Flockhart 
& Co Ltd. Greenford, England) at 150 mg/kg in 250 ml 5% dextrose over 15 minutes and 
then 50 mg/kg in 250 ml 5% dextrose for 45 minutes at a rate of 62.5 ml per hour. 
Control infusions (without N-acetylcysteine) at the volumes and rates described above 
were administered in 8  patients. Of these latter patients, 4 were studied as an addition to 
the protocol between the 2 treatment infusions, 3 were new patients and 1 patient was 
studied 28 hours before the treatment schedules. Administration of prostacyclin was not 
permitted 1 hour or N-acetylcysteine 12 hours before the study infusions were 
commenced. Two patients had previously received prostacyclin and six N-acetylcysteine. 
In those patients in whom benefit in systemic haemodynamics, oxygen transport or ICG 
extraction was found, the appropriate infusion was maintained.
Results are expressed as mean ± SD with differences between baseline and treatment 
values compared by a two-tailed paired Students t-test if normally distributed or by the 
WUcoxon signed rank if non-parametric. Percentage changes are also expressed as mean 
with 95% confidence limits.
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10.3 RESULTS
10.3.1 Haemodvnamics and oxygen transport
N-acetylcysteine and prostacyclin infusions both increased the mean cardiac index (table 
10.1). This effect of the N-acetylcysteine infusion was observed in 14 of the 15 patients, 
and could be attributed to both a reduction in systemic vascular resistance (mean change 
12% [95% Cl, -4, -19]) alongside a moderate inotropic action as seen by an increase in 
left ventriculai' stroke work index [LVSWI] (mean change +11% [95% Cl, 0, +21]). 
Mean arterial pressure was not significantly altered by N-acetylcysteine. In contrast, the 
increase in the cardiac index with prostacyclin was secondary to its significant 
vasodilatatory action (systemic vascular resistance index, mean change -22% [-12, -31]), 
an effect which was accompanied by a tachycardia and reduction in mean systemic arterial 
pressure. There was no change in LVSWI. Similarly, mean pulmonaiy arterial pressure 
and the pulmonary vascular resistance index, which were unaffected by N-acetylcysteine, 
were reduced during the prostacyclin infusion.
Although similar improvements in oxygen delivery were seen with both agents, only the 
infusion of N-acetylcysteine increased mean global V02 (150[30] to 169 [25] ml/min/mZ) 
(p 0.002). This effect was found in 14 (93%) patients with a mean increase of 15% [95% 
CI,+3, +27]. The oxygen extraction ratio, which was unaffected by N-acetylcysteine, 
showed a trend towards a reduction during the prostacyclin infusion. Neither agent 
affected the pulmonary capillary wedge or central venous pressures. Control volume 
infusions did not elicit any significant change in haemodynamic parameters.
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Table 10.1 Haemodynamic, oxygen transport and indocyanine green 
clearance profiles before and during the infusions o f  
prostacyclin and N-acetylcysteine.
variable Baseline 1 Pgl2 change % Baseline 2 NAC change%
Haemodynamics
heart rate 89 (26) 94 (25) +6 (+3,+9) 88 (26) 94 (26) +7 (+2,+11)
mean arterial pressure 75 (18) 68 (22)* -8 (-20,+3) 74 (17) 75 (16) 0(-8,+7)
pulmonary capillary wedge pressure 12 C3) 12 (3) +6 (-10,+21) 11 (3) 11 (4) -1 (-13, +12)
mean pulmonary arterial pressure 22 (5) 20 (6) -5 (-18, +7) 22(6) 23(5) +8 (-3,+19)
cardiac index 5.4 (2.0) 6.1 (1.6)** +18 (+3,+34) 5.6 (1.8) 6.5 (2.2)** +16 (+9, +22)
stroke volume index 61 (20) 64 (17) +7 (-3, +18) 63 (18) 69 (20)** +9 (+4, +15)
lelt ventricular stroke work index 48 (14) 45 (11) -1 (-29. +27) 53 (16) 58 (16)/' +11 (0, +21)
pulmonary vascular resistance 165(88) 131 (67)* -15 (-39, +8) 173 (65) 160 (71)/'/' -3 (-18, +13)
systemic vascular resistance 1055 (484) 802 (370)** -22 (-31,-12) 1012(351) 898 (350)* -12 (-19, -4)
Oxygen transport
oxygen delivery 670 (214) 753 (198)'»' +16 (-2,+35) 667 (154) 751 (166)** +13 (+7, +20)
oxygen consumption 153 (27) 158(33) +3 (-6, +12) 150(30) 169 (25)**^ +15 (+3, +27)
oxygen-extraction ratio 24 (6) 22(6) -8 (-19, +3) 23(6) 24(5) +5 (-8. +17)
Indocyanine green clearance
plasma disappearance rate 7.6 (4.2) 8.4 (4.8) +26 (-12,+191) 7.3 (4.2) 11.8 (4.0)*»"+100 (+9, +191)
values are expressed as either mean (SD) or as (95% confidence limits) with respect to the mean changes 
* p<0.05, **p<0.01 comparison witli baseline,
*p<0.05, *''p<0.01 comparison of N-acetylcysteine with prostacyclin
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10.3.2 Indocyanine green clearance
N-acetylcysteine infusion resulted in an improvement of ICG cleaiance in 12 (80%) of the 
15 patients with the mean clearance rising from a mean of 7.3% (4.2) to 11.8% (7.1) (p 
0.002) (figure 10.1). This increased clearance was often marked with a mean percentage 
increment of 100% [+9, +191] in the 12 patients; an increase significantly out of 
proportion to the modest improvements in cardiac index described above. Despite the 
consistent increase in cardiac index during the prostacyclin infusion, this agent had a 
vaiiable effect on ICG clearance with approximately similar patient numbers showing an 
increase or decrease (overall change from a mean of 7.6% [4.2] to 8.4% [4.8]).
10.3.3 Gas exchange
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The infusion of N-acetylcysteine had no effect on gas exchange, whereas administration 
of prostacyclin resulted in a marked deterioration of the pulmonary shunt and alveolar - 
arterial oxygen gradient (table 10.2). Extravascular lung water also rose significantly 
during the prostacyclin infusion.
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Figure 10,1 Effect of N-acetylcysteine infusion on indocyanine green 
clearance. Increments were reduced in those patients with low 
baseline levels.
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Table 10.2 R espiratory variables in patien ts before and during  
administration of N-acetylcysteine (NAC) and prostacyclin  
infusions.
variable Baseline 1 P g I2 change% Baseline 2 N A C change%
respiratory index 0.8 [0.7] 1.4 [1.0]^ * 122 (+20,+225) 1.1 [0.9] 1.1 [0.8D 19 (-6, +43)
(Qs/Qt) 16 [7] 24 [8]** 59 (+23,+95) 17 [8] 17 -2 (-15,+10)
(A-a) 02 gradient 235 [118] 316 [113]** 52 (+11,+94) 263 [133] 278 [1161^ 13 (-2, +28)
EVLW I (ml/kg/m^; 7 [4] 9 [6]* 23 (+4,+42) 8 [6] 9 [6] 104 (-109, +318)
change% = meaii percentage change 
n [SD], (95 percent confidence intervals)
*p<0.05 ** p<0.01 for comparison between infusion and treatment 
*p<0.05, ^p<0.01 for comparison between N-acetylcysteine and prostacyclin
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10.4 DISCUSSION
The results of this study extend the previous observations from this unit on the clinical 
usefulness of N-acetylcysteine in FHF, with the present evidence indicating both 
beneficial systemic and regional haemodynamic properties in a variety of liver disorders 
including those present following transplantation. That improvements in systemic V02 
were possible following administration of this agent infers the presence of tissue hypoxia 
and an accompanying oxygen debt. The finding of a pathological ‘supply-dependency’ in 
liver dysfunction (regardless of the clinical setting) and in particular following 
transplantation is not well recognised even in liver centres and clinicians should be made 
much more aware of this phenomenon and the potential of treatment modalities such as N - 
acetylcysteine in preventing further organ dysfunction and failure.
Consistent improvements in cardiac index and DO2 were accompanied by increments in 
systemic VO2 in the majority of patients following administiation of N-acetylcysteine. In 
contrast infusion of prostacyclin, despite resulting in similar improvements in DO2 did not 
affect V0%. This data provides evidence contrary to the hypothesis that increments in 
systemic V02 following increases in DO2 are a result of mathematical coupling of the 
cardiac index which is incorporated into both formula (where the reverse Fick equation is 
employed). The marginal effects of prostacyclin on the VO2 of patients in this study is 
consistent with results from a recent study in septic shock but in contradistinction to 
eariier results in FHF (De Backer et al 1993, Bihaii et al 1987). Such variations may be 
explained by the different severity and characteristics of the haemodynamic disturbance 
and shunting present in different disease states. Further evidence of different responses in 
critical illness to haemodynamic manipulation can be seen if comparison is performed of 
the results in the present cases to those in patients with FHF who were examined in the 
original report from this unit. In the present series, improvement in mean arterial
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pressure with administration of N-acetylcysteine as demonstrated in the patients 
experiencing paracetamol-induced FHF was not found. The less pronounced inotropic 
action of N-acetylcysteine in this study group versus FHF patients can be seen from 
comparison of the mean percentage change in LVSWI; +11 versus +21 for patients in 
FHF. From this data it can be recommended that clinicians should accordingly assess the 
effects of any agent they intend to utilise with respect to the haemodynamic changes and 
underlying disease in any individual patient.
Circumstantial evidence previously existed that N-acetylcysteine infusions may improve 
regional circulations. Administration of this agent in FHF was accompanied by a reduced 
frequency of renal failure and cerebral oedema. The improvements in cerebral blood flow 
with this agent may explain the decreased frequency of cerebral oedema (Wendon et al 
1994). Pharmacological nitric oxide donors (which includes N-acetylcysteine), improve 
cerebral blood flow in experimental systems (Harrison et al 1992, Zhang et al 1994). 
However, any beneficial effects on the hepatic-splanchnic circulation, as examined in this 
study, would have wider application given the postulated central role of derangements of 
these circulations in the pathogenesis of the sepsis syndrome and multi-organ failure (Ritz 
et al 1973, Dantzker et al 1993). The findings presented here on the improvement in the 
critical hepatic-splanchnic circulation following N-acetylcysteine are potentially of 
considerable importance. The large percentage increments in ICG clearance, in many 
patients out of proportion to the changes in systemic haemodynamics, suggests a 
significant local effect. These improvements, which were seen over short time intervals, 
can reliably be interpreted as reflecting blood flow changes rather than dynamic 
improvements in metabolism / extraction capacity. The improvement in clearance infers an 
increased local delivery of oxygen, nutrient and other regenerative factors which may 
promote cellular recovery and function.
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Provisional evidence exists indicating that prostacyclin can improve hepatic-splanchnic 
blood flow in man (Radennacher et al 1993, Hassan et al 1983). However, the effect of 
infusing this agent on ICG clearance was disappointing overall and, often at the penalty of 
a deleterious effect on gas exchange and occasionally severe vasodilatation resulting in a 
reduction in mean arterial pressure. Although individual patients did show significant 
increases in clearance, no discriminating characteristics of this sub-group could be 
identified. Whether prostacyclin could be promoting trans-hepatic shunting which would 
offset any beneficial effect on hepatic blood flow is speculative. The deterioration in gas 
exchange, which is a recognised complication of this agent, is pailicularly unwelcome in 
long-standing cirrhotic patients where pulmonary shunting is already a common feature 
and may limit this agents clinical usefulness in treatment (Radermacher et al 1990, 
Rodman et al 1960).
N-acetylcysteine therefore has considerable advantages to prostacyclin in optimising 
systemic and hepatic-splanchnic haemodynamics and with this the potential for 
considerable clinical application. Patients who may gain particular benefit are those with 
impairment of the hepatic or splanchnic microcirculations especially in the context of 
critical illness, a common set of circumstances in general intensive car e. In the context of 
liver transplantation, those recipients who are experiencing primary graft dysfunction, and 
who characteristically have pruned intrahepatic vasculature (see section 4.3) and impaired 
ICG clearance alongside systemic haemodynamic disturbance, could show significant 
improvement (Jalan et al 1994). The value of N-acetylcysteine in achieving further 
benefits in post-operative survival achieved through optimising systemic and regional 
haemodynamics prior to transplantation requires evaluation (Boyd et al 1994). A 
randomised controlled trial of N-acetylcysteine in improving post-operative survival and 
reducing complications following transplantation would appear to be justified from the 
present data.
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Some limitations to the haemodynamic measurements used in this study exist. The cardiac 
output measurements were derived from the now clinically standardised method of 
theimodilution via a pulmonary artery thermistor catheter. Technical events can reduce the 
accuracy of this technique - although a minimum of 3 measurements were performed. The 
method of ICG  extraction is novel and is presently the only clinically available method 
which gives a bedside measurement. This latter feature is a major advantage in liver 
intensive care when assessment of hepatic blood flow would be useful following some 
clinical intervention such as ventilation or introduction of an inotropic agent. This 
technique which relies on reflection densitometry has not previously been validated 
against cuiient gold-standard methods of ICG clearance. However, the measurement of 
IC G  would appear to be extremely accurate since the COLD machine employing the 
thermodilution technique is now acknowledged to be the most sensitive method for 
measurement of extravascular lung water (Pearce and Beazell 1966, Lewis et al 1982).
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CHAPTER 11
CLINICAL TOLERANCE IN LONG-TERM LIVER RECIPIENTS AND 
RELATIONSHIP TO SYSTEMIC DONOR-TYPE MICROCHIMERISM
11.1 BACKGROUND AND INTRODUCTION
Continued requirement for immunosuppression is perhaps the greatest hazard to the long - 
term welfare of liver recipients given the morbidity and mortality associated with the 
present anti-rejection agents. In chapter 2, a spectrum of the most serious complications 
resulting in graft loss and often death which were either initiated or aggravated by 
immunosuppressants was reported. In long-term patients, the main risk from the global 
inhibition of immunological surveillance is an increased risk of de novo malignancy and 
infection (Penn et al 1969a and 1983). Corticosteroids (Baserga and Shubik 1954), 
antilymphocyte preparations (Allison et al 1967), and azathioprine (Casey 1968) have aU
'been shown to promote the development of malignancies. However, this inhibition of
■immunity also promotes recurrence in the graft of primary malignant and viral transplant 
indications which can affect greater proportions of patients. In addition to these effects,
.
each of the drugs which comprise standard maintenance regimens have a significant 
toxicity profile. Chronic steroid usage is associated with well known systemic effects.
Short and medium-term effects of CyA are not well-recognised given the use of this agent 
for only just over a decade (Kahan et al 1989). The additional clinical hazard of 
azathioprine with respect to hepatotoxicity - which was previously seen in the early 
experimental and clinical studies (Haxhe et al 1967, Penn et al 1969b) - is also becoming 
more recognised (Gane et al 1994, Read et al 1986, Stemeck et al 1991).
Successful withdrawal of maintenance immunosuppressive agents would therefore
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represent a major advance in clinical transplantation with benefits derived from a return in 
natural immunity and a reduction in drug-related toxicity. The potential hazards of such 
an undertaking would be lessened if clinicians were able to base this on the identification 
of either a clinical or immunological marker of operational tolerance. The technical 
limitations surrounding the in vitro assessment of donor-recipient immune responsiveness 
are such that as yet no parameter reliably predictive of tolerance has found clinical 
application (Wood et al 1993). Considerable interest and debate presently surrounds the 
thesis recently proposed by Starzl that the establishment and augmentation of systemic 
microchimeiism, following multilineage cell migration from a graft or via additional donor 
cell infusion, is an important factor in immunomodulation of the allograft response with 
promotion of donor-specific unresponsiveness and hence long-term graft acceptance 
(figure 11.1) (Starzl et al 1992a, 1992b, 1993a, 1993b, Fontes et al 1994). This 
phenomenon of chimerism and its potential biological significance was recognised by 
Owen in 1945 (Owen et al 1945). These authors demonstrated that in-utero transfer of 
haemopoeitic and lymphoid cells as well as gonadal cells phenotypicaUy altered dizygotic 
twin calves. The most obvious manifestation of this transfer forming a chimeric animal 
was the dual gender expression rendering a naturally female cow a sterile animal with both 
sex organs, a so-called freemartin (figure 11.2). More interestingly, if skin grafts were 
performed between the twins they were spontaneously accepted. These historical 
observations were given further significance in the early liver recipients when it was noted 
that phenotypic changes in immunoglobulin production occurred in some recipients (Kano 
and Milgrom 1968). That non-graft cells are transferred at transplantation and can be 
functional for considerable periods is supported by reports of transfer of passive 
immunity and even donor-derived immunological conditions such as lymphomas, 
autoimmune disorders as well as the occurrence of graft-versus-host responses and 
collection of metabolic defects (Burdick etal 1988, Kano et al 1968, Ramsey et al 1984, 
Starzl et al 1993c). It has been established that a large pool of passenger cells from the
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lymphodendiitic lineage are present in liver grafts either in the adjacent hilar lymph nodes 
or trapped in the sinusoids (Schlitt et al 1993).
The demonstration of clinical tolerance in association with chimerism in long-term liver 
recipients at the University of Pittsburgh was the stimulus to the clinical trial reported here 
in which immunosuppression drug withdrawal was attempted in a group of long-term ®
liver recipients who were experiencing a number of side-effects or disorders related to 
continued immunosuppression. In addition to describing the clinical, biochemical and 
histological outcome of this patient cohort, it represents the first conelative data on the 
relationship between operational tolerance and the presence of chimerism in a group of 
solid organ recipients.
11 .1  SUBJECTS
11.1.1 Patients
18 orthotopic liver recipients with a functioning primary allograft for greater than 5 years 
(median 7 range; 5-11 years) were entered into a programme of immunosuppressive drug 
withdrawal. All patients had a minimum of one side effect or disorder either initiated or 
aggravated by maintenance immunosuppression: namely recuiTence of HCC [n=l] and
renal impairment [n=4], diabetes mellitus [n=3], hypertension [n=7], osteoporosis [n=3], 
severe weight gain [n=l], lipid metabolism abnoimalities [n=7], severe hirsutism [n=l], 
neurotoxicity [n=4], azathioprine related bone marrow toxicity [n=l] and various 
biochemical derangements (hyperkalaemia, hypomagnesaemia, hypemricaemia) [n=7]). 
The aetiologies of the primary disease comprised PBC [n=4], PSC [n-3], Budd-Chiari
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HCV related liver disease [n=2], de novo systemic [cervical and breast carcinoma n=2] 
and skin [n-2] malignancies, post-transplant lymphoproliferative disorder [PTLD] n=l,
I,
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DONOR RECIPIENT
cell migration
lymphodendritic passenger cell
Figure 11.1. Following transplantation, so-called passenger cells, 
migrate from the donor organs and pass into the 
recipient circulation. It has been postulated that these 
cells are functionally active and may exert an 
immunomodulatory role. In liver grafts, recipient 
Kupffer cell migration establishes this cell population 
in the donor organ in the early post-operative period.
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Male animal Original female cow masculinised (Freemartin)
Figure 11.2. In-utero exchange of gonadal cells from the male to the 
female in these unlike-sexed dizygotic animals renders 
the fem ale a sterile  herm aphrodite (so-ca lled  
freemartin) and both animals chimeras. Additionally, an 
exchange o f cells from  the lym phoid lineage  
populations creates a degree of tolerance between these 
animals. Skin grafts performed in later life between 
them are spontaneously accepted.
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- syndrome [n=2], AIH [n=2], cystic fibrosis [n=l], ALF [n=3], HCV and alcohol - 
related cirrhosis [n=l], HCC and HCV cirrhosis [n=l], hepatic métastasés from primaiy 
teratoma [n-l].
11.2.2 Immunosuppression withdrawal protocol
Following baseUne detennination of standaid liver biochemical tests and a hver biopsy to 
give a complete assessment of graft status as well as exclusion of allograft rejection, 
systematic immunosuppression withdrawal was performed to a standard protocol. The 
baseline maintenance regimens varied considerably; one patient was receiving azathioprine 
and corticosteroids only, one CyA only, three CyA and azathioprine and the remainder 
were administered all three agents. The median daily dosage schedules were prednisone 5 
mg (0.08 mg/kg), azathioprine 75 mg (1.1 mg/kg) and CyA 200 mg (2.7 mg/kg). In 
those patients still administered corticosteroids, prednisone dosage was gradually 
withdrawn over a period of 4-6 weeks. The remaining immunosuppressive agents were 
then discontinued and patient clinical status and biochemical graft function monitored 
initially in hospital (2 week period) and thereafter in the clinic at 1-4 weekly intervals. All 
patients experiencing an episode of significant biochemical graft dysfunction (level of any 
routine biochemical liver parameter x 2-3 upper limit of normal) underwent percutaneous 
biopsy of the graft and histopathological assessment with liver allograft rejection defined 
by standard criteria (Snover et al 1987). Immunosuppression was recommenced when 
episodes of liver biochemical abnormalities were accompanied by any significant 
deterioration in histological appearance when compared to baseline. Following 
stabilisation, a further slower weaning schedule of immunosuppressive drug withdrawal 
was then attempted.
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11.2.3 Determination of microchimerism
The presence of donor-derived microchimerism was examined by molecular analysis for 
class II MHC donor-type genotype sequences in recipient peripheral tissue. Whole blood, 
bone marrow and skin samples were collected from the patients prior to 
immunosuppression withdrawal and genomic DNA extracted from which the analyses 
were performed. Three separate methodologies were then evaluated for the determination 
of donor HLA-DRBl alleles following polymerase chain reaction (PCR) amplification of 
the DNA. These techniques were sequence-specific oligonucleotide analysis (PCR-SSO 
dot blot) (Doheity and Donaldson et al 1991) (British Society for Histocompatibility and 
Immunogenetics, Molecular Special Interest Group, c/o University of Bristol, UK), one - 
step PCR with sequence-specific primers (PCR-SSP) (Olerup et al 1991) (Dynal Inc, 
Wirral, UK) and two-step nested sequence-specific PCR (PCR-nested SSP) (Bein et al
1991) (British Society for Histocompatibility and Immunogenetics, see above). All 
recipients had previously been genotyped and assigned HLA-DRB1 specificities by 
molecular methods (restriction fragment length polymorphism [RFLP] and / or PCR - 
SSO). Further confirmation of recipient HLA-DRBl genotype was gained by PCR-SSP 
examination of genomic DNA retrieved from a fresh protocol liver biopsy. In appropriate 
male donor / female recipient pairings, the presence of Y gene-specific nucleotide 
sequences in recipient DNA was also determined by 2 separate primer pairs (Kogan et al 
1987, Nakagome et al 1991). See appendix for detailed protocol in relation to the 
preferred method for determining donor-specific microchimerism (i.e. nested PCR-SSP 
amplification for DRBl alleles).
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11.3 RESULTS
11.3.1 Clinical and histological outcome
Of the 18 patients, 5 experienced no deterioration in graft function continuing without 
significant abnormalities in biochemical tests and remaining clinically well when off 
immunosuppressive agents. Three of these patients had developed minor fluctuating 
elevations of serum AST and biliary enzymes activities to just above the upper limit of 
normal at some point following immunosuppression withdrawal which finally settled. All 
5 patients were transplanted for conditions with a non-immune pathogenesis (Budd-Chiaii 
syndrome 2 , alcohol-related liver disease 1 , acute liver failure 1 , cystic fibrosis-related 
liver damage 1). Biopsies of the liver graft, performed in 3 at a minimum of 8 months 
following withdrawal, showed no major changes from findings present at baseline and in 
particular no evidence of rejection changes.
The remaining 13 patients experienced derangement in biochemical tests such that 
immunosuppression was recommenced in 1 2  at a median of 3 weeks (range: 2-24 weeks) 
after initial withdrawal of drugs. In these patients, several patterns of abnormalities in 
graft dysfunction were observed with variable and often initially fluctuating elevations in 
AST activities (median peak value 288 lU/L [range:73-830 lU/L] occurring. These were 
first noted at a significant level (100 lU/L i.e.> x2 upper limit of normal) at a median of 
25 days (range: 10-176 days) post-withdrawal. Parallel rises in the biliary enzymes 
(alkaline phosphatase, y-glutamyltransferase) accompanied these changes in AST. A rise 
in serum total bilirnbin occuned in 7 patients (median peak value 53 pmol; range 28 - 474 
pmol) at a median of 32 days following withdrawal. The one patient of these 13 with a 
deterioration in graft dysfunction in whom immunosuppression was not deliberately 
recommenced was suffering from a post-transplant lymphoproliferative disorder as well
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as severe intra and extrahepatic biliary stricturing consequent on primary sclerosing 
cholangitis recun'ence for which retransplantation was finally cairied out at 4 months.
Histopathological assessment of the graft in these 13 cases, during the episodes of 
biochemical dysfunction, revealed characteristic histological features of acute allograft 
rejection in 4 patients. One specimen was graded as severe rejection and the others mild to 
moderate. A more common pattern of a mixed inflammatory portal tract infiltrate 
composed of predominately lymphocytes with fewer plasma cells and occasional 
eosinophils was seen in 7 patients (figure 11.3). Two of this group also had severe 
neuti'ophilic infiltration of the portal tract. In 3 patients of this group, minimal or mild 
limiting plate spillover and a lobular hepatitis in the form of occasional spotty necrosis and 
mixed inflammatoiy cells present within sinusoids was found. In 2 patients, these features 
were accompanied by minimal focal endotheliitis. Infiltration within bile ducts was rare.
This overall picture of a hepatitis-like disorder appeared to represent exacerbation of ®
similar but less severe baseline findings in 5 of the patients and a de novo appearance in 2 
cases. In two patients this histological picture was observed in the context of a co-existing : >
viral illness (Coxsackie in 1, unidentified in other). One further case showed features of 
acute hepatic necrosis with evidence of previous parenchymal necrosis along with a 
moderate mixed inflammatory cell infiltrate in post-necrotic areas and portal tracts.
Extensive hepatocyte ballooning and regeneration and severe cholestasis were also found.
This patient had a preceding history of a viral-like illness and non-steroidal anti - 
inflammatory agent usage. In the final patient in this group, no significant abnormalities 4
were detected in the liver biopsy. Overall, in these 13 patients no conelation between 
biochemical abnormalities and accompanying histological features was detected. In |
particular, no relationship between hepatitis / and or rejection and the height of the serum 
transaminase activity was found. I
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The réintroduction of immunosuppression and the schedule followed was determined 
predominantly on the basis of serum AST activities rather than pathological features. The 
4 patients with modest elevations of AST (approximately 150-300 lU/L) were managed 
with short courses of additional oral prednisolone (30 mg / day 2 weeks, 20 mg one week 
then gradually reduced to either 5 mg / day or withdrawn) in addition to réintroduction of 
approximately 50-75% of their maintenance baseline immunosuppression. In 8  patients, 
with higher AST activities, a conventional high-dose corticosteroid anti-rejection regimen i
(methylprednisolone Ig for 3 days) was administered in addition to a réintroduction of the 
complete baseline immunosuppression. Following such changes, AST activities returned 
to the normal range rapidly in 9 of 12 patients. The remaining 3 patients in whom graft 
function did not normalise quickly received an additional course of high-dose 
corticosteroids and, 2 patients underwent temporary conversion to tacrolimus. Elevations 
in the semm bilirubin level returned to within the nomial range considerably more slowly 
(median 3 weeks following commencement of treatment) than the rises in liver enzymes.
In 2 patients in whom the serum bilirubin was slow to fall and in whom histological 
features of only mild hepatitis or rejection had been present on biopsy, investigations of 
biliary drainage were performed. In botli patients, percutaneous cholangiograms revealed 
dilated biliary tracts and stasis within the gallbladder conduit which had been used in the 
original anastomosis. Biliary reconstruction was subsequently performed with resolution 
of the biochemical changes.
In these 12 patients in whom immunosuppression was reintroduced and following an 
interval allowing stabilisation of graft function, a further attempt at drug withdrawal was 
initiated except in the single case who had experienced a severe episode of acute cellular 
rejection. On occasion, a weaning regimen was employed which comprised a step-wise 
progressive reduction of immunosuppressive dnigs.
y.-.-
Figure 11.3 Liver histology 8 weeks after partial im m unosuppression  
withdrawal. There is moderate portal inflammation with 
periportal cell spillover and a mild lobular hepatitis. H&E x80
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This schedule is on-going with results presented at a minimum of 8  months following 
initial commencement. In 9 of the 12 patients, further elevations of liver enzymes have 
occurred. Despite this common pattern of enzyme elevation, 9 patients were successfully 
weaned to a significant degree and are presently receiving lower dosages than at baseline, 
with normal graft function at a minimum of 6  months following first discontinuation. 
Seven patients are presently receiving less than 50% the baseline corticosteroid and 
azathioprine dosage accompanied by either whole blood CyA levels below 60 ng/ml (the 
lower limit for maintenance immunosuppression) (n=5) or complete withdrawal of this 
agent (n~2). Prednisolone has been stopped in 4 patients and azathioprine in 6 . The 
median daily dosage schedules and percentage [range] changes for the 
immunosuppressive agents at latest follow-up are prednisolone (0.06 mg/kg (- 25% [1(K3 - 
0%]), azathioprine (0.39 mg/kg, (- 64% [100-0%]) and CyA 1.77 mg/kg (-37% [-18 - 
100%]).
Of the 18 original patients, 17 are alive and remain clinically well. The single  ^ ath in a 
patient 6  years post-transplant, was due to recurrence of hepatoceUulai'carcinoma at eight 
months after withdrawal of immunosuppressive drugs. Tumour recurrence had been 
evident at the time of study entry and had been the reason for attempting withdrawal in 
this patient. A further patient (described above) was successfully retransplantated 
following drug withdrawal and the one patient with an episode of acute hepatic necrosis, 
as already referred, has on-going graft dysfunction despite réintroduction of 
immunosuppression.
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11.3.2 Patterns of chimerism
Two-step nested sequence-specific PCR was the most sensitive methodology for the 
detection of donor-type genotypic sequences. This method detected HLA DRBl allele 
specificities of donor-type in 7 (39%) of the 18 patients. PCR-SSO and single-step PCR - 
SSP methodologies were less sensitive (22% with PCR-SSO and 11% with single-step 
PCR-SSP) and were abandoned after 12 and 9 patient samples respectively. 
Demonstration of donor genomic elements by Y-gene primers concurred entiiely with the 
positive and negative results achieved with aU of the above techniques and confirmed 
chimerism in 3 female recipients. No sample resulted in a false-positive result with respect 
to presence of Y-gene sequences and not the appropriate donor HLA-DRBl alleles. Of the 
tissues examined, the presence of donor genomic sequences was found most often in 
skin. Employing the nested PCR-SSP methodology, donor HLA-DRBl was found in 5 
patient samples from peripheral blood, 4 from bone marrow and 7 from the skin sample.
11.3.3 Relationship between chimerism and operational tolerance
From the 7 patients with evidence of microchimerism, 2 (29%) have been successfully 
withdrawn and maintained off immunosuppression at 6  months follow-up. A further 3 
(43%) have been weaned significantly following partial réintroduction of 
immunosuppression. The final 2 (29%) chimeric patients experienced severe graft 
dysfunction. Both these cases experienced an episode of acute allograft rejection 
confirmed histologically. Of the 11 patients who had no evidence of microchimerism, 3 
(27%) have successfully been removed from immunosuppression and a further 6  (55%) 
weaned significantly. In the final 2 (18%) non-chimeric patients, a return to the baseline
.immunosuppression level was required.
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11.4 DISCUSSION
This report provides further evidence for the unique immunologically privileged position 
of liver allografts as compared to other solid organ transplants. From the initial 
observations of Garnier (see section 1.5) that genetically disparate porcine liver allografts 
were spontaneously accepted in the absence of immunosuppression, considerable 
experimental and clinical observations of the reduced immunogenicity and tolerance - 
inducing properties of a liver graft have been reported (Gamier et al 1965, Caine et al 
1967 and 1969, Kamadaet al 1981). The clinical tolerance which has been demonstrated 
adds to the observations of a low incidence of immunological graft failures secondary to a 
reduced susceptibility to hyperacute rejection, resistance to positive cross-match, less 
frequent and severe acute and chronic rejection and also an ability to induce donor-specific 
tolerance (Iwatsuki et al 1981, Duquesnoy et al 1989). In the present series, it was 
possible to either completely withdraw (5 of 18 patients) or significantly reduce (9 of 18) 
maintenance immunosuppression, to previously considered sub-therapeutic levels. Such 
results differ from those seen in other solid organ recipients where the hazards of even 
partial immunosuppressive drug withdrawal from maintenance regimens are well 
recognised (Stiller and Opelz 1991).
The results in the present study confirms the earlier report from the University of 
Pittsburgh based on weaning immunosuppression in 15 patients, although a lower 
proportion of patients exhibiting complete operational clinical tolerance (5 of 18 [28%] vs 
12 of 15 [80%]) in that series was seen (Reyes et al 1993). There are several possible 
explanations for this difference. In the face of a developing episode of graft dysfunction, 
there was a low threshold for reintroducing the immunosuppressive agents, whereas it 
was clear from later experience in which withdrawal was performed in a slower manner, 
as was the procedure followed in Pittsburgh, many of these episodes resolved
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spontaneously or required only minor temporary increases in corticosteroid dosages. In 
addition to different withdrawal regimes, the characteristics of the study populations in the 
2 studies are also quite disparate. In the Pittsburgh series, the majority of patients were 
from the paediatiic age group with a large percentage suffering from a post-transplant 
lymphoproliferative disorder and already on lower baseline immunosuppression. The 
potential tolerising influence of lymphoma, which in the post-transplant situation is 
commonly of donor origin (unpublished observations), is one further possible explanation 
for the different frequencies of tolerance observed in the two series.
The presence of clinical tolerance in long-term recipients even in varying degree has the 
potential for improving the natural history of liver transplant patients. Longer follow-up is 
however required before the effect of immunosuppression withdrawal on drug-related 
toxicity or occunence of de novo and recunent infectious and malignant complications can 
be determined. Reports regarding the efficacy of partial immunosuppressive drug 
withdrawal in relation to reversal of drag toxicity complications are mixed, paiticulaiiy 
when these are long-standing as for instance with chronic CyA-related nephrotoxicity 
(Sandborn et al 1994). Nevertheless, data from a recent study in renal patients of steroid 
withdrawal and some preliminary observations suggest that significant reductions in the 
prevalence of hypertension and glucose and lipid abnormalities can be anticipated 
(Fabrega et al 1994).
Several novel patterns of liver blood test abnoimalities and histological graft appearances 
were observed following withdrawal of immunosuppressive drugs. The expected 
biochemical pattern of acute liver allograft rejection as seen in the early post-transplant 
period with elevations in biliary and hepatocellular enzymes and an associated rise in 
bilirubin was uncommon. Biochemically, the variable but occasionally very severe
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elevations in serum transaminase activities (up to 40 fold rises) indicates a hepatocellular' - 
directed reaction which is consistent with the predominant damage to this cell which is 
found in pharmacologically unmodified experimental and clinical recipients undergoing 
rejection (Starzl et al 1969, Williams et al 1973). As was also noted in the Pittsburgh 
patients, a biochemical flare of enzymes can resolve spontaneously or with minor 
réintroductions of immunosuppression. This pattern has also been observed in 
experimental animals when immunosuppression was discontinued (Hunt et al 1967, 
Porter et al 1969). However, classical features of liver allograft rejection, as characterised 
by the tiiad of endotheliitis, portal tract inflammation and bile duct damage, developed in a 
minority of patients only (4 of 18). More commonly when there was elevation in liver 
enzymes, the graft biopsy demonstrated moderate or severe portal tract inflammation 
occasionally with features of a lobular hepatitis. The significance of this pattern is 
unknown. Whether these graft-infiltrating cells represent an immune response to a latent 
serologically undiagnosed virus or a previously unrecognised forme fruste of allograft 
rejection is speculative. This unit has previously reported that this histological pattern is a 
common feature in liver graft biopsies from immunosuppressed long-term recipients and 
could not be attributed to known hepatitis viruses (Slapak et al 1995). The apparent 
influence of systemic viral infections on graft function, as seen in possibly 3 patients is of 
interest, and is in keeping with previous observations from this unit that such infections 
can be associated with late acute liver allograft rejection in conventionally 
immunosuppressed patients (Cakaloglu et al 1995). In non-transplan ted patients, 
withdrawal of both chemotherapy and immunosuppression can result in a biochemical and 
histological flare of an underlying hepatitis (Bird et al 1989, Galbraith et al 1975).
There has been considerable interest in the observation from Starzl’s group that the 
presence of microchimerism, derived from the donor, was a universal feature of long-tenu 
liver and renal recipients and was associated with graft acceptance. This phenomenon was
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present in approximately 40% of the long-term liver transplant patients studied in this 
series. The methodology used in this study does allow donor and recipient differentiation 
at the genomic level and it can be confirmed that the foreign DNA which was detected has 
donor, rather than third party, characteristics (such as could have been derived from a 
blood product transfusion). A variation in the detection rate of chimerism in relation to the 
recipient tissue, with skin having the highest incidence, was also observed. These results 
with respect to tissue distribution and also the overall proportion of patients with 
chimerism are, however, virtually identical to a recent study from Subereille perfoiTned in 
long-term renal recipients where they found chimerism in 33% of studied patients again 
predominantly in the skin (Subereille et al 1994). The preferred method for detection of 
donor class II MHC, based on the nested PCR methodology for donor HLA DRBl 
alleles, is both readily available in molecular’ transplant HLA laboratories and sensitive 
(Knoop et al 1994). However, a limitation of this present study is that this technique does 
not yield any information on the localisation or viability of the detected donor genotype or 
the cell type from which it is derived. This is a general limitation to PCR-based 
methodology. Whether, for example, the donor DNA which was detected is shed from the 
graft, and could be derived from the soluble class I antigen which is released from liver 
parenchymal cells, or represents lymphoid cells which have migrated and become 
established from the substantial passenger cell pool present in human liver grafts cannot 
be determined (Davies et al 1989, Schlitt et al 1993).
In this study, detection of systemic donor-type microchimerism did not allow 
identification of tolerance and accordingly cannot, as was hoped, be utilized as a tool in 
the patient selection for prospective drug withdrawal. A major role for microchimerism as 
either a mechanism or a marker for graft acceptance was not identified in the present series 
with similar proportions of chimeric patients experiencing rejection and non-chimeric 
patients exhibiting tolerance. Furthermore, a case-report of intractable acute allograft
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rejection developing in a liver recipient 8 years after transplantation, in whom 
immunosuppression was reduced, in the presence of chimerism has also recently been 
reported (Schlitt et al 1994). The present results also do not agree with the obseivation 
that the presence of chimerism was associated with donor-specific unresponsiveness, as 
assessed by mixed lymphocyte reaction (MLR) methodology in long-term lenal recipients. 
Furthermore, the sensitivity of in vitro observations of anti-donor reactivity, using MLR 
which employs recipient peripheral circulating rather than graft-infiltrating cells retrieved 
under the umbrella of immunosuppression is questionable.
Since the presence of chimerism cannot be employed as a marker of tolerance, further 
investigations into identification of this state ai^ e required, taking into account the several 
controversial but presently unsubstantiated hypotheses relating to the unique position of 
liver grafts. Whether clinicians can enhance or promote clinical tolerance remains 
uncertain. It is notable that all these patients and, indeed most liver transplant recipients, 
have received third-party blood transfusions which are known to inhibit T-celi 
responsiveness (van Twuyver et al 1993). These transfusion requirements at levels which 
are very much higher than required for renal transplantation could have functional 
significance and contribute to the tolerance.
Close clinical surveillance will be required to monitor other effects which may follow 
from the return of immunocompetence such as recurrence or deterioration of the primaiy 
diseases which have an immunological pathogenesis such as AIH or PBC. The hazards 
which may ensue in this instance are documented in the next section.
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11.5 HAZARD OF IMMUNOSUPPRESSION WITHDRAWAL
Recurrence of autoimmune hepatitis following withdrawal of 
immunosuppression
11.5.1 Background
As outlined in the previous discussion, the return of immunocompetence may promote 
recurrence of immune-mediated disorders inadvertently controlled by the anti-rejection 
drug therapy. Disease recurrence after liver transplantation is increasingly recognised as a 
major cause of graft damage with accompanying patient morbidity and, in certain viral and 
malignant disorders, mortality as discussed in chapter 2. Amongst the immune-related 
transplant indications, recurrence is less well documented and not presently considered a 
major cause of graft dysfunction.
Patients with end-stage AIH accounted for 2.6% of recipients in the ELTR (ELTR et al
1992). This disorder which is characterised by specific HLA associations and disordered 
immunoregulation frequently responds to immunosuppression. In particular, 
corticosteroids and azathioprine can induce clinical remission and remain the mainstay of 
current treatment protocols with anecdotal reports of response to CyA in certain cases 
(Cook et al 1971, Murray-Lyon et al 1973, Mistihs et al 1985). The use of these particular 
agents in conventional ‘triple therapy’ maintenance immunosuppression regimens 
following transplantation to control liver allograft rejection may, by secondarily inhibiting 
the autoimmune process, explain why there are so few reports of recurrence of AIH and 
other immune-related liver disorders. Recurrence of this disorder following 
transplantation was first reported from this unit in 1984 with a larger series also reported 
from the University of Pittsburgh (Neuberger et al 1984, Wright et al 1992).
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In this report, severe recuiTence of AIH in the primaiy liver graft of a recipient 10 years 
after tiansplantation who had received maintenance immunosuppression consisting of CyA 
alone is described. This case, as well as providing further evidence for recurrence of this 
disorder and highlighting the necessity for indefinite close clinical and pathological 
suiweillance post-transplant, additionally raises the potential hazards which may ensue with 
low or indeed as recently proposed withdrawal of pharmacological immunosuppression.
11.5.2 Case report
Patient (CS) initially presented as an 8  year old girl in 1975 with hepatomegaly and elevated 
serum transaminase activities. Investigations revealed characteristic histopathological 
features of chronic active hepatitis with elevated serum globulins and autoantibodies 
(positive for antinuclear antibody (ANA) 1:20, gastric paiietal cell antibody (GPC) 1:80). 
The patient was negative for anti-smooth muscle antibody and reti’ospective examination of 
stored serum subsequently demonstrated a positive liver-kidney-microsomal (LKM) 
antibody at a titre at 1:160. Following the diagnosis she was initially treated with 
corticosteroids and azathioprine. Due to haematological complications attributed to 
azathioprine and histological progression of the disease she was transferred to CyA 
following its clinical introduction in 1982. By 1984 after an 8 year period of clinical 
remission the patient experienced her first decompensation with the development of ascites 
and spontaneous bacterial peritonitis and at the age of 17 proceeded to elective orthotopic 
liver transplantation.
The patient was HLA A and B phenotyped by standard complement dependent 
microcytotoxicity assay, and DNA analysis was performed for HLA DRB, DQA and DQB 
alleles by a combination of RFLP and PCR amplification / oligonucleotide probing 
(Doherty et al 1994). The patient’s HLA type was characterised as A1 A24 B8  B39 Bw6
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DRB1*0101 DRB 1*0301 DRB3*0101 DQA1*0101 DQA1*0501 DQB 1*0201 
DQB 1*0501. The donor was serologically characterised only (data supplied by United 
Kingdom Transplant Service) as A11 A32, B 14 B22, DR2/DR7.
With the exception of surgical conection of a biliary fistula related to T-tube displacement 
the patient made an uneventful recovery. Induction immunosuppression comprised a dual 
therapy regimen of corticosteroids and CyA. Satisfactory rehabilitation was achieved and 
the patient resumed her educational and social activities. Puberty and sexual development 
which had been delayed now occurred. Annual clinical review in the second post - 
transplant year- confirmed normal liver biochemistry and immunological profiles. At this 
time-point the patient, now 19 year's old, was non-compliant for corticosteroids due to 
‘unacceptable’ cosmetic effects and was subsequently maintained on CyA only within a 
therapeutic blood level range of 130-500 ug/1 (polyclonal Sandimmun assay). In the third 
post-tr ansplant year, the patient suffered an episode of severe pelvic inflammatory disease 
with confirmed chlamydial infection and was found to have developed cervical intra - 
epithelial neoplasia (CIN - colposcopy grade II). Due to this condition and the presence of 
normal biochemical graft function, CyA levels were maintained towar'ds the lower limit of 
the above therapeutic range. Clinical reviews, performed on an annual basis, over the next 
6  years were satisfactory except for the presence of a clinically palpable spleen.
1
At 10 years post-transplant, the patient who had remained clinically asymptomatic .1throughout this time was considered for entry into the programme of immunosuppressive 
drug withdrawal. A complete assessment of graft function and systemic 
immunosuppressant-related complications was performed in April 1994 and showed for 
the first time that the patient had abnormal liver function tests: raised AST 164 IU/1,
[normal range (nr) 10-50 lU/L] and total bilirubin 28 umol/L [nr 3-20 umol/L]) levels 
were noted alongside mar'kedly elevated globulin levels (IgG 49g/l, nr 7-18.6 g/1) and
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Figure 11.4 Serial measurements o f antinuclear antibody (ANA) and 
amino aspartate transferase (AST) levels over the 10 years 
fo llow ing transplantation. The titre o f ANA fluctuated  
between 1:20 to 1:80 throughout the clinical course until the 
time o f diagnosis when they rose to an unprecedented titre of  
1:640. AST levels were reassuringly maintained in the normal 
biochemical range up till the point of diagnosis. Concurrent 
immunosuppression protocols administered over the above 
period are also shown.
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- autoantibodies (particularly ANF at titie of 1:640 and GPC 1:80) (see figure 11.4). Total 
serum alkaline phosphatase level was normal at 6 8  lU/L [nr 30-85 lU/L]. Ultrasound 
examination of the graft demonstrated a heterogeneous liver parenchymal texture with no 
evidence of biliary obstruction. A percutaneous biopsy of the graft with histopathological 
assessment revealed a severe combined lymphocytic and plasma cell infiltrate within the
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portal tracts accompanied by extensive periportal and bridging collapse. The interlobular 
bile ducts were preserved. Portal fibrosis with bridging septa formation and parenchymal 
hyperplasia were also present (figure 11.5). No hepatitis viruses were detectable by 
conventional serological methods (IgM HAV, HBsAg, IgM HBc antibody [Abbot, North 
Chicago, Illinois] and HCVAb [United Biomedical Inc. Lake Success, N.Y.] were aU 
undetectable). HCV RNA was not detected in serum (Amplicor, Roche, Basel, 
Switzerland]. Additionally, there was no serological or immunohistological evidence of 
cytomegalovims or Epstein-Barr viral infection. Following the diagnosis of recurrent 
AIH, corticosteroids (prednisolone 40 mg per day in a reducing regimen) and azathiopiine 
(100 mg per day) were added to CyA and induced biochemical remission by 6  weeks. No 
follow-up biopsy of the graft is presently available.
11.5.3 Discussion
The disordered autoreactivity which is the hallmark immunological abnormality present in 
AIH is unlikely to be conected by liver replacement. Hence, it is perhaps surprising that 
there are only sporadic reports of disease recurrence following transplantation. In the 
patient described in this report, serological and histological evidence of disease recuiTence
was convincingly diagnosed 1 0  years after transplantation (presently the longest recorded 
post-transplant interval to recurrence in the literature). Employing the international AIH 
diagnostic scoring system in relation to the required parameters, the patient had an 
aggregate score of 15 points consistent with ‘definitive’ disease (Johnson et al 1993). a
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Figure 11.5 Liver histology 10 years post-transplant, (a) Prominent
fib  ro-inflammatory portal expansion and bridging  
parenchymal collapse with active inflammation at the 
interface between fibrous areas and parenchyma. H &. E 
X  80. (b) same field as (a) stain for reticulin x 80
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The value of this particular scoring system, which was developed in non-transplant 
patients, in liver recipients is presently not known. Notably, recurrence developed 
following many years of immunosuppression consisting of CyA alone. This particular 
regimen which was driven by an unusual combination of patient and medical pressures 
may, with the benefit of hindsight, be considered a sub-optimal protocol omitting as it 
does both corticosteroids and azathioprine which are the present mainstays of inducing 
and maintaining remission in AIH. Withdrawal of these agents from non-transplanted 
AIH patients during clinical remission is associated with a high incidence of relapse 
(Hegarty et al 1983). This case report should therefore reinforce clinical caution before 
considering witlidrawal of immunosuppression in this group of long-term liver recipients. 
Early observations from the University of Pittsburgh programme suggest tliat withdrawal 
is accompanied by a high incidence of biochemical graft dysfunction in patients 
tr ansplanted for autoimmune liver disease (Reyes et al 1993). Although the pathological 
features of the patients in that report appear’ inconclusive and no data on autoantibody 
profiles are given, the presence of elevated liver enzymes in such a population demands 
close clinical surveillance. In contrast to the experience from the University of Pittsburgh, 
recuTTence of autoimmune hepatitis is a rarely diagnosed complication in this unit’s series 
with only 2  well-documented cases from forty-nine patients transplanted for this 
indication and who survived at least one year.
The natural history of long-term liver recipients is becoming clearer with clinical and 
histological follow-up of the first generation of patients. A recent review of long-term 
survivors in this unit revealed an alarming and unexpectedly high frequency of significant 
graft pathology, which included late development of primary disease reciuTence in 
asymptomatic patients (Slapak et al 1995). This individual report of AIH recurrence after 
such a long period of excellent biochemical graft function is further evidence for the 
requirement of close and indefinite clinical follow-up in liver recipients. Protocol graft
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biopsies, peifoimed at least every two years, could be considered part of this surveillance. 
In this instance, the persistent reluctance of this patient to undergo liver biopsy may have 
delayed the diagnosis although conventional liver function tests and autoantibody levels 
were normal up to the eventual time of histological assessment of the graft and diagnosis. 
However, the severity and characteristics of the pathological damage to the graft 
demonstrated at the time of initial biochemical abnormality suggest that the disease process 
had been on-going for a considerable period. Monitoring hepatocellular damage in AIH 
through standard laboratory indices (levels of AST and total bilirubin) is a hazardous 
undertaking with normal values being unreliable predictors of concurrent morphological 
activity (Czajaet al 1981). In this report, the striking discrepancy between the severity of 
the histological changes and the modest elevations in AST reinforces the comparative 
insensitivity of routine biochemical liver function tests. This case suggests that in the post - 
transplant setting there is justification in employing more sensitive markers of autoimmune 
reactivity and subsequent disease reactivation such as antibodies against the Hver-specific 
membrane lipoprotein preparation (anti-LSP) or against the hepatic asialoglycoprotein 
receptor (anti-ASGPR) which can be predictive of relapse in the non-transplant setting 
(McFarlane et al 1984, Treichel et 1993).
A consistent finding of the two previous published reports on post-transplant recurrence 
of AIH, which is also present in this case, is a mismatch of the donor and recipient for 
HLA DR3 (present in the recipient, absent in the donor [D-, R+] (Neuberger et al 1984, 
Wright et al 1992). Similar but less strong associations with recuiTence were noted for the 
B8  locus in the Pittsburgh study. These observations may be a chance finding reflecting 
the high prevalence of the A1-B8-DR3 haplotype in AIH liver recipients (79% in this units 
patients) and its comparative rarity in the randomly selected unmatched general donor pool 
(11% in the local population) (Donaldson et al 1991). This recipient haplotype, which is 
associated with a range of humoral and cellular immunological abnormalities, appears to
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be sufficient to generate AIH even in the presence of a completely unmatched liver. These 
observations have important implications for the proposed mechanistic role of HLA 
encoded disease susceptibility (Donaldson et al 1994). T-cell clones mediating the 
autohnmune process must remain immunoreactive despite liver and hence hepatocyte 
antigen replacement, indicating the major importance of the T-cell receptor repertoire 
compared to the apparently less crucial target cell MHC antigens once die autoimmune 
process is established. The hypothesis of Sheehy which proposes that HLA disease 
susceptibility alleles inefficiently present disease-associated antigen peptides and thereby 
prevent clonal deletion of autoreactive T cells would appear to best explain the 
development of recurrent disease (Sheehy et al 1992).
If a relationship between A1-B8-DR3 present in recipients and subsequent disease 
recuiTence was shown this would be consistent witii previous reports that this haplotype 
is a marker not only of susceptibility, but also of disease aggressiveness and indeed 
progression to transplantation (Doherty et al 1994, Donaldson et al 1991, Sanchez- 
Urdazpal et al 1991). Given that no effort to select recipients is based on donor HLA 
phenotype, it would be difficult to determine whether a match at the above loci confers 
either further susceptibility to, or protection from, recurrence, as the number of 
transplants required to generate a sufficient study population is considerable given the rare 
occurrence of spontaneous random matches.
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CHAPTER 12
GENERAL DISCUSSION
Achieving a successful outcome after clinical liver transplantation is an inexact science. 
Less than 30 years from the date of the first long-term survivor, clinical practice is still 
evolving rapidly. That a standardised clinico-pathological classification of transplant 
failures is not available reflects the immaturity of this emerging speciality. The 
classification proposed in chapter 2  which is based on the clinical experience of this unit, 
should stimulate discussion on this neglected topic. As with any classification, simplicity 
is sought at the possible expense of detail with the 8 -category scheme a compromise to 
these principals. Providing the structure of a classification scheme does not however 
assist in the equally problematic assignment of individual cases to the appropriate 
categories. A forum may be required amongst potential users of this classification to either 
refine the proposal or lay guidelines for achieving a consistency in allocating transplant 
failures.
One of the functions of data which is generated by a classification of pathological events 
should be to direct research to these major contributing categories. In this thesis, 
individual investigations in relation to the 6  largest categories from the proposed 8 -point 
classification of tiansplant failure ate examined. Rejection (classified under immunological 
transplant failure) accounted for the largest proportion of these failures and was separately 
examined in 3 chapters. Investigations examined a novel demographic risk factor, a new 
parameter proposed as an adjunct to immunological monitoring and finally the therapeutic 
efficacy of a newly introduced immunosuppressant in a high-risk recipient population. 
Identifying those liver recipients at increased risk of rejection could allow closer clinical
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surveillance, earlier therapeutic intervention as well as providing insight into the 
underlying mechanisms of this process. The importance of the ethnic origin of liver 
recipients was examined in chapter 6 . Solid organ donors in the UK, for several cultural
’ 4and religious reasons, are overwhelmingly of Caucasian ethnic origin i.e. are procured
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from a single and immunologically comparatively homogeneous population. The liver unit 
at Kings College Hospital is in a unique position to examine the influence of transplanting | |
such donor organs into an ethnically heterogeneous recipient population, given the
international referral base from which the transplant population is derived. A penalty of 
increased rejection and subsequent graft loss in those recipients from non-caucasian 
origins was demonstrated. Prospective confirmation and examination of the influence of 
both major and minor HLA disparities (perfomed by molecular analysis) will determine 
the significance of this phenomenon and the relationship to HLA determinants. It is 
possible that non-HLA donor or recipient factors may modify an increased susceptibility 
to rejection. For example, the increased prevalence of end-stage liver disorders secondaiy 
to viral hepatitis, which is present in non-caucasian liver recipients, may promote the 
rejection process. The logistics of graft procurement and allocation would not allow 
matching recipients and donors for ethnic origin.
Immunological monitoring of rejection remains an attractive, but as yet elusive, standard 
clinical practice. Conventional diagnosis of rejection in all solid organ allografts relies 
upon histopathological confinnation as the gold-standard method. Reliance on this method 
prevents serial and regular assessment of the rejection process and is also accompanied by 
an appreciable morbidity and occasional mortality. Measurement of nitric oxide generation 
is a potential clinically useful parameter of the in-vivo allograft response. The assay is 
robust, stable and cheap and appears to correlate with rejection and its severity. At 
present, however it is cumbersome to set-up and requires considerable laboratory space 
and facilities. Real-time analysis of prospective samples comparing measurement of NO
end-products to the presently employed liver function tests should confirm the realistic 
proposal of employing this agent in post-transplant monitoring. The source of the detected 
circulating nitric oxide end-products which have has now been found in two different 
organ allograft investigations of rejection (liver and cardiac) remains speculative. These 
results provide indirect evidence that the generation is derived from processes present in 
both disorders. Hence, the immunological cascade present in rejection or possibly 
endothelial cell damage which is targeted in both organ rejection processes are potential 
sources for the observed production. Elucidating the precise localisation of this generation 
has presently confounded immunohistochemical and in-situ hybridsation probing, for the 
inducible nitiic oxide synthase (iNOS) protein and mRNA lespectively, in clinical samples 
(unpublished observations). The precise pathogenic role of NO in inflammatory 
conditions is not yet adequately defined and was not addressed in this investigation. 
Proposals for either supplementing or inhibiting NO production during a rejection episode 
are premature.
The present immunosuppressant agents which aie employed clinically have unfavourable 
therapeutic indices. Efficacy is often only reliably achieved at the expense of elevated 
dosage regimens with significant accompanying multi-system toxicity. Tacrolimus 
(FK506) is a novel agent recently introduced to the transplant physicians 
immunosuppression armamentarium. Early clinical experience with this agent was centred 
around liver transplantation with provisional evidence indicating favourable properties. 
The data presented in chapter 7 provides further evidence that this agent is a viable 
alternative to CyA with potential advantages in relation to superior control of rejection and 
reduced infection rates. The randomised trial from which the presented data was derived 
did however have serious flaw designs with, in particular, a negative bias against 
tacrolimus. In particular, those recipients who were randomised to the conventional CyA 
based regimens could, in the event of intractable rejection, be administered tacrolimus for
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salvage or rescue treatment. A significant proportion of these grafts were successfully 
rescued and translate into favourable survival data for the conventional regimen. The 
convincing increase in efficacy which was obseiwed with tacrolimus is not matched by a 
decline in toxicity. Overall, the safety profile of tacrolimus is broadly similar to CyA with 
respect to neurotoxicity, nephrotoxicity and diabetogenicity. Whether the benefits of 
monotherapy with tacrolimus, which appears to provide adequate maintenance 
immunosuppression, will confer benefits in relation to toxicity over longer follow-up will 
require study. The pharmaco-economic benefits of a tacrolimus-based 
immunosuppression regimen compared to a conventional one now iiequire to be evaluated. 
Whether the reduced intensive care admissions seen in this study were accompanied by 
shorter hospital stays and reduced admissions over the study period in the large general 
population of recipients would be of major interest.
From the proposed classification of transplant failures, technical complications then 
primary graft dysfunction were the next largest groups after the category of 
immunological transplant failure. The commonest technical complication was hepatic 
artery thrombosis, which alongside other vascular pathologies, was examined by hepatic
'"Iangiography in chapter 4. This invasive investigational technique presently represents the |
optimal method in clinical assessment of graft vascular damage. Future studies will need
v ;tto address this traditional technique against new and less invasive angiographic "Iradiographic methods such as magnetic resonance imaging. The present study does •s
however confirm the sensitivity of conventional angiography in the diagnosis of the major 
vascular complications of hepatic artery thrombosis and stenosis and provides additional 
comparative data on their prognostic significance. The relationship between chronic 
rejection and vascular damage in liver transplantation, which is poorly characterised, was 
also examined. The data from this study demonstrates the very unfavourable prognosis of ;|
chronic rejection when there is an associated rejection vasculopathy, a phenomenon which
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is well recognised in other solid organs allografts. Future studies should address whether 
tacrolimus, which appears on occasion to be able to reverse the chronic lejection biopsy 
changes of ductopenia, can also reverse the associated arteriopathy. Finally, the 
angiographic changes in early graft dysfunction were examined revealing a non-specific 
pruning of the intrahepatic vasculature consistent with a high-resistance flow pattern. 
These features are mirrored by the reduced ICG extraction present in both this 
complication and, indeed to a lesser extent, all grafts in the early post-operative period 
which was examined in chapter 10. In that investigation, modulation of this parameter 
pharmacologically was demonstrated with infusion of N-acetylcysteine. This agent 
appears to have both beneficial systemic and regional haemodynamic properties which 
may improve graft function. A randomised trial of this agent in the early peri-transplant 
period is now justified in an attempt to determine whether it will affect clinical parameters 
of morbidity or mortality before there can be recommendation of routine administration of 
this agent.
In chapter 3, a biochemical analysis of the effluent preservation fluid which bathed the 
liver graft during storage was performed to assess whether changes in its biochemical 
composition could predict those grafts at risk of early dysfunction. As discussed in the 
chapter, this foim of graft assessment although reasonably accurate in this regai’d cannot 
assist in organ selection. This pragmatic approach accepts that a significant proportion of 
utilised donor organs will be of limited viability, reflecting the increasing disinclination of 
programmes to turn down this scarce resource against a background of appreciable 
waiting-list mortality rates. The parameters measured in the effluent fluid in this study 
were comparatively cmde indices of endothelial and parenchymal cell function and yielded 
no information on the potentially impoitant Kupffer cell viability. Further examination of 
new and more sensitive markers of these cell populations and comparison with more 
functional indices of viability are required.
208
Pretransplant clinical status of a liver recipient is undoubtedly a major risk factor for the 
subsequent post-transplant outcome. This is perhaps most visibly present in the 
population of critically ill patients transplanted for acute liver failure who were examined 
in chapter 7. Definition and characterisation of this generally perceived observation into 
some qualitative or qualitative index, which could be employed clinically, is however 
problematic. The deliberate use of ‘hard’ data sets such as laboratory parameters and 
critical illness scoring systems was an attempt to define unfavourable characteristics which 
could serve as a guide to identifying those patients where the hazards of proceeding with 
transplantation aie unacceptable. Limitations to the present investigation exist, not least of 
which was the prolonged period over which the study population was derived. Several 
advances in organ preservation, immunosuppression and general surgical and medical 
management occurred during this time which may influence outcome. Additionally, the 
study was retrospective and suffered from small numbers in certain groups. However, 
this study does provide the first data in this increasingly important area and identifies 
those indices which should be assessed prospectively.
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Recurrence of a disorder in the liver graft which was the primary transplant indication was |
identified in chapter 2 as accounting for approximately 10% of transplant failures.
Previously, such a pathological event resulted predominantly from recurrence of hepatic 
malignancies. Subsequent retrospective analyses have now identified the major 
unfavourable clinical characteristics which are asssociated with recurrence in these 
conditions and accordingly, selection criteria for Uansplantation are now more refined and 
stringent. In contrast, the position with regard to transplant selection of HBsAg-positive 
patients is considerably less well characterised and more contentious. Some centres in the 
US (where intramusculai* immunoprophylaxis is unavailable) now consider these patients 
to be an absolute contraindication to transplantation. In the single-centre experience |
described in chapter 9, the impact of long-term passive immunoprophylaxis and a more
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rigorous selection procedure were investigated. This data confirms the efficacy of HBIG 
but stresses the lequirement for indefinite administration if recurrence is to be prevented in 
a significant proportion of patients. Even with this prophylaxis those recipients who are 
HBVDNA-negative in the peripheral circulation can experience recurrent disease. Further 
studies which employ more sensitive assessments of HBV replication are required. The 
protective effect of coexistent HDV infection on recurrence of HBV is remarkable. The 
logical but possibly unethical conclusion from such powerful data is whether clinicians 
should be considering deliberate infection of HDV to those HDV-negative recipients who 
are actively replicating HBV. A further important clinical conclusion from this study is the 
ability to reduce maintenance immunosuppression in this particular group of recipients. 
Such a practice may decrease the liklihood of uncontrolled viral replication. Disease 
recurrence is less well recognised and characterised in those immunological liver disorders 
which are common liver transplant indications such as PBC and AIH. A case report 
presented in chapter 11 highlights the potential for recurrence of AIH with sufficient 
severity to compromise graft viability. In that report the comparatively low maintenance 
immunosuppression, alongside the well documented recipient HLA specificities, may 
have contributed to the recurrence. Management protocols cannot be recommended on the 
basis of one patient but this clinical case may represent a salutatory lesson on the hazards 
of immunosuppression reduction in such transplant indications, an issue which was 
examined in considerable detail inthe early part of chapter 11.
Clinical tolerance would greatly promote the health of liver transplant recipients. 
Immunosuppressant agents are associated with an appreciable morbidity and mortality and 
yet rejection remains the leading cause of graft failure and death as reported in chapter 2. 
From the early data presented in chapter 11, it is clear that tolerance allowing withdrawal 
of pharmacological immunosuppression (so-called operational tolerance) exists to a 
variable degree in a proportion of long-term liver recipients. However more questions
than answers result from these observations. Why does the phenomenon of chimerism 
exist in a significant proportion of patients? If microchimeiism cannot predict the tolerant 
population, then what clinical or laboratoiy parameter can? Certainly, clinical data such as 
rejection history from the early post-transplant period will have to be perused as will the 
underlying tiansplant indication and degree of HLA matching. If this type of clinical data 
is unhelpful then reliance on in vitro  assessments of donor-recipient immune 
responsiveness, with all the attendant pitfalls of this approach, may be required. The 
population of tolerant patients needs urgently to be characterised immunologically 
allowing identification of those characteristics which require to be promoted. The 
intragraft balance of Thl and Th2 cytokine gene expression or phenotyping the graft - 
infiltrating cells may yield important differences between the tolerant and non-tolerant 
populations. Programmes are unlikely to be in a position of being able to identify tolerant 
recipients within the next few years. Hence, what will be important at a practical level is 
some form of immune monitoring during immunosuppression withdrawal which will 
allow prediction of a rejection episode. The limitations of this approach were discussed in 
chapter 5, but nevertheless, assessment of nitric oxide generation or conventional 
phenotyping of circulating lymphocyte sub-populations in this distinct and unique clinical 
circumstance would be of potential value.
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i:Appendix
Details of donor-type microchimerism determination by the most sensitive nested PCR - 
g gP  mQthQdQlgy
Genomic DNA was prepared from recipient whole blood, bone marrow and tissues by 
phenol/chioroform extraction. 0.5 mi biood or bone marrow was aiiquoted and 1 ml red 
blood cell lysis buffer added and mixed for 2 minutes at room temperature. Cells were 
pelleted by centrifugation and resuspended, with this process repeated until the 
supernatant was clear. The following steps were then identical for these cells and the 
liver and skin tissue specimens.
The samples were resuspended in 300 gl digestion buffer (Tris-NaCI-EDTA solution) 
and 50 |xi of proteinase K added with an overnight incubation at 37°C. In the case of the 
tissue samples, further proteinase K was normally added (25 pi) for a further 24-48 
hours incubation. Following digestion, phenol / chloroform extraction of undigested 
protein, overnight ethanol precipitation of the DNA at -70OO was performed. The 
ethanol was removed by speed vacuum evaporation. The DNA was pelleted at 10000 g 5 
min and resuspended in 200 pi of distilled water and stored at 4^0 prior to analysis.
Following determination of the concentration of the DNA by optical density 
(measurement of absorbance at 260 nm wavelength using a LKB spectrophotometer), a 
standard concentration of 0.05 pg/pl DNA was prepared for analysis. The protocol for 
subsequent genotyping of the DRB1 alleles in the DNA was according to the method 
described in the literature accompanying the BSHI kit except for in-house 
modifications as described below.
The Perkin-Elmer 4800 thermal cycler was used for approximately 50% of samples 
as described in the recommended protocol. However, in the later samples the Perkin - 
Elmer 9600 thermal cycler was used which required a reduction in the reaction 
volume from 50p! to 21 pi. Accordingly in the first PCR amplification, a 8 pi primer 
mix (2 pi respectively of DRB7, DRB87, HGH 1, HGH II), 2 pi xIO buffer, 2 pi dNTPs 
(2mM each), 3 pi H2O, 3 pi glycerol / cresol red was added to 2 pi of denatured DNA.
The HGH I and ii primers were used as positive controls for genomic DNA 
amplification. The DNA was denatured at 940C for 5min then put immediately on ice.
i
0.8 pi of Tag was added to the stock. Glycerol and cresol red were used to promote heat 
dissipation and act as a tracker dye when running the gel respectively. A small 
reduction in cycle numbers in the first round from 23 to 20 was employed to reduce 
non-specific products and because of the use of glycerol the annealing temperature was 
decreased from 640C to 620C. Since, the faster PCR cycler was now being used, the 
denaturing and extension times were reduced by 50%. The cycling was commenced with 
a hot-start.
Similarly in the second round PCR amplification cycles, small modifications to the 
standard protocol were required. Again a final reaction mix of 20 pi was used which 
was made up of 8 pi of the 18 primers, 2 pi xIO buffer, 2 pi dNTP, 0.2 pi cresol red, 
1 pi glycerol, 1 pi Taq, 1.8 pi sterile HgO and 4 pi denatured and diluted first round
product (5 pi first-round product diluted in 495 pi sterile HgO). In this instance the
number of cycles was not altered from the recommended 30, but the denaturing and 
extension times were reduced by 50% and the annealing temperature increased from 
620C to 640C with a reduction in the time from 45 to 30 secs.
The final products were best viewed on a 2% rather than a 1% agarose gel (as 
recommended) with 20 pi of 10 mg.ml ethidium bromide added.
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